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Abstract
Tandem-repeat (TR) domains occur in approximately one third of all proteins, yet these
domains are less well understood compared with their globular counterparts. TR proteins
act as molecular scaffolds that facilitate protein-protein interactions (PPIs) in diverse bio-
logical contexts. In disease pathologies such as cancers, misfolded, mutated or deregulated
TR function is often the cause. However, targeting tandem-repeat proteins is challenging
due to their flat and large interaction interfaces. In this thesis, I have explored the devel-
opment of peptide-based inhibitors of PPIs involving two targets, Tankyrase (TNKS) the
Anaphase Promoting Complex/Cyclosome (APC/CCdc20).
TNKS belong to the poly-ADP-ribose polymerases (PARP) family of enzymes that
PARylate their substrates, leading to ubiquitination and subsequent degradation. TNKS
bind their protein substrates through an ankyrin-repeat domain comprising five so-called
Ankyrin Repeat Clusters (ARCs). TNKS is of particular therapeutic interest in cancers
due to its PARylation of Axin1, a subunit of the β-catenin destruction complex. We
investigated the design of peptide inhibitors of TNKS ARC domains through a structure-
guided approach. We first attempted to expand the range of biophysical assays to assess
ligand binding to TNKS ARCs. We then designed and tested a set of linear and chemi-
cally constrained peptides for their ability to bind to the ARCs.
The APC/C is an E3 ubiquitin ligase that has broad substrate-specificity via its two
WD40-domain co-activators, Cdc20 and Cdh1, which recognise three peptide motifs (de-
grons) on its substrates: the D-box, the KEN box and the ABBA motif. The regulation
of mitotic exit is tightly controlled by modulating the levels of Cdc20 and Cdh1 through
different stages of the cell cycle. Cdc20 overexpression is associated with many cancers.
Currently, no specific inhibitors of the APC/CCdc20 exist in the clinic or in clinical trials.
We designed a series of synthetic peptides based on the D-box to bind to Cdc20, and
thereby modulate APC/C activity. Peptides were tested using surface plasmon resonance
and differential scanning fluorimetry assays using recombinant Cdc20. Furthermore, D-
box peptides were able to bind exogenous Cdc20 in mammalian cell lysates using a Cellular
Thermal Shift Assay (CETSA). Lastly, I determined the co-crystal structures of three of
the highest affinity D-box peptides bound to Cdc20, providing high-resolution insights into
the binding interface, which should aid in the further development of Cdc20 inhibitors.
Rohan Sakariah Eapen

“The absence of evidence is not evidence of absence”
Carl Sagan
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Chapter 1
General introduction
1.1 Drug discovery approaches
Drug discovery is a broad and diverse field tackling a wide range of disease pathologies,
such as oncology, cardiovascular diseases and microbial infections, only to name a few.
Each disease pathology brings its own unique set of challenges, to which the drug dis-
covery field must constantly adapt and accommodate accordingly. The emergence of new
technologies, such as chimeric antigen receptor T-cells (CAR-T) are incorporated into new
therapeutics, which open largely unexplored avenues of harnessing the patient’s immune
system to treat the disease [1]. Another promising technology that has recently caused
ethical concerns, is the use of clustered regularly interspaced short palindromic repeats
(CRISPR), in which the possibility of eradicating the disease pathology can be tackled
at the gene level [2]. Despite the ongoing development of these promising techniques, the
vast majority of successful drugs that have made it into the clinic are small molecules or
larger biologics such as antibodies. In this section, the aim is provide a perspective of the
difficulties and challenges facing drug discovery and the more common modalities that
are typically explored.
1.1.1 A historical perspective of drug discovery
The earliest forms of drug discovery or rather the use of compounds as medicines to
treat ailments date back over 4000 years. Accounts of apothecaries with lists of ailments
and their remedies, define the first use of a modern-day prescription with the ancient
Mesopotamians, Babylonians, Egyptians, Greeks, Indians and Chinese [3]. In these times,
remedies often took the form of natural products, such as herbs, roots and spices in ground
forms mixed in a suitable liquid medium, often wine or beer. Of course, the medical and
pharmaceutical field has significantly advanced since these times, but more major ad-
vances were only prevalent in the last 150-200 years.
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Unfortunately for human society, major technological and medical advancements have
been made as a result of international war. The most notable example of advancement in
drug discovery arguably revolves around antibiotics in the early 20th century and their
pivotal use in saving the lives of soldier during World War II for treating infectious dis-
ease that were often acquired during life-saving amputations or surgery [4]. Alexander
Fleming’s most discovery of penicillin in 1928 was a landmark in of the development of
specific compounds that could be used to treat disease [5]. However despite it’s discovery,
it took several more years till it was widely used in humans [4]. The era of antibiotics
and in particular the search for new and more potent antibiotics to target gram-positive
and gram-negative bacteria sparked the evolution of more designed screening approaches
to be used. The study led by the then graduate student, Albert Schatz and his supervi-
sor Professor Selman Waksman was a landmark in systematic screening of antagonistic
Actinomycetes organisms that produced a growth inhibitory effect against a variety of
bacteria, but most notably against Mycobacterium tuberculosis [6]. The discovery of this
potent molecule, streptomycin, later resulted in the awarding of the Nobel Prize in Phys-
iology or Medicine in 1952 to Prof. Waksman. However, perhaps more influential than
the discovery of streptomycin itself was the concept of systematically screening molecules
(or rather organisms, in this case) against the cause of the pathology or indeed varying
extents of models to describe or replicate the underlying pathology or its cause. This
concept paved the way for high-throughput screening, in what is now considered standard
in modern day pharmaceutical drug discovery.
Evolution of drug regulation
It should be noted that in the last century, the growth of scientific knowledge has increased
at an incredible rate. As such, while medicines discovered early in this period do work,
the mechanisms by which they elicited their functional effect were not well understood.
Regulatory bodies, such as the United States Food and Drug Administration (FDA) are
in place to decide whether a new drug molecule is safe for use and elicits the desired/
expected phenotype. Whilst many drugs were deemed safe, and thus granted approval for
use in the clinic, this regulation was not sufficient in the case of thalidomide and marked a
turning point in scientific and clinical rigour for the safety of patients. The drug molecule
was found to alleviate morning sickness symptoms in pregnant mothers, however the ad-
vent of severe defects in offspring provided a important lesson to the drug industry and its
regulators of how impactful wrong decisions can be [7]. Since the advent of Thalidomide,
the FDA and other regulatory bodies now require significantly more information with the
introduction of the Kefauver-Harris Drug Amendments, and studies to define efficacy and
safety of the proposed molecule are now required [8].
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Whilst this was undoubtedly a move into the correct direction, the impact was signifi-
cant given how limited knowledge in the scientific community of biology at the molecular
level was (and perhaps still is). To provide some perspective of how limited our knowledge
was, the idea that DNA is transcribed to RNA, which then is translated into proteins had
just been suggested by Francis Crick in September of 1957, at University College Lon-
don [9]. Only one year preceeding this revolutionary concept, was Thalidomide in the
clinic. Coupled with the lack of knowledge at the time of what are now considered the
core fundamentals of cell and molecular biology, the true complexities of drug action can
also be unclear. Despite the use of Thalidomide from 1956 to 1961 worldwide, it’s bi-
ological effector remained elusive for many years. Even during this time, attempts to
repurpose the molecule in the treatment of Leprosy (which was later discouraged by the
World Health Organisation) and cancers with solid tumours lacked information on the
molecular interactions of the molecule. In cancers, it was used for its anti-angiogenic
properties as an inhibitor of basic fibroblast growth factor-induced angiogenesis. Only in
2010, over 50 years since it’s initial introduction as a drug molecule for pregnant women,
did we learn that the molecular target of Thalidomide was Cereblon [10]. This raises an
important question for the drug discovery community. Before a drug is used in humans,
how much should we know about the drug’s molecular interactions, downstream effects?
What are suitable models to determine safety and efficacy? If a molecule produces the
desired phenotype or therapeutic action, but the mechanism of action is unclear, should
it be used?
1.1.2 The growing problem in drug discovery
Fast forward from the early days of drug discovery to present day, the scientific field has
grown enormously. Despite this, the range of targets and success of projects pursued
by pharmaceutical companies is very limited. This owes to multiple and complex issues,
which often intertwine very heavily with each other. In this section, I will try briefly
outline some of the challenges the industry faces.
Is pharma only interested in profits?
One would like to believe that everyone involved in drug development from the research
scientists performing experiments up to group leaders and heads of departments directing
research and therapeutic areas and all the way to business leaders and chief executive
officers that everyone’s primary goal is to make a positive impact to patients. While
this might true, it would be naïve to assume that a business can survive without being
minimally financially sustainable. The largest and most established Pharmaceutical com-
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panies, such as AstraZeneca, reported a total revenue values of USD $24.4 bn [11] for
2019. Despite this, the money going back directly into R&D is only USD $6.059 bn [12],
approximately 25%. This raises the question, would better outcomes, i.e. more drugs
be made if more money was dedicated to R&D? Interestingly, significantly more money
(inflation-adjusted) has been made available towards research and development purposes
per approved drug over the years from 1950 to 2010, yet the number of drugs approved as
time has progressed has declined [13, 14]. It would therefore be illogical to think that a
lack of R&D funding is entirely responsible for this and the inefficiencies of bringing new
drugs to market must come from elsewhere.
How good is the model?
Models form a crucial element to the determination of whether a compound produces the
desired outcome. The definition of an outcome can be many things. Does it bind to the
target? Does it produce an inhibitory effect? Is there a phenotypic change? Does the
patient see an improvement in their disease? As knowledge has expanded over the past
century, the scientific community has been able to further dissect down and simplify ’the
model’ from the in vivo setting observing the final outcome towards more focused and
individual target oriented models in vitro. It can be argued that there are positives and
negatives from both perspectives and one must also take into account the feasibility of
doing so by taking into account the current technologies, knowledge and ethical consid-
erations.
If one considers the models originally used by Schatz et al. [6], where they screened
Actinomycetes strains that produced an inhibition of bacterial growth, this would class
as looking at the final output, i.e. did the strain kill the pathogenic bacteria? While this
is considered ethically sound, doing similar types of experiments in mice or even humans
with the large libraries of small molecule compounds, natural products or biologics that
are available today would not be acceptable on an ethical standpoint. Although, it would
be likely to find suitable candidates that produce the desired therapeutic effect, the sheer
numbers of negatives that would result in severe toxicity or even death make this approach
immoral. This has forced the scientific community to ’simplify’ the model from the in
vivo setting towards cellular models and even further towards examining the nature of
the ligand-receptor interaction.
The adoption of in vitro models has advantages, but also a major disadvantage. Firstly,
these simplified models provide a means to screen a larger number of compounds in a more
quantitative manner to provide an output of potential downstream success. These can be
done in highly controlled systems utilising many different models from assessing binding
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of the binary components, such as the ligand and the receptor in a purified system,
but also in more complex cellular models. However, with all of these models, they do
not take into account issues of dealing with a whole organism. This introduces several
unknowns, such as immune response, tissue distribution, metabolism of the drug molecule
and clearance from the organism to name but a few. Even then, at the in vivo level, is the
model organism itself correct? This can be a cause of concern as mice, dogs or monkeys
may not fully recapitulate the homology, complexities and intricacies for a given disease
phenotype [15, 16]. This leaves the drug discovery community in a state where the current
standard of in vitro and in vivo models are the only option for perform drug discovery,
without further innovation in developing more robust models that recapitulate the human
physiology and biology in its fullest extent.
Targeting what is easy
Pharmaceutical companies, in particular have a tendency to target the so-called ’easy
targets’. Easy, in this context doesn’t necessarily mean that the disease phenotype is easy
to overcome, but rather is an indication of the ease of developing a molecule to satisfy one
or several of the models developed for the disease pathology of interest. Kinases, GPCRs
and cell surface receptors form the majority of protein classes targeted in pharmaceutical
drug discovery research programs. Kinases, in particular are targeted since the role of
phosphorylation in the regulation of proteins is very central in the regulation of biolog-
ical activity [17]. The addition of a phosphate is produced by the hydrolysis of ATP or
GTP (in the case of GPCRs) to ADP and GDP, respectively, and thus these molecules
invariably form binding interactions in the active site of the enzyme. Therefore, there
are varying degrees of structural homology around the active sites of all kinases, which in
turn can be exploited for the development of inhibitors against these pockets. It is also
no surprise then, that pharmaceutical companies utilise kinases as targets for potential
cancer therapeutics when phosphorylation of a various proteins is fundamental in driving
cell cycle progression, (reviewed by Bhullar et al. [18] and references therein). With the
evolution of targeting proteins sharing conserved or structurally homologous active sites,
it is no wonder that the vast majority of molecules found in small molecule libraries that
are designed and synthesised by medicinal chemists are bias towards targeting these par-
ticular protein families [13, 14, 19].
A fundamental process of drug discovery, is the process of understanding the struc-
tural basis of the protein-ligand interaction. For this to be understood, the protein must
be structured. However, while many proteins contain ordered regions, approximately 44%
also contain regions (classified as greater than 30 amino acids) that form no defined sec-
ondary structural elements [20, 21] and these intrinsically disordered regions (IDRs) play a
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large and diverse number of roles regulating biological function. The typical response from
a drug discovery perspective is to ignore these ’difficult’ targets. However, these difficult
targets can often be of valuable therapeutic interest. To provide direct examples of these,
in relation to work conducted in this thesis and collaborative work, I will highlight two
such examples. The first is p53, whose transactivation domain (TAD) comprising residues
1-93 is reported to be intrinsically disordered [22, 23]. The TAD domain is able to form
numerous interactions with proteins such as Mdm2, MdmX, Taz2 and CBP/p300, among
others [24]. It’s ability to interact with so many proteins places it towards the centre of
cellular signalling pathways and its’ intrinsic disorder is crucial for this. Stabilising p53,
the so-called the ’guardian of the genome’ [? ] through blocking Mdm2/MdmX-mediated
ubiqutination and subsequent degradation has long been known as a important therapeu-
tic avenue. Efforts to stabilise wild-type or mutant p53, particularly in its intrinsically
disordered regions are far less explored, but are nonetheless valid approaches [25, 26]. The
second example is that of Cdc20 and Cdh1, of which the former is the greater focus of this
thesis. Briefly, Cdc20 and Cdh1 interact with the core Anaphase Promoting Complex/
Cyclosome (APC/C) through intrinsic disordered regions, which flank the core WD40
domain. Without these regions, functional output of both proteins is severely attenuated
[27, 28]. Particularly in the case of Cdc20, attenuating its function in oncology is of valu-
able interest and therefore is a potential avenue to be explored. It should be noted that
a more in-depth analysis of this protein is discussed later in this chapter and further in
Chapter 4, Figure 4.1.
The sections above are by no means intended to be a fully comprehensive overview of
the current issues in drug discovery. However, they do provide some insights that don’t
often reach the public and perhaps even academic readership. Having identified some of
the issues involved in the drug discovery pipeline, the more pertinent questions and issue
to address is how to change the industry to improve the number of successful drugs in the
clinic to positively impact the lives of patients? This is of course a multi-faceted challenge
and will require input not only from the pharmaceutical industry, but also academia and
biotech who play a large role in the development of new technologies and introduction of
new knowledge and principles that can be applied within the pharmaceutical industry.
1.1.3 Small molecule drug discovery
Small molecule are the most favoured drug class for intracellular targets and G-protein
coupled receptors (GPCRs). They typically target protein-ligand interactions, such as the
active sites of kinases and therefore are often developed against larger pockets within the
target. In the pharmaceutical industry, this makes targeting protein-ligand interactions
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more favourable than targeting protein-protein interactions (PPIs), which often do not
have well defined pockets within their binding interfaces [29].
High-throughput screening (HTS) campaigns using large libraries (>1 × 109 com-
pounds) of small molecules for screening in functional assays to identify molecules that
produce a desired phenotype. Hits identified in these screens need to be further validated
by biophysical methods (reviewed in [30]). These libraries can yield a number of hits for
targets such as kinases, yet the success rate of inhibiting PPIs is much lower [29, 31].
A major reason for the low success rate is the chemical and spatial diversity libraries
favouring the typically explored protein classes [19, 32, 33]. Additionally, PPI interfaces
are highly diverse in their general topology (Figure 1.1), which adds to the complexity of
generating small molecule libraries that can efficiently explore all of this space. Lastly,
these interfaces typically cover a larger surface area (1500-3000 Å2) versus the surface
area of small molecule binding sites (300-1500 Å2) [30]. Despite these challenges, mul-
tiple small molecule inhibitors against PPIs exist, such as Nutlin-3a for the Mdm2-p53
interaction [34] and (+)-JQ1 for the BRD4-H3K13ac interaction [35]. However, develop-
ing potent ligands to target PPIs often necessitates a fragment-based approach, in which
multiple low-affinity fragments are identified and then ’stitched’ together to generate a
high-affinity ligand [36, 37]. While these methods do provide ligands, their efficacy down-
stream might be limited due to the smaller interaction surface compared to the native
PPI and thus transient or limited activity due to the native PPI may still occur [38]. In
order to improve functional efficacy, larger molecules, such as macrocycles and peptides
offer suitable alternatives.
1.1.4 Macrocycles
The term ’macrocycles’ encompasses a broad range of compounds of both natural and
synthetic origin [39, 40]. This class of molecule bridges the gap between small molecule
and larger biological therapeutic molecules, such as peptides mini-proteins and antibodies.
Their increased structural complexity allows the targeting of larger interfaces found in
PPIs [41]. However, this poses a challenge to rational design of macrocyclic compounds,
especially in the absence of a starting structure, and hence complicates structure-based
drug design (SBDD). As a result, many synthetic macrocyclic compounds are produced
by library screening methods and are further optimised by SBDD [42, 43]. Without the
use of libraries, the discovery of macrocycle PPI inhibitors is a difficult task, unless the
design in based on existing natural macrocycles such as Rapamycin, which targets the
mammalian Target of Rapamycin (mTOR) [44].
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Figure 1.1: Protein-protein interactions vary in their chemical and structural features.
PPIs can be formed by primary amino acid sequences without defined secondary struc-
tures, also known as Short Linear Motifs (SLiMs). Formation of secondary structure
elements such as α-helices or β-sheet structures further increases the complexity of the
interaction. Tertiary interactions are formed by elements of primary and/or secondary
structures in the context of a protein, e.g. antibodies. Figure adapted from Arkin et
al.. [31]
.
1.1.5 Peptides
The use of peptides as therapeutic agents originated with insulin being used to treat pa-
tients suffering from diabetes mellitus [45]. Insulin itself, is composed of two polypeptide
chains, A (21 amino acids) and B (30 amino acids) that are cross-linked by two inter-
molecular disulfide bonds. Early extractions of insulin for use in humans were sourced
from fetal calf pancreas, though later this would be extracted from porcine source which
is more structurally homologous to human insulin with only one amino acid difference.
Several other natural peptide hormones were gradually introduced over the years, such
as the Adrenocorticotropic hormone [46], Calcitonin [47] and Oxytocin [48]. The field
of peptide therapeutics has largely revolved around targeting extracellular binding sites,
such as those on GPCRs (Figure 1.2) [38]. Most notably, and relevant to aspects of the
work presented in this thesis, intracellular targets make a very small proportion of those
that have entered clinical trials. One example of such a peptide is the p28 peptide, which
has been indicated for used in p53(+) patients with solid tumours and central nervous
system (CNS) tumours [49, 50]. These studies alongside others, such as Aileron’s Mdm2
and MdmX dual stapled peptide inhibitor, ATSP-6924 [51–54], highlight that intracellu-
lar targets for peptide modalities is a viable option, that may have success in the clinic.
Exploring intracellular targets using natural peptides, unlike macrocycles or small
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Figure 1.2: Distribution of targets for peptides entering clinical trials over the years.
Figure adapted from J.L. Lau and M.K. Dunn [38].
molecules, is more challenging to develop efficient screening methods due to their lack
of cell permeability (further discussed later). To identify binding motifs, amino acid
sequences that are responsible for mediating PPIs are often determined by mutagenesis
studies, e.g deletion and/or alanine substitution of specific residues [55, 56]. This approach
is limited in its effectiveness and may not fully capture the complexity of the binding in-
teraction. In addition, biology has not necessarily evolved to produce high-affinity PPIs,
but has instead designed transient and weak affinity PPIs to mediate complex biological
pathways [57, 58]. Therefore, it is quite common that peptides derived directly from a
protein-protein interaction do not consist of the optimal amino acid sequence for high
affinity binding.
Similar to small molecules and macrocycles, the generation of high-affinity peptides
against a target is often performed by library screening in a cell free environment. Several
library screening approaches have been developed, such as Phage [59, 60], mRNA [61]
and ribosome display [62]. While these techniques often produce a high-affinity peptides,
diverse libraries of the required peptide length are not always available or indeed accessible.
In addition, not all PPIs can be targeted using these methods. For example, if the protein
of interest is part of a larger macromolecular assembly, valid targeting approaches may
have to consider the complex as a whole.
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1.2 Challenges of peptides as therapeutics
1.2.1 Cell permeability
Lipinksi’s ’rule of 5’ defines the ideal characteristics of a drug molecule and includes
parameters for the molecular weight (≤ 500 Da), logP (logarithm of 1-octanol/water par-
tition coefficient, ≤ 5), number of H-bond donors (≤ 5) and H-bond acceptors (≤ 10) [63].
Although these rules are gradually being broken down as new and existing technologies
improve, they still form a major basis of drug discovery at present and therefore pose a
challenge to the successful development of peptide inhibitors, which rarely adhere to these
rules. Diffuse cell permeability of designed peptides is rarely observed unless specifically
selected for. During the past decade, Lokey and co-workers have investigated passive cell
permeability of cyclic pentapeptides and hexapeptides [64–67]. All natural and designed
cyclic peptides were able to traverse the cell membrane if their estimated AlogP values
were between between 3-5, thus adhering to Lipinski’s rule of 5 [68, 69]. At present, these
rules have not been applied to linear peptides motifs, possibly due to their increasing
conformational complexity.
In efforts to deliver peptide and larger biologic therapeutic molecules intracellularly,
several different techniques have been explored. Nanoparticle-mediated and liposomal
delivery methods have been explored extensively for the delivery of small molecules, pep-
tides and biologics (reviewed in [70, 71] and references therein). However, these methods
require extensive expertise in formulation of the specific delivery vehicle for each respec-
tive drug, and therefore are not ideal for the identification of positive hits early in the
screening process. However, once an active peptide or biologic is found, nanoparticles
offer an attractive route of administration. Typically biologics and peptides would have
to be administered through the intravenous route. This is generally not favourable since
administration will always have to be performed by a medical professional. Thus, orally
availability of drug molecules is often preferred. Nanoparticle offer this administration
route due to their ability to traverse the gastrointestinal tract via endocytosis mecha-
nisms [72]. The physical barrier of the nanoparticle provides shielding of the cargo from
excreted proteases. These properties can be extensively modified through the variation
of nanoparticle material, diameter, surface charges and modification.
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1.2.2 Cell penetrating peptides
An alternative approach to intracellular delivery is the use of, cell penetrating peptides
(CPPs) to mediate the entry of a cargo molecule (reviewed in [73, 74]). Early examples
of polycationic CPPs in the literature were derived from trans-acting activator of tran-
scription (TAT) protein from human immunodeficiency virus (HIV-1). A short sequence
derived from this protein (YGRKKRRQRRR) was shown to be sufficient for cell entry in
mouse fibroblasts [75, 76]. Another commonly adopted sequence is the amphipathic pen-
etratin CPP (RQIKIWFQNRRMKWKK) [77, 78]. In addition, poly(R) peptides such as
R9 (RRRRRRRRR) [79], and many others (see Table 1.1) have been used. Interestingly,
amphipathic CPPs appear to contain cationic residues at positions i,i+3, i,i+4, i,i+7 and
i,i+11, which correspond to one face of an α-helix. Two studies have linked the relative
position of cationic residues and the helix-forming propensity of CPPs to cellular uptake
efficiency [80, 81].
Table 1.1: List of common cell penetrating peptides. Cationic residues are coloured
in red. Table adapted from Fonseca et al.. [73].
Cell-penetrating peptide Amino acid sequence
TAT49−57 RKKRRQRRR
Polyarginine RRRRRRRRR
R9F2 RRRRRRRRRFF
Decalysine KKKKKKKKKK
Penetratin RQIKIWFQNRRMKWKK
Transportan GWTLNSAGYLLGKINLKALAALAKKIL
HIV-Tat derived PTD4 YARAAARQARA
Hepatitis B Virus
Translocation Motif (TLM)
PLSSIFSRIGDP
mPrP1−28 MANLGYWLLALFVTMWTDVGLCKKRPKP
POD GGG(ARKKAAKA)4
pVEC LLIILRRRRIRKQAHAHSK
ARF1−22 MVRRFLVTLRIRRACGPPRVRV
EB1 LIRLWSHLIHIWFQNRRLKWKKK
Rath TPWWRLWTKWHHKRRDLPRKPE
CADY GLWRALWRLLRSLWRLLWRA
Histatin 5 DSHAKRHHGYKRKFHEKHHSHRGY
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1.2.3 In vivo half-life
Peptides are intrinsically subject to proteolytic cleavage at amide bonds, which often
leads to short in vivo half lives. This severely limits the administration route, whereby
peptides delivered orally to a patient are subject to the acidic conditions and peptidase-
rich environment of the digestive system. Additionally, uptake of peptides through the
gastrointestinal tract is particularly poor due to poor penetration of the mucosal mem-
brane [82]. To begin addressing these issues in early stage drug discovery, researchers have
adopted multiple strategies applicable to both peptide and protein therapeutics. The ad-
dition of D-amino acids at the N- and C- terminals of a peptide can improve the half-life
of the peptide in serum [83, 84]. These can also be incorporated at cleavage ’hotspots’ to
further protect peptides from proteolysis. Furthermore, ’retro-inverso’ peptides, in which
the entire L-peptide is substituted for a mirrored D-amino acid-containing sequence, have
been shown to resist proteolysis [85, 86]. However, as noted by Li et al.. these peptides
do not always yield inhibitors that are able to bind the target protein [87].
Another commonly explored technique within the biologics field is the use of human
serum albumin (HSA)-targeting moieties, which serve to increase the plasma half-life of
the biological agent (reviewed extensively in [88]). This strategy has been effective for
different classes of biologics such as DARPins [89] and bicyclic peptides [90], which would
otherwise be cleared rapidly in vivo. A further example, includes the use of fatty acid
chains to improve the serum half life of the glucagon-like peptide-1 receptor agonist, Li-
raglutide [38, 91]. The C16 fatty acid, incorporated from a lysine sidechain is able to bind
to HSA at one of its seven fatty acid binding sites (Figure 1.3) [92], therefore increasing
its retention in the plasma and decreasing its clearance.
1.2.4 Macrocyclic peptides
Macrocyclisation, also commonly known as stapling or constraining, in the context of a
peptide refers to the bridging of two or more amino acids with a chemical moiety to con-
form and constrain the peptide towards its bioactive conformation. Compared to other
peptide modifications, macrocyclisation has now formed its own field of research and in-
cludes a variety of different cyclisation strategies (reviewed in [93]). Macrocyclisation is
generally categorised into one-component (two reactive groups within one molecule) or
two-component techniques (two or more molecules that react with each other). Side-
chain lactamisation [94], Cu(I)-catalysed azide-alkyne cycloadditions (CuAAC) [95, 96],
and ring-closing olefin metathesis (RCM) [97] can be used in one-component macrocyclisa-
tion techniques. However, these reactions also form the basis of two (or more)-component
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Figure 1.3: Fatty acid binding sites of human serum albumin (HSA). HSA shown car-
toon as cartoon representation in green and decanoic acid shown as spheres in magenta.
PDB: 1E7E [92].
techniques, thereby increasing the chemical space that can be explored [98–101]. Each of
these strategies provide different physical and geometrical properties to the constraining
macrocycle and it is not necessarily clear which strategy is best for a given PPI system,
particularly in the context of non-helical peptides.
One major advantage of these macrocyclisation strategies is the increased in vitro
stability of the constrained peptide versus the native or non-cyclised peptide [102, 103].
Resistance to proteolysis is likely due to the shielding of cleavable amide bonds by the
staple itself and/or the induced conformation. In the context of p53-hydrocarbon sta-
pled peptides targeting Mdm2/MdmX, the macrocycle has a two-fold effect. On the one
hand, the peptides are resistant to proteolysis and the other hand the staple mediates cell
permeability [104–106]. The uptake mechanism of these peptides is thought to involve
endocytotic pathways, although the exact mechanism is not fully understood. It is be-
lieved that the aliphatic hydrocarbon staple is crucial for uptake, since non-metathesised
peptides are not cell permeable (Dr. Christopher Brown, A*STAR, personal communica-
tions). The success of macrocyclisation strategies in peptide therapeutics is highlighted
by the development of stapled peptides that targets the interaction of Mdm2/MdmX and
p53, ATSP-6924 (Aileron therapeutics), which is currently in Phase 1b/2a clinical trials
for the treatment of small cell lung cancer and solid tumours [51–54].
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1.2.5 The future of peptide therapies
Targeting protein-protein interactions provides a significant challenge due to the complex
nature of the interactions and their regulation. Although small molecules often fulfil the
category of cell permeability and target binding, their smaller binding interfaces and there-
fore antagonism of the problematic interaction can be limited and the molecule is therefore
not efficacious. In addition, finding suitable molecules in small molecule libraries, which
contain bias towards protein-ligand interactions often results in poor quality hits. While
fragment-based drug design offers an alternative to tackling this issue, it is by no means
simple to do so and the protein systems must be amenable to the methods used for these
studies, such as X-ray crystallography and NMR, which is not always feasible for a given
target.
Peptides, with their larger interfaces, compared to small molecules mitigate this initial
issue. However, the many challenges that still face small molecules of affinity, efficacy,
tissue targeting and half-life to name a few are still relevant to peptides. However, I
strongly believe that as new technologies are introduced and are applied within the peptide
therapeutic field such as those already mentioned in previous sections, will drastically
improve the number of intracellular and extracellular targets that peptide therapies can
be applied to. While it may still be a number of years till we see a breakthrough that can
be applied more universally, I have no doubt that it will come.
1.3 Tandem-repeat proteins in oncology
Repeat proteins comprise approximately one-third of all proteins within the genome [107,
108]. Solenoids and toroids are two major subclasses, defined by their open-ended and
closed structures, respectively, which are composed of multiple repeats of small structural
units (typically 20-40 residues repeated multiple times in tandem) [109, 110]. Members
of these two classes have a multitude of functions within organisms, including scaffolds
of catalytic complexes (e.g. PR65 [111] and Tankyrases [112]) and transcription factors
(e.g. β-catenin [113, 114]). However, in many disease states, the deregulation of these
repeat proteins causes an increase in the expression of oncogenes [113]. In contrast,
overexpression of the ankyrin-repeat protein, Gankyrin, leads to the increased degradation
of the retinoblastoma and p53 tumour suppressor proteins [115–117]. For many of these
tandem-repeat proteins, small molecule therapeutics are unlikely to yield suitable drug
candidates due to the intrinsically flat surfaces through which these proteins interact with
their binding partners. The remainder of this chapter will focus on two tandem-repeat
proteins involved in oncogenic processes, Tankyrase and the APC/CCdc20.
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1.4 Tankyrase
Tankyrases (TNKS) belong to a family of enzymes known as poly-ADP-ribose polymerases
(PARPs). Small molecule inhibitors are readily explored due to the intrinsic ’druggability’
of these active sites. However, targeting PARP domains comes at a cost of specificity
leading to off-target activity due to the similarity of ligand binding sites between family
members [112]. It is also clear that normal function and disease pathology of some PARP
proteins can be independent of PARP function and so there is a need to target these
proteins through an alternative strategy. Aberrant TNKS activity is implicated in many
disease states, ranging from cancer [118–120] and diabetes [121, 122] to rarer disorders
such as cherubism [123, 124].
1.4.1 Tankyrase structure
HPS
ARC1 ARC5ARC4ARC3ARC2
ARC1 ARC5ARC4ARC3ARC2
TNKS1
TNKS2
SAM PARP
SAM PARP
1 173 961 1090 1327
1 1164936776
Figure 1.4: Domain structure of Tankyrase 1 (TNKS1) and Tankyrase 2 (TNKS2).
TNKS1 contains a unique HPS domain. Both proteins contain an ANK domain con-
sisting of five so-called ankyrin repeat clusters (ARCs), a sterile alpha motif (SAM)
domain and a catalytic PARP domain. All ARCs, excluding ARC3 (grey) are able
to bind substrate proteins. Approximate domain boundaries are highlighted for both
Tankyrase proteins. Not all start and ends of boundaries have been included for each
domain for clarity. Schematic of the x-ray crystal structure of TNKS2 ARC4 (PDB
ID: 5BXO) is also shown.
Within the human genome, there are two TNKS proteins, TNKS1 and TNKS2 (Figure
1.4). Both proteins share high sequence homology and structural domains. TNKS1 is
unique as it contains a Histidine Proline Serine-rich (HPS) region at its N-terminus. Both
proteins share an ANK domain comprising five ankyrin repeat clusters (ARCs), a SAM
domain involved in self-oligomerisation and a PARP domain at the C-terminus. Each
of these shared domains has high homology, with 83%, 74% and 94% sequence identity
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Figure 1.5: Reaction schematic for enzymatic mono-ADP ribosylation of substrate
proteins. Mono-ADP ribosylation occurs on substrate aspartic and/ or glutamic acid
residues. Mono-ADP-ribosylated are further elongated by the PARP domain.
between the ANK, SAM and PARP domains, respectively [125]. The role of the HPS
domain remains unknown to date, although it is expected to be intrinsically disordered
[126]. The SAM domain is known to modulate TNKS oligomerisation [127, 128], but until
recently its exact function was still largely ambiguous. More recent work by the Guettler
laboratory defined the SAM domain as crucial in the formation of localised signalling
puncta [129]. TNKS1 and TNKS2, also known as PARP-5a and PARP-5b, respectively
PARylate substrate proteins through the reaction depicted in Figure 1.5.
1.4.2 Tankyrase cellular function and signalling
Tankyrase substrates are recruited to ARCs 1, 2, 4, and 5 through their short linear mo-
tifs (SLiMs). Early work from Sbodio and Chi described a minimal hexapeptide motif
of RxxPDG (where x represents any amino acid) that was derived from Nuclear Mitotic
apparatus protein 1 (NuMA) that was reported to bind the ARC domains [130]. An op-
timised motif was reported by Guettler et al.., which comprises an eight-residue peptide
(REAGDGEE) that bound the ARC domains with approximately 10-fold higher affinity
[131]. All peptides bind in a largely conserved surface of the ARCs, in which the canonical
contacts are defined by the guanidino group of Arg1 binding the ’arginine cradle site’. In
addition, Gly6 is wedged between the sidechains of Tyr or Phe that form pi − pi stacking
interactions (Figure 1.6).
PARylated substrates of TNKS are recognised by RING finger protein 146 (RNF146),
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Glycine 
sandwich
Arginine
cradle
Figure 1.6: Canonical binding of the IRAP peptide to TNKS1 ARC2, described by
Arg1 sitting in the arginine cradle site and Gly6 situated between Tyr379 and Tyr412.
Arginine cradle and glycine sandwich are highlighted in the dashed box. PDB ID:
5JHQ [126].
an E3 ubiquitin ligase that specifically binds the iso-ADP-ribose moiety of the poly-ADP-
ribose chain and ubiquitinates the substrate, leading to its subsequent degradation by the
26S proteasome [132]. Interestingly, TNKS regulate themselves by autoPARylation re-
sulting in their ubiquitination by RNF146 and downstream degradation [122, 133]. More
recently it was discovered that RNF146 binds to Tankyrase at the substrate-binding sites
via up to four non-canonical SLiMs [134]. These sequences contain either one or two extra
amino acids between positions 1 and 4 of the canonical binding peptide. Currently, it is
not understood whether all four sequences are used for binding TNKS or if the interaction
is of biological relevance. However, if such interactions do occur, the presence of a ternary
complex containing TNKS, RNF146 and TNKS substrates may provide an explanation
for PARP-independent substrate degradation.
Tankyrases have roles in several cellular pathways including the regulation of glucose
uptake [121], telomere maintenance [130, 133], DNA repair [133, 135], and cancer (re-
viewed in [112, 136], and references therein, see Figure 1.7). The interaction between
TNKS and Axin1 (the most studied of the Axin isoforms) within the WNT signalling
pathway has garnered the most attention in the oncology field. This is due to its pivotal
role in the formation of the β-catenin destruction complex, where Axin1 is a limiting
factor in the destruction complex formation. Axin1 binds to TNKS through two non-
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Figure 1.7: Overview of normal cellular processes and disease pathologies associated
with TNKS function. (a) Tankyrase 1 (TANK1) PARylates telomeric repeat binding
factor 1 (TRF1) resulting in its degradation by the 26S proteasome. Telomerase can
then access and extend the telomere. (b) TANK1/2 PARylate Axin1 resulting in its
ubiquitination and degradation by the 26S proteasome, allowing β-catenin to translo-
cate to the nucleus and activate the transciption of downstream oncogenes. (c) TANK1
PARylates NuMA among other mitotic proteins. (d) TANK1 PARylates 3BP2 target-
ing it for proteasomal degradation resulting in normal downstream function. Mutations
in 3BP2 blocking PARylation result in a lack of degradation and lead to cherubism.
Figure adapted from Riffel et al.. [112].
identical, canonical SLiMs in its N-terminal region (residues 1-80), as seen in the X-ray
crystal structures of mTNKS1 ARC2-3 and mAxin1 1-80 [118].
Small-angle X-ray scattering (SAXS) in and X-ray crystallography data of provided
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further structural insights between the ARC domains and Axin [126]. In the context
of the full-length ANK domain (ARCs 1-5), Axin1 binds preferentially to ARC2 and
ARC5 simultaneously. It was demonstrated that shortening the linker regions between
the two canonical tankyrase-binding peptides of Axin1 can induce binding between adja-
cent ARC1 and ARC2 or ARC4 and ARC5 domains. These findings suggest the length of
the linker between two SLiMs of a single TNKS substrate could be functionally relevant.
Lastly, conformational changes in the TNKS ANK domain were observed as a result of
binding Axin1, though it is not yet understood if this is relevant to its PARP activity [137].
Tankyrases, in addition to other PARP domain-containing proteins, have been the sub-
ject of multiple drug-discovery campaigns in both academia and the pharmaceutical indus-
try. Inhibition of the catalytic activity of PARP domains is a highly attractive therapeutic
strategy such as that of PARP1 in BRCA1/2 malignancies [138, 139]. PARP1 is highly
involved with the sensing of DNA single-stranded breaks, which is a hallmark of genome
instability that is often associated with cancers [140]. Inhibition of PARP1 has been a
major focus for pharmaceutical companies and has resulted in a large number of molecules
being produced preferential for PARP1, such as Olaparib (AZD-2281, AstraZeneca) and
Veliparib (ABT-888, AbbVie) among many others listed in references [112, 141]. Most
TNKS PARP inhibitors target either the nicotinamide-binding site (XAV939 [120, 142])
or the adenosine-binding site (IWR-1 [143], G007-LK [144], WIKI4 [145]), and some in-
hibitors are able to target both (PJ34 [142], Long quinazolinone [146]). The molecular
mechanism or therapeutic strategy between targeting different PARPs is very different
owing to the varying functions of individual PARP domain-containing proteins. How-
ever, the substrate binding domains have often been neglected. This is largely due to
the binding interface being large, flat and extended, classifying it as ’undruggable’ by
small molecule therapeutics. To date, targeting the ARC domains has been explored by
fragment-screening [147] and macrocyclised peptide approaches [102], of which the latter
resulted in the most potent inhibitors.
1.5 Anaphase Promoting Complex/Cyclosome
The discovery of the Anaphase Promoting Complex/Cyclosome (APC/C) was reported
independently by Sudakin et al.. and King et al.. in 1995 [148, 149]. They were the first
to identify the large multi-protein complex of approximately 1.5 MDa as an E3 ubiquitin
ligase that ubiquitinates cyclin B in mitosis, thereby mediating its proteasomal degrada-
tion. Since its discovery, significant technological advances have enabled researchers in
the field to gain structural insights that underpin APC/C function as a master regulator
of the cell cycle.
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1.5.1 Structure of the APC/C
The groups of David Barford and Brenda Schulman have focused on gaining a structural
and mechanistic understanding of the APC/C using X-ray crystallography, negative-stain
electron microscopy and cryogenic electron microscopy (Cryo-EM) [28, 150–154]. The core
APC/C comprises a total of 19 subunits [155], of which 14 are unique and five are present
as dimers (Table 1.2). An illustration of the molecular architecture of the APC/CCdh1
is shown in Figure 1.8; in general the APC/C is subdivided into the Platform, the TPR
(tetratricopeptide repeat) lobe, which enclose the catalytic and substrate binding subunits
at its centre. The co-activator subunits (Cdc20/Cdh1), which interact with subunits in the
TPR lobe, are responsible for recruiting substrates for ubiquitination by the E2 enzymes.
Ube2C adds the initial ubiquitin monomer [156], while Ube2S is primarily responsible
for ubiquitin-chain elongation via K11-linkages [157]. Ubiquitin chain branching is also
catalysed by Ube2C [155].
Table 1.2: Subunits comprising the APC/C. Abbreviations: IR-tail - Isoleucine-
Arginine tail motif, MCC - Mitotic Checkpoint Complex, PC - Proteasome/cyclosome
repeat, TPR - Tetratricopeptide repeat, RING - Really Interesting New Gene. Table
adapted from [155].
Subunit Mass (kDa) N Function Location Domains
Apc1 216.4 1 Scaffolding Platform WD40, mid-helix, PC
Apc4 92.1 1 Scaffolding Platform WD40, four helix bundle
Apc5 85.1 1 Scaffolding Platform N-terminal helical
domain, 13 TPR
Apc3 91.9 2 Scaffolding TPR lobe 14 TPR
Apc6 71.7 2 Scaffolding TPR lobe 14 TPR
Apc7 66.9 2 Scaffolding TPR lobe 14 TPR
Apc8 68.8 2 Scaffolding TPR lobe 14 TPR
Apc12 9.8 2 TPR-accessory TPR lobe α-helix
Apc13 8.5 1 TPR-accessory TPR lobe α-helix
Apc16 11.7 1 TPR-accessory TPR lobe α-helix
Apc2 93.8 1 Catalytic Catalytic module Cullin
Apc11 9.8 1 Catalytic Catalytic module RING
Apc10 21.2 1 D-box recognition Substrate binding IR-tail
Apc15 14.3 1 MCC interaction Platform α-helix
APC/C 1167.4 19 - - -
Both co-activator proteins (Cdc20 and Cdh1) bind to the same site on the APC/C,
whereby a region of their respective N-terminal intrinsically-disordered regions (IDRs)
associates with both Apc1 and Apc8, becoming partially structured [150, 151, 159, 160].
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Figure 1.8: Cryo-EM model of the APC/CCdh1-Hsl1 ternary complex at 7.4 Å res-
olution. (a) Front, (b) back and (c) Bottom views of the APC/C. Substrate binding
and ubiquitination occurs in the space framed by the Apc2, Apc10 and Cdh1/Cdc20
triad. Figure adapted from [158].
The so-called C-box motif buries into a pocket in Apc8 in a loop conformation (Figure
1.9a). Two other regions of the N-terminal IDR adopt α-helical structures, Helix 1 and
Helix 2, that bind the interface between Apc1 and Apc8, and the surface of Apc1, re-
spectively (Figure 1.9b). In addition to the N-terminal domain, both Cdc20 and Cdh1
share a conserved isoleucine-arginine dipeptide motif (IR-tail), which binds to Apc3 in a
region that is structurally homologous to the C-box binding site of Apc8 (Figure 1.9c)
[150, 151, 161, 162].
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(a) Cdc20 C-box motif
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Figure 1.9: Co-activators bind to the APC/C using conserved motifs contained in
their N- and C-terminal regions. (a) The Cdc20 C-box motifs forms a tight loop
configuration burying R78 and Y79 into a groove formed by Apc8. (b) Cdc20 α-helices
(magenta, cartoon and stick representations) bind to sites formed by Apc1 (orange,
surface) and the interface between Apc1 and Apc8 (cyan, surface). (c) The Cdc20
IR-tail binds the structurally homologous site of Apc3 (lime green, surface). Images
were generated from PDB:5LCW [151].
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1.5.2 Cell cycle regulation by the APC/C
The APC/C temporally regulates various cell cycle proteins by ubiquitination leading to
their subsequent proteasome-mediated degradation (Figure 1.10) [163]. The APC/C is
able to exert its E3 ligase activity via its co-activator proteins that recruit substrates
through three principal peptide sequences, known and hereby referred to as degrons: the
Destruction box (D-box), Lysine-Glutamate-Asparagine-box (KEN-box) and ABBAmotif
[164–167], which are further discussed in Chapter 5. Identification of APC/C substrates
and their degrons is a very active field of research, and their numbers are steadily increas-
ing. A repository containing all known APC/C substrates has been collated by Davey
and Morgan [168, 169].
Figure 1.10: The APC/C regulates the cell cycle through ubiquitination and
proteasome-mediated degradation of cell cycle proteins. Figure adapted from Zhou
et al.. [163].
Prior to the onset of the mitosis, Cdc20 is phosphorylated by Cyclin-dependant kinase
1 (Cdk1), which initiates the association of Cdc20 with the APC/C and thereby activation
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Figure 1.11: The structural basis for MCC-mediated inhibition of the APC/CCdc20.
(a) Overall architecture of the MCC bound to the APC/CCdc20. (b) The BubR1 subunit
of the MCC binds to Cdc20 molecules within both the MCC and the APC/C using
pseudo-degron peptides (indicated by red arrows). Figures produced using PDB:5LCW
[151].
of the APC/CCdc20 [170, 171]. The APC/CCdc20 remains active, degrading Nek2A [172]
and Cyclin A [154], until the spindle is correctly aligned and kinetochores are correctly
attached to sister chromatids in pro-metaphase. The APC/CCdc20 is tightly regulated un-
til the spindle assembly checkpoint (SAC) is satisfied, after which degradation of Cyclin
B1 and securin occurs allowing the cell to proceed from metaphase into anaphase [163].
After the SAC arrest, the APC/CCdc20 is inhibited by the Mitotic Checkpoint Complex
(MCC), which contains BubR1, Cdc20 and Mad2A [160, 173]. Alfieri and co-workers
determined the structure of the APC/C engaged with the MCC (APC/CMCC), providing
evidence for the molecular mechanism by which the MCC inhibits the APC/CCdc20 [151].
BubR1 interacts with the APC/C-bound Cdc20 while simultaneously engaging MCC-
bound Cdc20. This interaction across both complexes is mediated by pseudo-degron mo-
tifs in BubR1 that encompass two D-box, two KEN-box and two ABBA motif peptides
(Figure 1.11). Cdc20 is auto-ubiquitinated in an Apc15-mediated interaction, and re-
placed by de-phosphorylated Cdh1 in the remainder of mitosis [174–176]. The APC/CCdh1
maintains low levels of Cdc20 until S-phase by targeting it for ubiquitination to prevent
premature mitotic entry [177].
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1.5.3 APC/C in oncology
Although temporal regulation of Cdc20- and Cdh1-bound APC/C is tightly regulated
in healthy cells, the opposite occurs in the vast majority of cancer cells. APC/CCdh1
provides tumour suppressive functions, e.g. by inhibiting premature mitotic entry, and
hence Cdh1 is often found to be down-regulated in cancers [163]. However, Cdc20 drives
mitotic entry and therefore is often found to be up-regulated at the mRNA and protein
levels of patients with a wide variety of cancers, which include those listed in Figure 1.12
and several more [178–185]. Such widespread upregulation of the Cdc20 across multiple
cancer tissues implies necessity of its function to cancer progression. Indeed its overex-
pression has already been implicated in poor prognosis for patients with colorectal cancer
[181], breast cancers [186], cutaneous squamous cell carcinomas [187] and various solid
tumours [182]. In addition, many of these reports indicate that Cdc20 may prove to be a
valuable biomarker for the diagnosis of these diseases. While most studies have focused
on the relative levels of Cdc20, none have attempted to identify whether the CDC20 gene
is particularly prone to mutation that can cause loss or gain of function. To investi-
gate this, clinical datasets from The Cancer Genome Atlas (TGCA, [188], the Catalogue
Of Somatic Cancer Mutations in Cancer (COSMIC, [189]) and the International Cancer
Genome Consortium (ICGC, [190] were analysed using BioMuta version 4.0 [191] for the
search query of the CDC20 and TP53 genes, focusing of hotspot or frequently mutated
residues (Figure 1.13.
Of particular importance to note, the TP53 is commonly known to be mutated in
many cancers and this can be clearly observed in Figure 1.13b [192]. In stark contrast,
paying particular attention to the scale of y-axis, i.e. the frequency of variations found in
cancer patients, the CDC20 gene is far less commonly mutated when comparing the same
datasets (Figure 1.13a). It is difficult to evaluate whether the frequency of mutations
seen in CDC20 are truly relevant to the the progression of oncology. However, it appears
that R445 has a tendency to mutate to either glutamine or tryptophan in these samples.
R445 lies within the WD40 domain, and so it was hypothesised whether this mutation
might be directly linked with degron binding. All the residues mapped in Figure 1.13a
were then subsequently mapped onto the crystal structure of human Cdc20 bound to a
Bub1B-derived KEN-box peptide shown in Figure 1.14 [193]. R445 maps directly to a in-
termolecular hydrogen bond from the Arginine 445 side chain to the conserved Glutamic
acid carbonyl and Aspargine carboxamide group on the side chain. It is possible that
mutation of R445 to Q or W could be detrimental, but it could also be beneficial. How-
ever, given that there is no further literature to suggest that the R445Q/W mutations is
functionally relevant to the activity of the APC/CCdc20 in its ubiquitination of substrates
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Figure 1.12: Overexpression of Cdc20 from cDNA microarray analysis. Levels are
relative between tumourigenic tissue (T) and non-tumourigenic tissue (N) across the
various tissue types. Figure adapted from Kidoro et al. [178].
mediated by the KEN-box degron, further speculation is severely error prone. The lack
of hotspot mutations in CDC20, in comparison to the TP53 gene, is perhaps unsurpris-
ing. One must consider that p53 acts as a tumour suppressor protein and so mutation
of this function can result in oncogenesis. Conversely, wild-type Cdc20 is itself a driver
of mitosis and thus simple overexpression is sufficient to drive oncogenesis. In addition,
it makes very little sense to knockout any degron binding sites as the ubiquitination and
proteasomal degradation of substrates is a crucial factor in the progression of the cell cycle.
Despite its pivotal role in many cancers, very few inhibitors against the APC/CCdc20
exist, none of which are in clinical trials or are approved drugs at present. To date, only
two compounds, Apcin and TAME (and its pro-drug analog, proTAME), were identified
as competitive inhibitors against the APC/CCdc20 (Figure 1.15). They were originally
discovered in a high-throughput screen comprising 109,113 molecules, that monitored the
drug-induced stabilisation of a Cyclin B1 (2-97)-luciferase reporter in Xenopus extracts
as a readout of the inhibition of mitotic exit [197]. While the original article describing
the discovery of these compounds include Apcin and TAME (referred to as the Class
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R445Q/W
(a) CDC20
(b) TP53
Figure 1.13: Frequency plot of mutations occuring in the (a) CDC20 (Uniprot ID:
Q12834) and (b) TP53 (Uniprot ID: P04637) genes from clinical datasets of human
cancers [188–190]. Figures generated using BioMuta version 4.0 [191].
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R445
E27
N28
Figure 1.14: Somatic mutation of R445Q/W may result in altered binding to sub-
strate proteins containing KEN-box degron motifs. Cdc20 in grey (mutations are high-
lighted in green according to Figure 1.13a, and the Bub1B KEN-box peptide bound to
Cdc20. E27 carbonyl and N38 carboxamide form intermolecular H-bonds with R445.
PDB: 4GGD, [193].
Apcin TAME proTAME
CPV5
Figure 1.15: Structures of current validated APC/CCdc20 inhibitors. Apcin competes
for the D-box binding site of Cdc20 and TAME/proTAME competes for the C-box and
IR-tail binding sites on Apc8 and Apc3[28, 194, 195]. The PROTAC molecule CPV5
has also shown efficacy in vivo to reduce tumour size in mouse xenograft models [196].
IIA compounds), the authors focus is rather towards the Class IIB compounds that they
describe, which were not designated as Cyclin B1 ubiquitination inhibitors. The mecha-
nisms of action for Apcin and TAME remained unknown for several years following their
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discovery. Further investigation revealed TAME to compete for co-activator (Cdc20 and
Cdh1) binding to the APC/C [194, 198]. TAME in it’s active form is not cell permeable
and it therefore the proTAME derivative was made containing N,N’-bis(acyloxymethyl
carbamate) groups, which can be cleaved by intracellular esterases [194]. However, since
these broad specificity esterases also exist in the serum, proTAME will be modified before
it reaches the intracellular space, posing a major problem for the molecule. The second
molecule, Apcin was shown to be a competitive inhibitor for the D-box degron-binding
site of Cdc20 (with limited binding to Cdh1) [195]. The functional activity of Apcin
is however not so straight forward and its effects can produce mitotic arrest, but also
increase the rate of mitosis under high SAC activity [199]. However, the use of both
Apcin and proTAME in combination, have a synergistic effect on the inhibition of mitotic
exit due to their alternative inhibitory mechanisms [195]. One recent study developed a
proteolysis targeting chimera (PROTAC) molecule, CP5V, by coupling Apcin to a Von-
Hippel Lindau (VHL) ligand using a five-membered polyethylene glycol (PEG)5 linker.
In response to CP5V treatment, degradation of Cdc20 was observed in multiple cancer
cells lines, and tumour sizes were reduced in 4T1 xenograft mouse models [196]. Even
though CP5V is provides evidence that degradation of Cdc20 is promising as a mode of
therapeutic intervention, the failure rate of compounds reaching and succeeding in clinical
trials is high. Due to the poor efficacy of Apcin as a monotherapeutic agent, issues with
cell permeability of TAME/proTAME, and the lack of ligand diversity available for use
in PROTACs such as CPV5, the development of novel molecules is desperately needed to
pave the way towards new therapeutic agents that are required across a large number of
cancers where Cdc20 activity is high.
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1.6 Project aims and objectives
The inhibition of protein-protein interactions (PPIs) in biological systems has presented
a challenge to small molecule drug campaigns. In the context of cancer, targeting these
interactions has been largely unmet and requires alternative strategies. Two such targets
are Tankyrase and the APC/CCdc20, and a major goal of my doctoral studies was to design
peptides that could function as inhibitors of these proteins.
The work encompassing the development of Tankyrase inhibitory peptides was built
upon previous work performed by Dr. Wenshu Xu in the Itzhaki laboratory. Although
peptides of sub-micromolar affinities had already been obtained and cell permeability had
been achieved, their cellular efficacies required improvement. Therefore, the main aim of
the Tankyrase sub-project was to develop peptides with higher affinities. To achieve this
aim, both the consensus sequence and the macrocycle positions required further optimi-
sation (Chapter 3).
The main focus of the PhD, was to target the APC/CCdc20’s oncogenic activity. The
aims of the project were to:
1. Design and synthesise peptides to bind the E3 ubiquitin ligase APC/CCdc20,
2. Characterise the binding of the peptides to Cdc20 using biophysical methods,
3. Investigate their inhibitory function in a biological context.
Structure-based drug design and consensus analyses in combination with various mod-
elling approaches formed the basis of the design process (Chapter 5). Given the vast
chemical space that can be explored within peptide chemistry, it was logical to also em-
ploy macrocyclisation and the incorporation of non-natural amino acids. In order to
characterise Cdc20-peptide interactions and thereby understand the structure-activity re-
lationship, it was necessary to express and purify recombinant Cdc20 (Chapter 4) and
establish biophysical assays that could probe the interactions (Chapter 6). The aim was
to test the inhibitory function of lead peptides using in vitro ubiquitination assays (in
collaboration with David Barford, MRC-LMB) and cellular assays to examine the inhi-
bition of mitosis (in collaboration with Catherine Lindon, Department of Pharmacology,
University of Cambridge). However, due to time constraints these experiments were not
conducted prior to submission of the thesis.
Chapter 2
General materials and methods
2.1 Buffers and reagents
All chemicals were purchased from Sigma-Aldrich, Thermo Fisher Scientific or Merck,
unless otherwise stated. Oligonucleotides for cloning were purchased from either Sigma-
Aldrich or Integrated DNA technologies (IDT). All molecular biology enzymes were pur-
chased from New England Biolabs (NEB) or Thermo Fisher Scientific. Molecular grade
agarose was purchased from Bioline. 2x Yeast-Tryptone (2xYT) powder was purchased
from Formedium. All chromatography columns were purchased from GE Healthcare.
Polyethersulfone (PES) centrifugal concentrators were purchased from Sartorius Stedim.
All primary antibodies were puchased from Cell Signalling Technologies (CST) and sec-
ondary antibodies from DAKO. General buffers and stock solutions are listed below. All
solutions were prepared using MilliQ H2O (18.2 MΩ/cm), unless otherwise stated. Vectors
and E. coli strains used are listed in Tables 2.1 and 2.2, respectively.
• Ampicillin: 100 µg/mL, sterile filtered.
• Kanamycin: 50 µg/mL, sterile filtered.
• Chloramphenicol: 34 µg/mL in ethanol.
• Ethylenediaminetetraacetic acid (EDTA): 0.5 M, pH 8.0 (adjusted with NaOH),
sterile filtered.
• Isopropyl-β-D-thiogalactoside (IPTG): 1 M, sterile filtered.
• Dithiothreitol (DTT): 1 M, sterile filtered.
• Tris(2-carboxyethyl)phosphine (TCEP): 0.5 M, pH 7.0 (adjusted with NaOH), ster-
ile filtered.
• P2 buffer: 200 mM NaOH and 1% (w/v) sodium dodecyl sulfate (SDS)
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• N3 buffer: 4.2 M guanidinium hydrochloride and 0.9 M potassium acetate (KOAc),
pH 4.8 (adjusted with glacial acetic acid).
• DNA wash buffer: 10 mM Tris-HCl, 80 % (v/v) ethanol, pH 7.5
• Lysogeny broth (LB): 25 g/L, autoclaved 121◦C, 15 minutes.
• 2xYT: 31 g/L, autoclaved 121◦C, 15 minutes.
• LB-Agar: 35 g/L, autoclaved 121◦C, 15 minutes. Appropriate antibiotics added
when cooled below 50◦C, if required.
• Transformation buffer I (TfbI): 30 mM KOAc, 100 mM RbCl, 10 mM CaCl2, 50
mM MnCl2, 3 mM [Co(NH3)6]Cl3 and 15% (v/v) glycerol, pH 5.8 (adjusted with
glacial acetic acid). Sterile filtered.
• Transformation buffer II (TfbII): 10 mM 3-(N-morpholino)propanesulfonic acid (MOPS),
10 mM RbCl, 75 mM CaCl2 and 15% (v/v) glycerol, pH 6.5 (adjusted with KOH).
Sterile filtered.
• Tris-acetate-EDTA (TAE) buffer: 40 mM Tris base, 1 mM EDTA, (adjusted with
5.71 mL glacial acetic acid). Sterile filtered.
• Separating gel buffer: 1.5 M Tris-HCl and 4% (w/v) SDS, pH 8.8.
• Stacking gel buffer: 0.5 M Tris-HCl and 4% (w/v) SDS, pH 6.8.
• 2× SDS PAGE loading buffer: 100 mM Tris-HCl, 4% (v/v) SDS, 0.2% (w/v) bro-
mophenol blue, 30% (v/v) glycerol and 715 mM β-mercaptoethanol, pH 6.8.
• Tris-Glycine-SDS (TGS) buffer: 25 mM Tris base, 192 mM glycine and 1% (w/v)
SDS, pH 8.8.
• Transfer buffer: 25 mM Tris base, 192 mM glycine, 20% (v/v) MeOH, pH 8.4
• Phosphate-buffered saline (PBS): 8 mM Na2HPO4, 2 mM KH2PO4, 137 mM NaCl
and 2.7 mM KCl, pH 7.4.
• Phosphate-buffered saline-Tween20 (PBST): 8 mM Na2HPO4, 2 mM KH2PO4, 137
mM NaCl, 2.7 mM KCl and 0.1% (v/v) Tween 20, pH 7.4.
• Western blot blocking buffer: 5% (w/v) Marvel non-fat dry milk powder in PBST.
• Coomassie brilliant blue G-250: 80 mg/L, add 3 mL concentrated HCl.
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Vector Resistance Description Source
pRSET Ampicillin High-copy number vector encoding for
N-terminal His6-tagged recombinant
proteins, with a thrombin cleavage
site between His6-tag and recombi-
nant protein. Expression controlled
by the T7 promoter.
Itzhaki lab
pRSET-TEV Ampicillin As above, except thrombin cleavage
site is replaced by a tobacco etch virus
(TEV) protease cleavage site.
R.S. Eapen
pGST Ampicillin As pRSET, except His6-tag is replaced
by a glutathione S-transferase tag.
Itzhaki lab
pOWEN Ampicillin Derivative of pOPIN F vector. High-
copy number vector encoding for
N-terminal His6-tagged recombinant
proteins with a thrombin cleavage
site between His6-tag and recombi-
nant protein. Expression of proteins
in E. coli (T7), baculovirus (p10) and
mammalian systems (CAG).
Dr. O.D.
Burbidge
pTriExMOD Ampicillin Modified pOPIN E vector. High-copy
number vector. CAG promoter re-
placed by the human cytomegalovirus
(CMV) immediate early enhancer and
CMV promoter. Expression of pro-
teins in E. coli (T7), baculovirus (p10)
and mammalian systems (CMV).
R.S. Eapen
pET19M Ampicillin Low-copy number vector for bet-
ter control by the lac repressor, for
N-terminal His6-tagged recombinant
proteins with a TEV protease cleav-
age site between His6-tag and recom-
binant protein. Expression is con-
trolled by the T7 promoter.
Rahman lab,
Dept. Phar-
macology
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pU1 Chloramphenicol Derivative of pUCDM vector. High-
copy number vector, with R6Kγ origin
of replication. Designed for expres-
sion of multiple open-reading frames
for downstream baculovirus expres-
sion under control by the p10 or poly-
hedrin promoters.
Barford lab,
LMB [200]
pcDNA3.1(-) Ampicillin Plasmid for expression of constructs in
mammalian cells under control by the
human cytomegalovirus (CMV) im-
mediate early enhancer and CMV pro-
moter.
Invitrogen
Table 2.1: Vectors used for expression in E. coli, baculovirus and mammalian cell
cultures.
Strain Resistance Description Source
DH5α - K-12 strain derivative for routine
molecular cloning. High transfor-
mation efficiency cells purchased,
and chemically competent cells were
propagated in-house.
NEB
C41 (DE3) - BL21 derived for high-level expres-
sion of recombinant proteins. Induc-
tion with IPTG induces the expres-
sion of T7 RNA polymerase.
Kommander
lab, LMB
PIR1 - Used for molecular cloning and
maintenance of plasmids containing
an R6Kγ origin.
Barford
lab, LMB
DH10
MultiBaccre
Ampicillin,
Kanamycin, Tetra-
cyclin, Zeocin
Used to produce Bacmid for insect
cell transfection. Stably expressing
Cre-recombinase for incorporation of
plasmids containing loxP sites into
Bacmid genome.
Barford
lab, LMB
Table 2.2: E. coli strains
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2.2 Molecular cloning
2.2.1 Preparation of chemically competent E. coli
E. coli cells from a master glycerol stock were streaked onto a LB-Agar plate and incubated
overnight at 37◦C. The following day, a single colony of cells was picked into 5 mL 2xYT
broth and cultured overnight with shaking at 37◦C. The following day, 2.5 mL of overnight
culture was diluted into 250 mL of LB medium and incubated at 37◦C until an OD600 of
0.25-0.30 was achieved. The cell culture was split into 50 mL falcons and cooled on ice for
10 minutes. Cell suspensions were pelleted at 4000 × g for 5 minutes and supernatants
were carefully removed. Cell pellets were resuspended and pooled in 50 mL TfbI and
incubated on ice for 5 minutes prior to repeated centrifugation. The supernatant was
removed and the pellet was resuspended in 5 mL of TfbII and incubated on ice for 15
minutes. Competent cells were aliquotted in 50 µL in 2 mL tubes and were stored at
-80◦C until required.
A modified protocol was used for the preparation of DH10 MultiBaccre cells. Cells
were streaked onto a LB-Agar plate with 100 µg/mL ampicillin, 50 µg/mL kanamycin, 10
µg/mL tetracyclin and 25 µg/mL zeocin and grown overnight at 37◦C. The following day,
a single colony was picked into a 5 mL overnight culture with the above antibiotics. The
following day, 2.5 mL of the overnight culture was added into a 250 mL of LB medium,
supplemented with 100 µg/mL ampicillin, 50 µg/mL kanamycin, 10 µg/mL tetracyclin
and 25 µg/mL zeocin. The culture was grown with shaking at 37◦C to OD600 of 0.25
before induction with 1 µg/mL L-arabinose to induce the expression of cre-recombinase
for 1 hour (final OD600 = 0.50) prior to harvesting and chemical competent cell preparation
as described above.
2.2.2 Polymerase chain reaction (PCR) methods
Two main strategies to obtain the desired DNA construct were used throughout the PhD
research. Q5 polymerase (NEB) DNA polymerase was chosen due to its high-fidelity and
high speed of amplification. Primers were designed for exponential amplification of the
PCR product. All primers were designed with the melting temperatures (Tm) of annealing
base pairs to fall between 62-67◦C, which were calculated using an online tool provided
by NEB [201]. In addition, the Tm of all primer pairs were designed to be within 1-2◦C
of each other with the 3’-end base pair ending with cytosine (C) or guanine (G).
Standard restriction endonuclease (RE) cloning
This method was primarily used in the transfer of genes from one vector to another.
Oligonucleotides were designed with restriction enzyme cleavage sites suitable for the
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destination vector at the 5’-end of the primer. PCR reactions were set up in 50 µL reaction
volumes and thermocycling was conducted according to the manufacturers’ instructions.
Round-The-Horn (RTH) mutagenesis
The second methodology, so called Round-The-Horn (RTH) mutagenesis was primarily
used for the addition, deletion or mutation of base pairs at any site within the vector
of interest, as depicted in Figure 2.1. Crucially, this methodology does not require the
use of restriction enzymes, thus unwanted and additional amino acids encoded by the
restriction enzymes are not incorporated into the open reading frame (ORF). All primers
were designed end-to-end at the site of modification. Primers used in this method were
first 5’- phosphorylated using T4 Polynucleotide Kinase (PNK). Oligonucleotides were
dissolved to 100 µM in MilliQ H2O. Phosphorylation reactions were prepared with 2 µL
of 10× PNK Buffer A, 2 µL of 10 mM ATP, 15 µL of 100 µM primer, 1 µL of 10 U/µL
PNK and incubated at 37◦C for 20 minutes followed by heat inactivation at 75◦C for 10
minutes. Phosphorylated primers were then diluted to 10 µM as a working stock solution.
PCR reactions were set up in 50 µL reaction volumes and thermocycling was conducted
according to the manufacturers’ instructions.
2.2.3 Agarose gel electrophoresis
Molecular grade agarose was melted in Tris-Acetate-EDTA (TAE) buffer to an appropriate
weight-to-volume percentage dependant on the separation required. SYBR safe DNA
stain was added to the molten agarose to a 1× final concentration. Gels were loaded
with samples and appropriate base pair ladder(s). Gels were run at 120 V in 1× TAE
buffer for 20-35 minutes depending on the separation required before visualising under a
UV-transilluminator.
2.2.4 Restriction endonuclease digests and ligations
All restriction endonuclease digests were performed using FastDigest (FD) enzymes and
buffer system (Thermo Fisher Scientific) according to manufacturers’ instructions. Prod-
ucts from RTH mutagenesis were incubated with FD DpnI to digest parental vector di-
rectly in the Q5 polymerase buffer. Vectors prepared for insertion of a PCR product were
5’- and 3’- dephosphorylated using Fast Alkaline Phosphatase (FastAP, Thermo Fisher
Scientific) to reduce re-ligation efficiency without the desired insert. Prior to ligation, all
DNA were purified using PCR clean up or gel extraction protocols (Qiagen). DNA liga-
tions were performed using AnzaTM T4 DNA ligase Master Mix (Thermo Fisher Scientific)
with a downscaled protocol from 20 µL to 4 µL reaction volumes at room temperature
for 30 minutes. Ligations with an insert and vector were prepared with a 3:1 molar ratio,
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Gene of interest
Method 1: Standard restriction endonuclease molecular cloning  
Vector A
Gene of interest
Vector B
RE1
RE
2
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R
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PCR, RE digest, ligation
Gene of interest
Vector A
Gene of interest
Vector A
PCR, DpnI digest, ligation
Method 2: Round-The-Horn mutagenesis  
Figure 2.1: Schematic of molecular cloning methods. Method 1: Standard restric-
tion endonuclease (RE) cloning used to transfer genes between two vectors. RE sites
coloured in green and yellow. Method 2: Examples of three primer pairs, used for the
addition (cyan), mutagenesis (green) and deletion (red-dashed) of base pairs.
not exceeding 100 ng of vector. Ligations from RTH PCR did not exceed 100 ng of PCR
product.
2.2.5 Transformation into chemically competent cells
Plasmid DNA (10-50 ng) were used for the transformation of whole plasmids and for the
transformation of ligation reactions, 4 µL (not exceeding 100 ng vector) were used. The
relevant E. coli strain for the downstream application was thawed on ice. Plasmid or
38 General materials and methods
ligation reaction was added to the cells, giving a gentle flick to mix the contents and was
then incubated on ice for 30 minutes. E. coli were heat shocked at 42◦C for 35-45 seconds
before returning immediately to ice for 2 minutes. SOC medium (200 µL, NEB) was
added and cells were recovered at 37◦C, shaking at 800 rpm for 30 minutes (ampicillin)
or 60 minutes (kanamycin and chloramphenicol). The cell suspension was then spread
onto LB-Agar plates with the appropriate antibiotics, using sterile glass beads. LB-Agar
plates were then incubated overnight at 37◦C.
Transformations into DH10 MultiBaccre were performed with a modified protocol. A
50 µL aliquot of DH10 MultiBaccre was thawed on ice and 1 µg of pU1 vector was added.
The cells were incubated on ice for 30 minutes and heat shocked at 42◦C for 40 seconds.
The cells were then placed on ice for 2 minutes before diluting into 6× 0.5 mL of 2xYT
medium. Cells were recovered overnight at 30◦C, shaking at 800 rpm. The following day,
cells were pooled and centrifuged at 500 × g for 1 minute prior to resuspending in 250
µL 2xYT medium. The cell suspension was spread on a LB-Agar plate supplemented
with 100 µg/mL ampicillin, 50 µg/mL kanamycin, 34 µg/mL chloramphenicol, 40 µg/mL
IPTG and 100 µg/mL X-gal. The LB-Agar plate was incubated at 37◦C for approximately
72 hours until positive (blue) colonies were observed.
2.2.6 DNA purification from recombinant source
Plasmid preparation
Single colonies from transformation plates were picked into 5 mL 2xYT medium supple-
mented with the appropriate antibiotics. Cultures were grown overnight at 37◦C, shaking
at 180 rpm. The following day, 2 mL of overnight culture was pelleted in a 2 mL tube.
The supernatant was decanted and the cell pellet was resuspended by vortex in 250 µL
of P1 resuspension buffer (Qiagen) with 100 µg/mL RNase A (Qiagen). P2 buffer (250
µL) was added and tubes were inverted 5 times to mix, followed by the addition of 350
µL of N3 buffer. The resulting suspension was inverted several times to mix thoroughly
prior to centrifugation at 20,000 × g for 15 minutes. The resulting supernatant (700
µL) was applied to a DNA spin column (Expedeon) and spun through, discarding the
flow-through. The spin column was washed with 700 µL DNA wash buffer, discarding
the flow-through. Centrifugation was repeated to remove residual wash buffer. Bound
DNA was eluted using 50 µL of MQ H2O into a 1.5 mL tube. DNA concentrations were
measured using a Nanodrop 2000 (Thermo Fisher Scientific) against a blank of MQ H2O.
Plasmid DNA was stored at -20◦C until required. All plasmids were Sanger sequenced by
Eurofins Genomics before use in downstream experiments.
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Bacmid preparation
A single blue colony from a transformed DH10 MultiBaccre LB-Agar plate was picked into
10 mL of 2xYT medium supplemented with 100 µg/mL ampicillin, 50 µg/mL kanamycin,
34 µg/mL chloramphenicol and grown overnight at 37◦C, shaking at 180 rpm. The fol-
lowing day, cells were pelleted at 7000 × g for 2 minutes, discarding the supernatant. The
cell pellet was resuspended in 500 µL of P1 buffer in a 2 mL tube. P2 buffer (500 µL) was
then added and tube was inverted several times, gently. N3 buffer (700 µL) was added and
the tube was inverted until the suspension was thoroughly mixed before centrifugation
at 20,000 × g for 10 minutes. Bacmid DNA was precipitated by the addition of 1 mL of
ice-cold isopropanol to 1 mL of the resulting supernatant. Precipitated DNA was then
pelleted at 20,000 × g, 4◦C for 5 minutes and the supernatant was carefully removed. The
DNA pellet was washed with 1 mL of 70% (v/v) ethanol and was centrifuged once more
before removing the supernatant. The DNA pellet was allowed to air-dry briefly before
dissolving in 75 µL of MQ H2O. DNA concentrations were measured using a Nanodrop
2000 (Thermo Fisher Scientific) against a blank of MQ H2O. Bacmid DNA was stored
at -20◦C until required. All bacmids were sequenced by Eurofins Genomics before use in
downstream experiments.
2.3 Protein expression and purifications
Methods describing protein purifications for Tankyrase and Cdc20 domains are included
in chapters 3 and 4, respectively. This section describes the expression and purification
of proteins used downstream in the above projects and for collaborative work conducted
on Mdm2, Appendix C. Amino acid sequences for all proteins are provided in Appendix
A.
2.3.1 Analysis of proteins
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE)
Gels were cast using Biorad mini-casting cassettes. Cassettes were constructed with appro-
priate spacers depending on sample load volume. Separating gel solutions were prepared
with separating buffer, MQ H2O, ammonium persulphate (APS), tetramethylethylene-
diamine (TEMED) and the required percentage of acrylamide/ bis-acrylamide solution
(37.5:1 ratio). The gel was cast into the cassette and levelled with a layer of isopropanol
(IPA). Once set, the IPA was removed and residual solvent was dried off. Stacking gel was
prepared with stacking buffer, MQ H2O, APS, TEMED and 5.1 % (w/v) acrylamide/bis-
acrylamide. Stacking gel were added and a 15 or 10-well comb was used to set the wells.
SpectraTM Multicolour Broad Range protein ladder (Thermo Fisher Scientific) was loaded
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on all gels. Gels were run in Tris-Glycine-SDS buffer at 120 V (constant) for 10 minutes
followed by 50-65 minutes at 180 V (constant), depending on the percentage of acry-
lamide. Gels were removed from the glass plates and were washed thrice in hot tap water
to remove SDS from the gel. Gels were then stained in Coomassie brilliant blue for at
least 30 minutes and destained in water. Gels were subsequently imaged using a Gel-doc
(UVP) under white light.
Electrospray-ionisation mass spectrometry (ESI-MS) of proteins
Selected proteins were mass verified by ESI-MS using a Xevo G2-S QTOF (Waters) in-
strument, in the mass spectrometry facility, Department of Chemistry, University of Cam-
bridge. All samples were injected onto an Acquity Protein BEH 300A, 1.7 µm, 2.1×50
mm, UPLC column (Waters) connected to an Acquity UPLC (class I) system (Waters).
The liquid chromatography used HPLC grade H2O, 0.1% (v/v) formic acid (A) and MeCN,
0.1% (v/v) formic acid (B) at 0.2 ml/min in a linear gradient from 95:5 (A:B) to 0:100
(A:B) over four minutes, before returning to original conditions. The LocksprayTM was
set with Leucine enkephalin and was injected at regular intervals during the run as a
known reference mass. Data collection and processing were performed using MassLynx
4.1. Protein masses were calculated using the maximum entropy function with appropri-
ate boundaries set for the expected molecular weight of the protein. Calculations were
allowed to iterate until data no longer improved.
Calculation of recombinant protein concentration
Full amino acid sequences for all recombinant proteins produced were known and ex-
tinction coefficients at 280 nm (280) were estimated using ExPASy’s ProtParam server
[202]. Absorbance at 280 nm was then measured against a buffer blank using a Nan-
odrop 2000 (Thermo Fisher Scientific) and molar concentrations calculated according to
Beer-Lambert’s law, equation 2.1
A = cl (2.1)
where, A is the absorbance at a given wavelength,  is the molar extinction coefficient
at the same wavelength, c is the molar concentration and l is the path length in cm.
For the purpose of crystallography, where protein is more commonly dealt with in
units of mg/mL, molar concentrations were converted according to the protein’s estimated
molecular weight.
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Calculation of total protein concentration
Total protein concentrations of mammallian cell lysates were calculated using Pierce Bicin-
choninic acid (BCA) assay kit (Thermo Fisher Scientific). BCA assays were performed
as per manufacturers’ instructions. Experimental sample concentrations were determined
against a standard curve generated from serial dilutions of 2 mg/mL bovine serum albu-
min, supplied with the kit.
2.3.2 Tandem Immobilised Metal ion Affinity Chromatography
(IMAC)
Affinity chromatography is a commonly used technique to obtaining relatively pure protein
from the crude source. The His6-tag is a convenient tag due to its small size and its affinity
to Ni2+. Ni2+ ions can be immobilised to solid support matrices such as agarose beads
or similar resins to aid chromatographic separation of His6-tagged biomolecules. Some
proteins do not tolerate the elution conditions, which can be lower pH (< pH 7.0) resulting
in protonation of the His6-tag or more commonly the addition of high concentrations of
imidazole to outcompete the imidazole rings of the His6-tag. To minimise the denaturation
of proteins during IMAC elution due to the presence of imidazole, a new method was
developed. This method relied on the direct and immediate desalting of the IMAC eluent
thereby minimising the contact time of proteins with imidazole-containing buffers. This
was achieved by coupling the outlet from the IMAC column directly to the inlet of a pre-
equilibrated 26/10 desalting column (Figure 2.2). A maximum of 25 mL IMAC elution
can be applied to the desalting column to achieve optimal separation. Proteins then elute
from both columns, with the protein immediately desalted into the buffer of choice.
2.3.3 Tobacco Etch Virus (TEV) protease (S219V)
The gene for N-terminally His6-tagged TEV protease was provided in an unknown vector
(Itzhaki lab). The S219V mutation was introduced into the gene by RTH-mutagenesis
resulting in a construct that is less prone to self-cleavage [203]. The plasmid encoding for
His6-TEV protease (S219V) was transformed into C41 cells and grown in 2xYT medium
supplemented with 100 µg/mL ampicillin at 37◦C, shaking at 200 rpm to an OD600 of 0.6
- 0.7 in 2 L baffled erlenmeyer flasks. Cells were induced with 200 µM IPTG overnight
at 20◦C, shaking at 200 rpm. The following day, cells were pelleted at 7,000 × g for
15 minutes. For every 2 L of culture, cell pellets were resuspended in 40 mL of lysis
buffer (50 mM Tris-HCl, 300 mM NaCl, 20 mM imidazole, 1 mM TCEP, pH 8.0) and
stored at -20◦C until purification was required. Resuspended cells were thawed at room
temperature, and crude DNase I (Sigma Aldrich) was added to reduce the viscosity during
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Figure 2.2: Chromatography setup on ÄKTA Pure system for tandem IMAC-desalt
of proteins elutions.
lysis. The cell suspension was lysed by 3 passes on a C5-Emulsiflex (Avestin) at 15,000-
20,000 psi. The lysate was clarified by centrifugation at 45,000 × g, 4◦C for 45 minutes.
All chromatography steps were performed using an ÄKTA Pure with a sample pump.
First, a 26/10 desalting column was equilibrated into desalting buffer (50 mM Tris-HCl,
300 mM NaCl, 1 mM TCEP, pH 8.0) and disconnected from the system. Next, a 5 mL
HisTrap Excel column was pre-equilibrated in wash buffer (50 mM Tris-HCl, 300 mM
NaCl, 20 mM imidazole, 1 mM TCEP, pH 8.0) prior to loading the clarified supernatant
at 3 mL/min. The column was washed with 20 column volumes (CV) of wash buffer
to remove contaminant proteins. Proteins were then eluted as described in 2.3.2 using
elution buffer (50 mM Tris-HCl, 300 mM NaCl, 300 mM imidazole, 1 mM TCEP, pH
8.0) into a 96 deep-well block in 2 mL fractions. Elutions were pooled and concentrated
using a Vivaspin 20, 10K Molecular weight cut off (MWCO) centrifugal filter at 8000 × g,
4◦C until a concentration of 270 µM was achieved (280 = 33460 M−1cm−1). Protein was
then diluted with an equal volume of 100 % glycerol, resulting in 135 µM protein in 25
mM Tris-HCl, 150 mM NaCl, 0.5 mM TCEP, 50 % (v/v) glycerol, pH 8.0. Proteins were
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analysed by SDS PAGE and estimated to be >75% pure (Figure 2.3). Due to its use in
early stage purifications and at relatively low concentrations, this purity was considered
sufficient. Protein was then aliquotted, flash frozen in liquid N2 and stored at -80◦C until
required.
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Figure 2.3: SDS PAGE gel of His6-TEV-protease (S219V) elution fraction from IMAC
purification (lanes A8-B6). His6-TEV-protease (S219V) appears to migrate slightly
faster through the SDS PAGE gel than its expected molecular weight of 28.6 kDa.
2.3.4 Mouse double minute 2 (Mdm2)
The gene for human Mdm2, residues 6-125 was cloned into the pRSET-TEV vector. The
ORF encodes a N-terminal His6-tag, followed by a 10 residue asparagine linker and TEV-
cleavage site followed by Mdm2 (6-125). The plasmid was transformed into C41 cells and
grown in 2xYT medium supplemented with 100 µg/mL ampicillin at 37◦C, shaking at
200 rpm to an OD600 of 0.6 - 0.7 in 2 L baffled erlenmeyer flasks. Cells were induced
with 300 µM IPTG overnight at 18◦C, shaking at 200 rpm. The following day, cells
were harvested by centrifugation at 7000 × g for 15 minutes. The cell pellet from 2 L
of cell culture was resuspended in 25 mL ice-cold lysis buffer (50 mM Tris-HCl, 300 mM
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NaCl, 15 mM imidazole, 1 mM DTT, SigmaFAST EDTA-free protease inhibitor cocktail
tablet (Sigma-Aldrich) and crude DNase I (Sigma-Alrdich), pH 8.0). The cell suspension
was lysed by 3 passes on a C5-Emulsiflex (Avestin) at 15,000-20,000 psi. The lysate was
clarified by centrifugation at 45,000 × g, 4◦C for 45 minutes. All chromatography steps
were performed using an ÄKTA Pure with a sample pump. First, a 26/10 desalting
column was equilibrated into desalting buffer (20 mM Tris-HCl, 180 mM NaCl, 1 mM
DTT, pH 8.0) and disconnected from the system. Next, a 5 mL HisTrap Excel column was
pre-equilibrated in wash buffer (50 mM Tris-HCl, 300 mM NaCl, 15 mM imidazole, 1 mM
DTT, pH 8.0) prior to loading the supernatant at 3 mL/min. The column was washed with
20 column volumes (CV) of wash buffer to remove contaminant proteins. Proteins were
then eluted as described in 2.3.2 using elution buffer (50 mM Tris-HCl, 300 mM NaCl, 300
mM imidazole, 1 mM DTT, pH 8.0) into a 96 deep-well block in 2 mL fractions. Elutions
were pooled and His6-TEV protease (S219V, 0.5 µM final concentration) was added to
remove the His6-tag from Mdm2 overnight at 4◦C. The following day, precipitates were
removed by brief centrifugation and supernatant was flowed over a 5 mL HisTrap Excel
column at 3 mL/min, collecting the flow-through. The flow through was diluted to a final
concentration of 30 mM NaCl in MonoS low salt buffer (LSB; 20 mM Bis-Tris, 1 mM DTT,
pH 6.5). A MonoS 10/100 GL column was equilibrated in 20 mM Bis-Tris, 30 mM NaCl,
1 mM DTT, pH 6.5 prior to loading the diluted protein sample from above at 4 mL/min.
Bound proteins were then eluted at 2 mL/min over 20 CV in a linear gradient with MonoS
high salt buffer (HSB; 20 mM Bis-Tris, 1 M NaCl, 1 mM DTT, pH 6.5). Mdm2 eluted
in a sharp peak around 200 mM NaCl and fractions were analysed by SDS PAGE prior
to being pooled and concentrated in a Vivaspin 20, 5K MWCO centrifugal filter at 8000
× g, 4◦C. Protein concentration was determined to be 195 µM (280 = 10,430 M−1cm−1)
and was estimated to be >95% pure by SDS PAGE analysis (Figure 2.4). Mdm2 (6-125)
was also verified to be the correct expected mass by ESI-MS. Proteins were flash frozen
in liquid N2 and stored at -80◦C.
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Figure 2.4: SDS PAGE gels monitoring the purification process. (a) IMAC elutions
of proteins bound to the HisTrap Excel resin. TEV-cleavage efficiency is monitored
taking fractions before and after cleavage. (b) Most contaminant proteins precipitate
out of solution and could be separated by centrifugation. MonoS purification cleans up
remaining major contaminants.
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2.4 Software
GraphPad Prism
Graphs were plotted and data were fitted using GraphPad Prism version 7.00 for Windows,
GraphPad Software, La Jolla California USA, www.graphpad.com. Data were fitted using
in-built mathematical models, where available. For all other fits, data were fitted using
equations described in the relevant method section of the chapter. Unless otherwise
specified, error bars are plotted as the standard error (SE).
ChemDraw Ultra 12.0
Structures of synthesised peptides were drawn using ChemDraw Ultra 12.0 (Cambridge-
Soft, PerkinElmer).
PyMOL
Open-source PyMOL (Schrödinger, LLC, latest version updated as it is released) [204] was
installed using Python 3.6 using a pre-compiled .whl file for Windows operating systems
by Christoph Gohlke [205]. PyMOL additionally requires the NumPy+MKL library and
Pmw to function, which were also obtained from Golhke’s website. All models and images
of protein structures were produced using PyMOL software.
CCP4i
CCP4i (version 7.0.077) was installed for Windows OS [206]. Subsiduary programs con-
tained within CCP4i, which were also used include Matthews coefficient [207, 208], Phaser
[209], Refmac5 ([210] and references therein) and PDBset.
BUSTER
BUSTER (Global Phasing) version 2.10.3 was used for X-ray structure refinement [211,
212].
WinCoot
Coot (version 0.8.9.2) [213] for Windows OS was installed from Bernhard Lohkamp’s
pre-compiled installer [214].
Chapter 3
Targeting the Tankyrase
substrate-binding domains using
constrained peptides
3.1 Introduction and aims
The work presented in this chapter was conducted in the first year of the PhD. The project
was aimed at developing improved peptide-based inhibitors against the substrate recruit-
ment domains of TNKS. The project largely built on the work carried out by a former
PhD student (Dr. Wenshu Xu), who had screened several iterations of macrocyclisation
with the double-click stapling technologies developed in the Spring lab [99]. While the
lead peptides developed were cell permeable and able to inhibit WNT signalling, their
affinities were only 2-fold improved in comparison to the optimised sequence by Guettler
et al. [131]. However, improvements of the peptide binding affinity upon constraining
were not expected due to the extended nature of the binding interface. The initial goal
was to improve the peptide binding affinity to TNKS, which in turn should subsequently
lower the IC50, yielding a more potent inhibitor.
3.2 Methods
3.2.1 Expression and purification of wild-type & mutant Tankyrase
ARC domains
His6-tagged TNKS1 ARC2-3 (residues 315-662) and His6-tagged TNKS2 ARC4 (residues
488-649) were expressed and purified using the same protocols. Wild-type and mutant
GST-tagged TNKS2 ARC4 were expressed and purified using the same protocols. C41
cells containing a transformed TNKS gene were grown to OD600 ≈ 0.6, in a shaking
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incubator at 37◦C prior to induction with 150 µM IPTG at 20◦C overnight. Cells were
harvested by centrifugation at 4000 × g, 4◦C. Pellets were resuspended in 20 mL of lysis
buffer (50 mM Tris-HCl, 500 mM NaCl, 2 mM DTT, 0.1% (v/v) Tween 20, and one
SigmaFAST EDTA-free Protease inhibitor cocktail tablet, pH 8.0) per 0.5 L of culture.
Pellets of His6-tagged proteins also included 10 mM imidazole. Cells were incubated
with lysozyme and DNase I at 4◦C on a roller for at least 30 minutes prior to lysis
by sonication on ice. Lysed cells were clarified by centrifugation at 40,000 × g, 4◦C
for 40 minutes. Supernatants were bound to 5 mL of Ni-NTA or glutathione-agarose
resin (Expedeon) in a gravity-flow column, for 30 minutes at 4◦C. Resins were washed
with 250 mL of wash buffer (50 mM Tris-HCl, 500 mM NaCl, 2 mM DTT, pH 8.0
(+ 10 mM imidazole)). Bound proteins were eluted with elution buffer (50 mM Tris-
HCl pH 8.0, 500 mM NaCl, 2 mM DTT) containing either 500 mM imidazole (His6-
tagged protein) or 20 mM reduced glutathione (GST-tagged protein). Proteins were
subsequently pooled and desalted into 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 2 mM DTT
using Centripure P25 columns (Generon) according to the manufacturer. To remove the
His6-tag, 125 U of thrombin (Sigma-Aldrich) were added, incubating overnight at room
temperature on a rotating mixer. Cleaved proteins were clarified by brief centrifugation
and the supernatant containing His6-tagged protein were subjected to reverse-IMAC,
collecting the flow through. Proteins were concentrated using a 10K MWCO centrifugal
filter (Sartorius Stedim) to ≈10 mL. Samples were then separated by SEC using a 26/60
Superdex 75 column in SEC buffer (50 mM HEPES pH 7.5, 300 mM NaCl, 2 mM DTT).
Elutions were verified for purity via SDS PAGE and appropriate fractions were pooled and
concentrated to > 500 µM as determined by absorbance at 280 nm. For each construct,
molecular weight and molar extinction coefficients (cysteines reduced) were determined
using ProtParam from the ExPASy web server [202] and are listed in Table 3.1. Proteins
were flash frozen in liquid N2 and stored at -80◦C until required.
3.2.2 Peptide synthesis and macrocyclisation of T1-1
Peptide T1 was synthesised on Rink amide resin (Novabiochem) using standard Fmoc-
chemistry on a Liberty Blue peptide synthesiser (CEM). Fmoc-L-Ornithine(N3) was syn-
thesised as described by Lau and Spring [215]. The amino terminus of peptide T1 was
then deprotected with 20% (v/v) piperidine in DMF and acetylated in a cocktail of 40%
(v/v) acetic anhydride, 40% (v/v) DMF and 20% (v/v) DIEA to cap the peptide. The
resin was then washed 3 times in DMF and dried twice in MeOH and then twice in Diethyl
Ether. T1 was cleaved from the Rink amide resin in a cocktail containing 95% (v/v) TFA,
2.5% (v/v) H2O and 2.5% (v/v) TIPS. Eluate was dried under N2 gas and triturated with
diethyl ether. T1 was then purified by reverse-phase HPLC and the mass was verified by
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Table 3.1: List of all constructs used in this chapter. Theoretical molecular weight
and extinction coefficient at 280 nm are tabulated. All values are calculated using
Expasy ProtParam web tool [202].
Protein Molecular weight (Da) 280 (M−1 cm−1)
His6-TNKS1 ARC2-3 39790.47 15930
TNKS1 ARC2-3 38013.47 15930
His6-TNKS2 ARC4 19717.17 12950
TNKS2 ARC4 17708.97 12950
GST-TNKS2 ARC4 43988.59 55810
GST-TNKS2 ARC4 (G558S) 44018.61 55810
GST-TNKS2 ARC4 (G558T) 44032.64 55810
GST-TNKS2 ARC4 (G558D) 44046.62 55810
LCMS.
Double-click stapling was performed in degassed 50% (v/v) t-BuOH, ddH2O. Peptide
T1 was dissolved at 1 mg/mL. A molar ratio of 1.1:1 of hepta-1,6-diyne linker to T1 was
added to the mix. To catalyse the reaction, a 4× stock of sodium ascorbate, CuSO4.5H2O
and THPTA was dissolved in a 3:1:1 molar ratio in the click chemistry solvent system.
The catalyst stock solution was then added to the peptide-linker solution at a 1× final
concentration. The reaction was stirred at room temperature under nitrogen for 20 hours.
The reaction progress was monitored by LCMS. The final T1-1 peptide was purified by
reverse-phase HPLC. The concentration of working stock peptide solution was verified by
amino acid analysis (Peter Sharrat, former PNAC facility, Department of Biochemistry,
University of Cambridge).
3.2.3 Differential scanning fluorimetry
Experiments were performed on Roche Lightcycler 480 II or BioRad CFX Connect ma-
chines in 384-well or 96-well formats, respectively. SYPRO Orange probe was used as the
reporter dye molecule at a 5× final concentration. TNKS1 ARC2-3 and TNKS2 ARC4
were prepared at a final assay concentration of 5 µM diluted in SEC buffer, in the presence
or absence of ligands, maintaining 1% (v/v) DMSO. Thermal melt profiles were obtained
by ramping the block from 20◦C to 95◦C at a rate of 0.5◦C/min. The SYPRO Orange
dye was excited at 483±35 nm and the fluorescence was monitored at 568±20 nm. Data
were fitted in GraphPad Prism 7.0 using
Y = (Ymin +M2×X) + (Ymax +M1×X)− (Ymin +M2×X)
1 + e
V 50−X
m
, (3.1)
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where Y is the fluorescence intensity at a given temperature, X, Ymin and Ymax describe
the minimum and maximum fluorescence intensity, respectively, M2 and M1 are the
pre- and post- transition baseline gradients, V 50 describes the midpoint of the melting
transition and m is the gradient of the melting transition.
3.2.4 Fluorescence polarisation
Direct FP experiments
The dissociation constant, Kd, of the fluorescent peptide ligand TAMRA-pep1 was de-
termined against the Tankyrase substrate-binding domains; TNKS1 ARC2-3, TNKS2
ARC4 and GST-TNKS2 ARC4 (G558X) mutants, hereby referred to as TNKS. TNKS
were titrated in a 1.5-fold serial dilution against 20 nM TAMRA-pep1 in black 384-well
plate (OptiPlate-384 F, Perkin Elmer). Protein and peptide solutions were diluted in
PBS+0.01% Tween 20, pH 7.4. Endpoint equilibrium measurements were read after
a thirty minute incubation at room temperature using a ClarioStar microplate reader
(BMG, Labtech). TAMRA was excited at 540± 20 nm and the emmission was measured
at 590± 20 nm, with a dichroic filter at 566 nm. Polarisation is then calculated using
mP =
1000× (F‖ − F⊥)
F‖ + F⊥
, (3.2)
where F‖ is the fluorescence from vertically polarised light and F⊥ is the fluorescence from
horizontally polarised light and 1 polarisation unit (P ) = 1000 mP .
Dissociation constants of TAMRA-pep1 to TNKS proteins were calculated by fitting
the data to
r = r0 + (rb − r0)× (Kd + [L]t + [P ]t)−
√
(Kd + [L]t + [P ]t)2 − 4[L]t[P ]t
2[L]t
(3.3)
where r is the calculated polarisation, r0 is the polarisation of free peptide, rb is the polar-
isation of the protein-ligand complex, Kd is the dissociation constant of the protein-ligand
complex, [P ]t is the total protein concentration and [L]t is the total ligand concentration.
Competition FP experiments
In competition fluorescence polarisation experiments, unlabelled peptides competing for
the same binding site were titrated against a TNKS-TAMRA-pep1 complex. Since the
dissociation constant, Kd of the TNKS-TAMRA-pep1 complex is known, it is possible to
determine the dissociation constants for unlabelled ligands using [216]
r = r0 + (rb − r0)×
2
√
d2 − 3e cos θ
3
− d
3Kd1 + 2
√
d2 − 3e cos θ
3
− d, (3.4)
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where d is described as
d = Kd1 +Kd2 + [L]st + [L]t − [P ]t, (3.5)
and e is described as
e = ([L]t − [P ]t)Kd1 + ([L]st − [P ]t)Kd2 +Kd1Kd2, (3.6)
and θ is
θ = arccos
−2d3 + 9de− 27(−Kd1Kd2[P ]t)
2
√
(d2 − 3e)3 . (3.7)
Parameters in Equation 3.4 are the same as in Equation 3.3, with the exception of [L]t,
which now describes the total concentration of competing peptide and [L]st, which de-
scribes the total concentration of TAMRA-pep1. The dissociation constant of the TNKS-
TAMRA-pep1 complex, Kd, is now referred to as Kd1, and the dissociation constants of
unlabelled competing peptides to TNKS is now referred to as Kd2.
3.2.5 Surface plasmon resonance
Experiments were run using a Biacore T200 instrument (GE healthcare) using a Series
S, Ni-NTA chip (GE healthcare). Experiments were conducted in the following running
buffer; 50 mM HEPES, 150 mM NaCl, 2 mM TCEP, 0.005% (v/v) Tween 20, pH 7.5. To
maintain continuity of nomenclature in the SPR field, proteins are hereby considered the
ligand or receptor, whereas peptides are considered analytes.
Ligand immobilisation
The Ni-NTA chip was docked and primed three times in running buffer. Each flow cell
was processed in succession. First, flow cells were stripped of Ni2+ with 350 mM EDTA,
followed by re-equilibration with running buffer. The flow cell was then recharged with
500 µM NiSO4. EDC and NHS were then mixed and immediately flowed over to activate
the surface for covalent coupling. 2 µM His6-TNKS2 ARC4 (Fc 2), 10 µM His6-TNKS2
ARC4 (Fc 3) and 200 nM His6-TNKS1 ARC2-3 (Fc 4) were flowed over their respective
flow cells with a ligand target capture set at 4000 RU (Fc 2, 3) and 6000 RU (Fc 4). All
flow cells were blocked using 100 mM Tris-HCl, pH 8.0. Non-covalently bound ligands
were removed with an injection of 350 mM EDTA.
Analyte binding experiments
Peptides that are previously known to bind TNKS ligands, were run as positive control
molecules. Stock solutions at 10 µM of pep1, TAMRA-pep1 and sp4n2m3-AntP were
titrated from in a 2-fold serial dilution against the immobilised ligands with 120 second
association and 180 second dissociation times.
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3.2.6 Isothermal titration calorimetry
All experiments were performed using a MicroCal ITC200 (Malvern panalytical) at 25◦C.
Proteins were dialysed in 50 mM Tris-HCl, 150 mM NaCl, 2 mM TCEP, pH 7.5. Pep-
tide was diluted in the dialysis buffer and solutions were appropriately ’buffer matched’.
Twenty injections of 2 µl were performed over 4 seconds each, spaced by 120 seconds
between injections. Data collection was filtered to 2 seconds. Reference power was set at
6 µcal/sec, with a a spin speed of 800 rpm. Data were then fitted in Origin 7.0 software
with a one-site binding model.
3.2.7 X-ray crystallography
Commercial or in-house screens developed by AstraZeneca were dispensed into 96-well
MRC 2-drop plates. For custom grid screens, plates were dispensed using a Dragonfly
crystal (TTP Labtech). Dispensed solutions were then mixed for 5 minutes using a MXone
(TTP Labtech). His6-TNKS2 ARC4 or TNKS2 ARC4 were used in crystal trials at 20
mg/ml. Proteins and well solutions were dispensed using a Mosquito HTS (TTP Labtech).
Plates were sealed with Crystal clear sealing tape (Hampton Research) and stored at 20◦C
in a Rock Imager (Formulatrix). Visible light and UV images were collected along the
incubation period to monitor each drop.
3.3 Results
3.3.1 Cloning and expression of wild-type Tankyrase proteins
Plasmids encoding for TNKS1 ARC2-3 and TNKS2 ARC4 were provided by Dr. Wenshu
Xu. TNKS1 ARC2-3 was encoded in a modified pRSETa vector with an N-terminal
His6 tag, whereas TNKS2 ARC4 was provided in a modified pGST vector. To ease
the processivity and purification of both recombinant proteins side-by-side, the TNKS2
ARC4 ORF was transferred by standard restriction-endonuclease cloning into a modified
pOPIN F vector (Dr. Owen Burbidge) containing an N-terminal His6 tag. For the work
exploring the binding cavity around Arg1 of the TNKS-binding peptides, mutations were
incorporated in GST-TNKS2 ARC4 at G558 to S, T and D by Round-the-Horn SDM.
Expression of all constructs were very high, typically yielding > 50 mg of purified
protein per litre of induced E.coli culture. Proteins were either purified by IMAC or GST-
glutathione affinity chromatography. For wild-type proteins affinity tags were typically
removed by thrombin cleavage for downstream biophysical or crystallographic applications
and further purified by Reverse IMAC (His6-tagged proteins only) and size-exclusion
chromatography. The GST-TNKS2 ARC4 (G558X) proteins were characterised without
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removal of the GST-tag. All proteins were deemed >95% pure, analysed by SDS PAGE.
3.3.2 Biophysical method development
We wanted to expand the biophysical assays that Dr. Wenshu Xu had previously set up
to assess peptide binding to the TNKS proteins (FP and ITC). We initially deemed SPR
to be a highly useful tool for this purpose due to the ability to extract kinetic information
from the system. This data could be very useful in building up a SAR with the goal of
improving peptide binding affinity. Although we were able to immobilise sufficiently high
RU of our protein ligands to observe analyte signals at ≈100 RU, we observed particularly
poor activity of the ligand after immobilisation. Although both pep1 and TAMRA-pep1
were able to achieve a similar response, it was very clear that sp4n2m3-CPP was binding
to the reference flow cell significantly. This is likely to be due to an interaction between the
net-positively charged Antennapedia cell-penetrating peptide to the negatively charged
dextran surface of the Ni-NTA sensor chip. We sought to investigate the reason behind
the lack of activity on the chip despite the high density of ligand on the chip surface. We
used ITC as our first method as it would give an indication to the ability of the reagents
to bind each other in a stoichiometric manner.
The data presented in Figure 3.1 highlights that both protein and peptide were bind-
ing competent, where a stoichiometry of N = 1.250± 0.004 was observed, indicating that
protein and peptide reagents were not the reason for failed SPR experiments. Allowing
for slight errors in the calculation of peptide and protein concentrations, these results are
also in accordance with the previously published data [102]. The initial project goals were
to explore several pertubations of the Tankyrase binding peptides and thus experimental
throughput was critical. While ITC is considered a gold-standard technique for measur-
ing protein-ligand interactions, it is very expensive with regard to time and sample [217].
Thus we wanted to explore a more high-throughput approach, which could be used to
screen several compounds in a much shorter time, orthogonally to FP experiments. As a
proof of principle, we approached DSF with pep1 as a benchmark for the technique.
Figure 3.2 shows that TNKS1 ARC2-3 displays the characteristic DSF melting curve,
with a linear pre-transition baseline, defined melt transition and linear post-transition
baseline. As result of this typical behaviour, the model used to describe the data and
the unfolding transition (see Equation 3.1), provides an accurate melting temperature for
unfolding transition of TNKS1 ARC2-3. However, this is not seen to the same extent in
TNKS2 ARC4 DSF experiments (Figure 3.2b). Instead, TNKS2 ARC4 shows a tempera-
ture dependant increase of the fluorescence between 20◦C to 40◦C that is does not adopt
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Figure 3.1: ITC thermogram of 300 µM pep1 against 20 µM TNKS2 ARC4 at 25◦C
in 50 mM Tris-HCl, 150 mM NaCl, 2 mM TCEP, pH 7.5.
the linear nature that is described by our model, describing a two-state transition. This
indicates that an intermediate state or more specifically that Sypro Orange dye is grad-
ually binding and increasing its fluorescence intensity within this region. Nevertheless,
there is a defined unfolding transition between 40◦C and 60◦C. Since the model doesn’t
describe this data properly in this early region, it is possible that absolute melting tem-
perature calculations are systematically incorrect. The data for pep1 without any protein
clearly indicate that the change in fluorescence with increasing temperature is due to
TNKS unfolding. pep1 thermally stabilises TNKS2 ARC4 more than TNKS1 ARC2-3,
at both 50 µM and 500 µM.
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Figure 3.2: DSF melt curves of (a) TNKS1 ARC2-3 and (b) TNKS2 ARC4 with
or without pep1 at the indicated concentrations. (c) DSF melt curves of pep1 at the
indicated concentrations without any TNKS proteins. (d) Calculated melting temper-
atures of TNKS proteins with and without pep1 at indicated concentrations. Black
lines indicate the data fit using equation 3.1. Temperature ramp from 20◦C to 90◦C in
50 mM Tris-HCl, 150 mM NaCl, 2 mM TCEP, pH 7.5.
3.3. Results 57
0.001 0.01 0.1 1 10 100
0
50
100
150
200
250
[TNKS1 ARC2-3]mM
F
lu
o
re
s
c
e
n
c
e
p
o
la
ri
s
a
ti
o
n
(m
P
)
Kd = 215 ± 12 nM
(a)
0.001 0.01 0.1 1 10 100
0
50
100
150
200
[TNKS2 ARC4]mM
F
lu
o
re
s
c
e
n
c
e
p
o
la
ri
s
a
ti
o
n
(m
P
)
Kd = 614 ± 18 nM
(b)
Figure 3.3: Titrations of (a) TNKS1 ARC2-3, and (b) TNKS2 ARC4 against 20 nM
TAMRA-pep1. All reagents were diluted in PBS + 0.01% (v/v) Tween 20. Measure-
ments read at 25◦C. Black dashed lines indicate the calculated Kd of TAMRA-pep1 to
the Tankyrase subdomains according to Equation 3.3.
We then sought to improve the FP protocol described by Xu et al. [102] by trans-
ferring the assay into 384-well plate format. This allowed us to reduce sample volumes
per well, while at the same time increasing the density of data points for a given end-
point equilibrium titration experiment using a 1.5-fold serial dilution series over twenty
points versus a 2-fold dilution series over twelve points. With the modified assay set up,
we then confirmed the dissociation constant of the tracer peptide, TAMRA-pep1 against
both TNKS1 ARC2-3 and TNKS2 ARC4 at 215 ± 12 nM and 614 ± 18 nM, respectively.
This data allowed us to set up competition FP experiments to analyse pertubations of
peptide inhibitors against these binding sites.
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3.3.3 Towards selective inhibitory peptides of ARCs 2/5 versus
ARCs 1/4
Despite the high sequence identity between the ARC domains of TNKS1 and TNKS2,
there are structural differences around the peptide-binding site. Namely, in both TNKS
proteins, ARCs 1 and 4 and ARCs 2 and 5 are most similar. Initially, we wanted to
investigate whether we could exploit these differences highlighted in Figure 3.4, where a
large and extended surface is potentially accessible in ARCs 2 and 5. In comparison, this
binding surface is inaccessible in ARCs 1 and 4, due to the protrusion of the benzyl ring
from F222 (ARC1) from the surface of the protein. In contrast, ARC2 has its equivalent
residue in the ARC replaced by a smaller hydrophobic residue, L375. We believed we
could make use of this extended surface on ARC2 and ARC5 to improve the affinity.
Since Guettler et al. only explored pertubations of Tankyrase binding peptides against
the TNKS2 ARC4 domain [131], we hypothesised that those trends may not be entirely
applicable to the ARC2 or ARC5 domains, given their structural differences. Although a
pairwise matrix screen could have been performed against the TNKS1 ARC2-3 domain,
it was believed that this would largely not result in a significantly improved compared
to the pep1 sequence (Ac-REAGDGEE-NH2) and indeed purchasing such a large set of
peptides would be not be economical. To explore this hypothesis in a more rational and
focused manner, a set of seven peptides were purchased from Mimotopes, to explore a
series of natural amino acid point mutations at position 5 of the peptide, which are listed
in Table 3.2. These peptides were specifically designed in an attempt to explore the
region highlighted in Figure 3.4b, with a variety of the larger side chain-containing amino
acids to explore various chemical properties associated with them, such as aromaticity,
aliphatic characteristic and positive charge. Peptides T5-T11 were then tested in the
competition FP assay to assess their dissociation constants to both the TNKS1 ARC2-3
and the TNKS2 ARC4 constructs.
It was evident from the data presented in Figure 3.5 that none of the purchased
peptides in Table 3.2 were of similarly high affinity compared to pep1. At maximum
concentrations of 1 mM, none were able to fully compete off the TAMRA-pep1 peptide
in the context of TNKS1 ARC2-3 or TNKS2 ARC4. Due to this, any affinities calculated
by Equation 3.4, will not be accurate and are therefore absolute affinities are not worth
presenting here. Upon closer inspection of the data, we noticed that peptide T5 (Ac-
REAGRGEE-NH2) was able to displace TAMRA-pep in the context of TNKS1 ARC2-3,
but not TNKS2 ARC4 (Figure 3.5c). These data suggests an apparent affinity that ex-
ists for TNKS1 ARC2-3, containing the Leucine residues versus the Phenylalanine residue
3.3. Results 59
(a) TNKS1 ARC1 (b) TNKS1 ARC2
(c) ARC1 - ARC2 alignment
Figure 3.4: IRAP peptides bound to (a) Human TNKS1 ARC1 and (b) Human
TNKS1 ARC2. Black circles indicate area of interest to exploit for further rational
design. (c) Structural alignment of human TNKS1 ARC1 and ARC2. F222 and L375
are highlighted. Figures produced from PDB ID: 5JHQ [126].
found in the ARC1 and ARC4 domains. This indicates that this surface may be conducive
for further inhibitor design efforts to specifically target the ARC2 and ARC5 domains of
Tankyrases.
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Table 3.2: Peptides exploring natural amino acid point mutations at position 5 (high-
lighted in red), with a bias towards large side chains. All purchased peptides were
>95% purity by analytical HPLC.
Peptide Sequence
T5 Ac-REAGRGEE-NH2
T6 Ac-REAGHGEE-NH2
T7 Ac-REAGLGEE-NH2
T8 Ac-REAGMGEE-NH2
T9 Ac-REAGFGEE-NH2
T10 Ac-REAGYGEE-NH2
T11 Ac-REAGWGEE-NH2
(a)
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(b)
(c)
Figure 3.5: Competition FP experiments with T-series peptides against (a) TNKS1
ARC2-3, TAMRA-pep1 complex and (b) TNKS2 ARC4, TAMRA-pep1 complex. (c)
Competition FP experiments, with T5 competing for TNKS1 ARC2-3 (red circles) or
TNKS2 ARC4 (red triangles), in the presence of TAMRA-pep1. Protein and peptide
solutions were diluted in PBS+0.01% Tween 20, 1% (v/v) DMSO. All measurements
read at 25◦C.
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3.3.4 Macrocycle interactions to TNKS
Peptide design
Since the previously described efforts did not lead to any improved binding affinity to
the TNKS proteins, we next took some inspiration from the literature. It has long been
known that macrocycles in stapled peptide inhibitors are able to improve their affinity
to the target protein by clustering peptide conformations towards the bound state of the
ligand, thus reducing the entropic cost of binding. One of the more studied stapled pep-
tide systems, targeting the p53-Mdm2 interaction, has garnered a lot of attention over
the years from both academia and the pharmaceutical industry. One such inhibitor of
Mdm2, peptide M06, was observed to make use of the macrocycle constraint to produce
favourable interactions with the surface of Mdm2 as depicted in Figure 3.6 [218]. We
attempted to utilise this principle in the design of our macrocyclised peptides against
Tankyrase.
Figure 3.6: X-ray crystal structure of M06 stapled peptide bound to Mdm2. Peptide
(green) is depicted in cartoon and stick configuration, with staple amino acids coloured
separately in cyan. Mdm2 surface is shown in orange. PDB ID: 4UMN [218].
To approach this, we first analysed the co-crystal structures of TNKS2 ARC4 bound
to sp4n2m3 (PDB ID: 5BXO) and sp4n4m5 (PDB ID: 5BXU) [102]. In both structures,
the macrocycle is inserted at positions 3 and 7 in the primary amino acid sequence. While
both peptides were slightly improved in their affinity to TNKS2 ARC4, the macrocycles
in both cases were solvent exposed and thus not able to contribute an interaction with
the protein, (Figure 3.7a). We then decided to change the macrocycle positioning in an
attempt to dock the macrocycle within the groove formed between Y569 and K602, (Figure
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3.7b). Although this groove is not particularly well defined in the crystal structure, K602
is resolved in two different conformations implying a degree of flexibility in the side chain
that could perhaps be exploited for our design.
(a) (b)
Figure 3.7: (a) Alignment of sp4n2m3 (turqoise) and sp4n4m5 (pale green) peptides
bound to TNKS2 ARC4. (b) Groove formed between Y569 and K602 between the
ANK repeats.
With guidance from our collaborator, Dr. Yaw Sing Tan (BII, A*STAR, Singapore),
we re-designed the macrocycle to positions 3 and 8 in the primary sequence. We believed
this may work since the side chain from Glu8 already points towards the defined groove
(Figure 3.7b). This led to the design of the T1 series of peptides using L-Ornithine (N3)
unnatural amino acids, and differing dialkynyl linkers. Their proposed binding models
are depicted in Figure 3.8. At the time of design, we favoured the hepta-1,6,-diyne linker
due to the availability of similar linkers to which additional modifications could be incor-
porated downstream, such as the addition of a cell-penetrating peptide to the carboxyl
group of the T1-4 linker.
The synthesis of T1 and subsequently T1-1 was relatively simple and straightforward.
However, practically it was fraught with difficulty due to the hygroscopic properties of the
peptides. This was made more difficult by the low milligram scale at which synthesis, pu-
rification and double-click reactions were performed. For this reason, the other iterations
of T1 peptides were not synthesised. Peptide synthesis data is provided in Appendix B.
Biophysical characterisation of T1-1
Due to the hygroscopic nature of T1-1, we could not be confident in the concentration
of dissolved peptide from the mass of peptide weighed out. A small sample was submit-
ted for amino acid analysis (Dr. Peter Sharrat, Former PNAC facility, Department of
Biochemistry, University of Cambridge), where the concentration of the working stock
solution was confirmed. We then determined the dissociation constant of T1-1 by ITC
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(a) T1-1 (b) T1-2
(c) T1-3 (d) T1-4
Figure 3.8: In silico models of T1 series peptides bound to TNKS2 ARC4. (a)
T1-1. Linker: hepta-1,6-diyne. (b) T1-2. Linker: hexa-1,5-diyne. (c) T1-3. Linker:
di(prop-2-yn-1-yl)amine (d) T1-4. Linker: di(prop-2-yn-1-yl)glycine.
and competition FP, where we observed binding by both techniques. Using ITC we de-
termined the peptide dissociation constant of 6.62 ± 0.13 µM, which was 2.5-fold weaker
than pep1 measured by ITC (Figure 3.1). Likewise, using competition FP we observed
a similar trend, obtaining a dissociation constant of 3.41 ± 0.08 µM, which was 5.5-fold
weaker than TAMRA-pep1 measured by direct FP (Figure 3.3b). Co-crystallisation of the
peptide was then attempted with TNKS2 ARC4. However, despite numerous attempts
following protocols/ conditions described by Xu et al. [102], none were successful in pro-
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ducing crystalline material. Lastly, Apo-TNKS2 ARC4 crystals were produced and it was
attempted to obtain co-crystals by ligand-soaking. However, these approaches were also
unsuccessful.
3.3.5 Exploring Arginine mimetics
Our final attempt at improving the binding affinity of TNKS ARC-binding peptides was
also guided by structural information. This effort focused around the conserved arginine
residue at position 1 of the peptide sequence. Guettler et al. had described this amino
acid as being crucial for binding, adopting the ’arginine cradle’ site (Figure 3.10) [131].
Analysing several peptide bound structures, the backbone atoms of residues 1-3 of the
peptide pull away from the protein surface in order to accommodate the large arginine
sidechain. Since it is understood that this interaction between the guanidinium moiety
of the arginine sidechain is necessary, we explored synthesising a TNKS peptide with
a shorter arginine sidechain. Specifically, shortening the chain length by one or two
Figure 3.9: Biophysical characterisation of peptide T1-1 binding to TNKS2 ARC4.
(Left) Competition FP experiment titrating T1-1 against a TNKS2 ARC4, TAMRA-
pep1 complex. Protein and peptide solutions were diluted in PBS+0.01% Tween 20,
1% (v/v) DMSO. All measurements read at 25◦C. (Right) ITC thermograms of T1-1
titrated into the cell containing TNKS2 ARC4 at 25◦C in 50 mM Tris-HCl, 150 mM
NaCl, 2 mM TCEP, 1% (v/v) DMSO, pH 7.5.
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methylene groups may enable the backbone atoms of residues 1-3 to form interactions
with TNKS2 ARC4.
Figure 3.10: Schematic of arginine 1 of TNKS binding peptides binding in the ’argi-
nine cradle’ site, composed of D589, W591, F593 and E598 of TNKS2 ARC4.
Unfortunately, obtaining these modified Fmoc-amino acids or similar derivatives was
prohibitively expensive, thus we attempted to approach this from the opposite perspective.
We sought to mutate a non-conserved residue of the ANK repeat, G558 of TNKS2 ARC4
in order to ascertain whether it was possible to gain affinity through extra interactions
to the peptide. G558 is located in the loop region of the ANK repeat prior to the repeat
containg W591. We visualised these mutations by simple in silico mutagensis of the 5BXO
structure in Figure 3.11 (a-d).
We then assayed wild-type GST-TNKS2 ARC4 and its mutants in a direct FP assay
against TAMRA-pep1 (Figure 3.12 and Table 3.3), to see whether we had improved
the binding affinity by introducing additional interactions to the peptide. Unexpectedly,
the hypothesis proved incorrect, with a loss in binding affinity observed across all three
mutants. The decrease in affinity appeared to correlate with an increase in side chain
length. However, it was unclear whether this effect was due to the mutation disrupting
the structure of the protein, or whether these residues directly disrupted the interaction.
3.4 Discussion
We first aimed to expand the repertoire of biophysical assays to assess ligand binding
using SPR. Although binding was observed, the response of a known peptide analyte was
significantly lower than expected. It is known that some proteins do not tolerate the
immobilisation process often used in SPR, whereby proteins are covalently coupled to
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(a) G558 (b) G558S
(c) G558T (d) G558D
Figure 3.11: In silico mutagensis models of TNKS2 ARC4 mutations adjacent to the
’arginine cradle’ site.
Table 3.3: Dissociation constants of TAMRA-pep1 against GST-TNKS2 ARC4
(G558X) mutants.
Protein Dissociation constant, Kd (nM) Fold change
G558 320 ± 14 -
G558S 1229 ± 55 4
G558T 987 ± 32 3
G558D 4410 ± 226 14
the dextran matrix by EDC/NHS coupling. Furthermore, cross-linking can occur near
the analyte-binding site and thus occlude the analyte sterically. In addition, EDC/NHS
coupling is not performed in a site-specific manner, such that multiple surface-exposed
primary amines can be modified within the same protein molecule. According to a study
by Papalia and Myszka, a coupling stoichiometry of the protein to the surface that is
greater than 1:1 is detrimental to the activity of the ligand [219]. Unfortunately we only
became aware of this work after the Tankyrase project had been discontinued. Otherwise,
it would have been beneficial to explore non-covalent attachment strategies to establish a
more robust TNKS SPR assay.
In parallel to SPR experiments, binding affinites were also assessed using two orthog-
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Figure 3.12: Direct FP measurements of TAMRA-pep1 against wild-type GST-
TNKS2 ARC4 (G558) and mutants G558S, G558T and G558D. Protein and peptides
were diluted in PBS+0.01% (v/v) Tween 20 and measurements read at 25◦C.
onal methods, DSF and ITC. Since some ITC data had already been published, it was
clear that the assay would work as expected. The data subsequently obtained confirmed
that the poor data from SPR experiments was unlikely due to the issues with protein
or peptide samples, such as aggregation or partial unfolding. However, for the purpose
of ligand screening, ITC is a low throughput method and therefore, DSF was explored
to overcome this limitation. Initial experiments were conducted in a 384-well plate for-
mat using a Roche LightCycler 480 II at AstraZeneca. However this instrument was not
routinely available and hence subsequent DSF experiments were performed in a 96-well
plate format using a Biorad CFX Connect machine located in another department of the
university. These two instruments were found to differ greatly in the quality of raw data
produced. Since the data obtained from the Biorad machine was of insufficient quality to
be further analysed, the DSF data presented here was limited to the initial experiments
performed with pep1 at AstraZeneca. All melt curves generated with TNKS1 ARC2-3
could be fitted using Equation 3.1 resulting in accurate melting temperatures, whereas
transition mid-points of TNKS2 ARC4 melt curves were skewed by the non-linear pre-
transition behaviour.
The next goal was to improve the affinity of peptide ligands targeting the ARC do-
mains. Instead of following the same strategy as set out by Dr. Wenshu Xu, it was thought
most reasonable to improve the peptide prior to macrocyclisation, for example by devel-
oping ligands that could distinguish between the binding surface of TNKS1 ARC2-3 and
TNKS2 ARC4. While the peptides listed in Table 3.2 did not bind with high affinity to
either TNKS construct, ARC specificity was observed peptide T5. ARC selectivity may
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be relevant in the regulation of Axin1 as Eisemann et al. observed wild-type Axin 1 to
bind primarily to ARC2 and ARC5 simultaneously rather than ARC1 and ARC4 [126].
Since Tankyrases rely on avidity [129], the rationale to selectively inhibit the ARC do-
mains responsible for Axin1 binding may be beneficial. Although the data presented here
suggests that such selectivity can be achieved, at the time it was not possible to further
the T5 peptide as it required medicinal chemistry knowledge.
Given the limited success of improving the natural peptide sequence, macrocycles
were re-designed with the aim of introducing the macrocycle-protein interactions through
hydrogen-bonding. One peptide, T1-1, was successfully synthesised and characterised
although its binding affinity to TNKS2 ARC4 was at least 2-fold weaker than pep1.
Co-crystallisation of the TNKS2 ARC4-T1-1 peptide complex were attempted to further
understand why the peptide is weaker and where subsequent modification could be intro-
duced to improve the it. However, despite multiple attempts all efforts were unsuccessful.
Given the practical issues involved with this particular peptides due to its severely hygro-
scopic nature, we ultimately ceased to pursue this approach to the project.
3.5 Conclusions
The project to inhibit the Tankyrase substrate binding domains continued on from a
project of a previous PhD student. The project aimed to further improve the peptide
binding affinity to the ARC domains towards that of a typical therapeutic molecule.
This was a significant challenge since work by Guettler et al. and Dr. Wenshu Xu had
seemingly explored these peptides in a thorough manner. Nonetheless, it was possible to
identify a peptide that displayed selectivity towards TNKS1 ARC2-3 over TNKS2 ARC4,
in addition to rationally design novel macrocycles. Lastly, TNKS2 ARC4 G558X mutants
were used to explore the surface cavity adjacent to the arginine cradle site, which indicated
that G558 was either necessary for binding or crucial to protein stability.

Chapter 4
Production of Cdc20 for biophysical
characterisation
4.1 Introduction
The laboratories of David Barford and Brenda Schulman have published the expression
and purification of full-length human Cdc20. These groups have primarily used full-length
Cdc20 to obtain cryogenic electron microscopy (cryo-EM) structures of the APC/C in the
context of its co-activators, substrates and sub-complexes [28, 150–154]. However, the
APC/C co-activators, Cdc20 and its homolog Cdh1, contain intrinsically disordered re-
gions (IDRs) at the N- and C- termini (Figure 4.1). These IDRs are not responsible for
binding to the APC/C substrates and were considered unnecessary for the biophysical
characterisation of designed peptide molecules. The laboratory of Xuelian Luo has pub-
lished multiple X-ray crystal structures of the Cdc20WD40 domain, containing residues
161-477 [193, 195]. Since one of the project goals was to produce co-crystal structures
of Cdc20 bound to inhibitory peptides, it was rational to focus construct design around
published data. Over the years, all groups producing recombinant Cdc20 have used bac-
ulovirus expression vector systems (BEVS). There are no reports on the expression of
Cdc20 using E. coli, and conversations with David Barford highlighted the necessity of
eukaryotic chaperones to aid the folding of Cdc20. Therefore, BEVS were used to generate
Cdc20 protein for biophysical characterisation.
4.2 Methods
4.2.1 Molecular biology
A plasmid encoding His6-MBP-Cdc201−499 with a TEV cleavage site between the MBP
and Cdc20 genes in the pU1 vector was a kind gift from Ziguo Zhang and David Barford
72 Production of Cdc20 for biophysical characterisation
WD40 domain
N-terminal
Intrinsically disordered
region
IR-tail
C-box
C-terminal
Intrinsically disordered
region1 161 477 499
Figure 4.1: Illustration of Cdc20 domains. The WD40 domain is flanked by two
intrinsically disordered regions. The N-terminal region spans residues 1-160, containing
the C-box motif. The WD40 domain spans residues 161-477 and is responsible for
binding to substrate proteins via degron motifs. The C-terminal intrinsically disordered
region comprises residues 478-499, with the IR-tail comprising the terminal residues.
The WD40 domain depicted is from PDB: 4GGC, [193].
(MRC-LMB, Cambridge) [200].
RTH mutagenesis (see Section 2.2.2) was used to remove the MBP tag and the N-
and C- terminal IDRs of Cdc20 in an iterative process, creating a variety of intermediate
constructs that could be useful for this project or for the Barford laboratory (Table 4.1).
In addition to producing recombinant Cdc20 in BEVS, full-length Cdc20 was tagged
with the HiBiT peptide (Promega) in a pcDNA 3.1(-) vector for transient transfection in
mammalian cells. All plasmids and bacmids were produced as described in Section 2.2.6
and are listed in Table 4.1.
4.2.2 Baculovirus expression of recombinant Cdc20 constructs
Generating recombinant virus
Insect cells were transfected in duplicate with bacmid DNA in 24 deep-well blocks. First,
20 µL of SuperFect transfection reagent (Qiagen) and 10 µg of Bacmid DNA (1µg/µL)
were added to 150 µL of SF900 II medium (Gibco) in each well and were incubated at
room temperature for 30 minutes to allow the Bacmid-SuperFect complex to form. To
each well, 5 mL of mid-log Sf21 cells at 5×105 cells/mL in Sf900 II medium, supplemented
with 50 µg/mL gentamicin and 10 % (v/v) FCS, were added. Blocks were sealed with
4.2. Methods 73
Table 4.1: Cdc20 constructs produced for BEVS or transient transfection in mam-
malian cell lines. Theoretical molecular weights (MW) and extinction coefficients at
280 nm (280) are listed for the total gene product and for the final desired product
after cleavage of the purification tag. Molecular weights and extinction coefficients were
calculated using the Expasy ProtParam Web-tool [202].
Construct
Total gene product Cdc20 protein
MW (Da) 280 (M−1cm−1) MW (Da) 280 (M−1cm−1)
His6-MBP-TEV-
Cdc20 (1-499)
99526.0 178190 54850.7 105880
His6-MBP-TEV-
Cdc20 (1-477)
96926.0 178190 52250.7 105880
His6-MBP-TEV-
Cdc20 (161-499)
82122.4 162720 3447.1 90410
His6-MBP-TEV-
Cdc20 (161-477)
79522.4 162720 34847.2 90410
His6-MBP-TEV-
Cdc20 (165-477)
79049.8 162720 34374.6 90410
His6-TEV-Cdc20
(161-477)
39331.7 96370 34847.2 90410
His6-TEV-Cdc20
(165-477)
38859.2 96370 34374.6 90410
HiBiT-Cdc20
(1-499)
56444.6 - 54722.6 -
Cdc20 (1-499)-
HiBiT
56588.8 - 54997.9 -
a breathable membrane and incubated at 27◦C, shaking at 700 rpm (small orbit) for 7
days. After the incubation period, cells were pelleted at 3400×g, 4◦C for 10 minutes and
supernatant containing viral stocks of duplicate wells were pooled and stored at 4◦C.
Baculovirus test expressions
Insect cell small-scale expression tests were performed in two formats which were depen-
dant on the location where the test expressions were performed (AstraZeneca or Depart-
ment of Pharmacology).
At AstraZeneca, mid-log Sf21 cells were added to a 24 deep-well block at 3 × 105
cells/mL with 180 µL of the relevant virus added. In addition to the various Cdc20 con-
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structs, a virus expressing Yellow Fluorescent Protein (YFP) was included as a positive
control. Blocks were sealed with a breathable membrane and incubated at 27◦C, shaking
at 700 rpm (small orbit) for 48 hours. Following the incubation period, cells were counted
using a Vi-Cell cell counter (Beckman Coulter) prior to harvesting. The cell suspension
was pelleted at 3400×g, 15 minutes, 4◦C. The resulting pellet was resuspended in 1 mL
PhyNexus wash buffer (40 mM HEPES, 300 mM NaCl, 20 mM imidazole, 1 mM TCEP,
1 × cOmpleteTM mini EDTA-free protease inhibitor tablet (Roche), 1 × benzonase, pH
7.4). Resuspended cells were freeze-thaw lysed and centrifuged as above to separate cel-
lular debris. Supernatants were loaded onto a PhyNexus robot with Immobilised Metal
ion Affinity Chromatography (IMAC) tips (PhyNexus). IMAC resins were equilibrated
in 1 mL wash buffer, supernatants loaded and then washed twice in 1 mL wash buffer,
prior to recovering the protein in elution buffer (40 mM HEPES, 300 mM NaCl, 500 mM
imidazole, 1 mM TCEP, pH 7.4). Elution fractions were analysed using a NuPAGE 4-12
% acrylamide gel (Novex).
At the Department of Pharmacology, mid-log Hi5 or Sf9 cells (25 mL) were added
to a 50 mL erlenmeyer flask at 5 × 105 cells/mL with 100 µL of His6-TEV-Cdc20 (161-
477) virus. The cell cultures were incubated at 27◦C, shaking 140 rpm for 48 hours.
After incubation, cells numbers were determined using a LUNA-II cell counter (Logos
Biosystems). The cells were then pelleted at 7000×g, 4◦C for 5 minutes and resuspended
in 10 mL IMAC wash buffer (50 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, 1 mM
MgCl2, 5 % (v/v) glycerol, 1 mM TCEP, 1 SigmaFAST EDTA-free protease inhibitor
tablet, pH 8.5). Resuspended cells were freeze-thaw lysed in liquid N2 and were centrifuged
at 15,000×g, 4◦C for 45 minutes. Clarified lysates were loaded onto a 1 mL HisTrap Excel
column at 1 mL/min via a sample line on an ÄKTA Pure chromatography system. The
column was washed with 10 CV of IMAC wash buffer before eluting in IMAC elution
buffer (50 mM Tris-HCl, 300 mM NaCl, 300 mM imidazole, 1 mM MgCl2, 5 % (v/v)
glycerol, 1 mM TCEP, pH 8.5). Samples were prepared and loaded onto a 12 % (w/v)
acrylamide gel and run as described in 2.3.1.
Large-scale expression cultures
Sf21 or Sf9 cells were used for large scale expression cultures and were grown in Sf900
II (Gibco) or Insect-XPRESS (Lonza) medium, respectively. To expand the virus stock,
so-called ’short virus preps’ were prepared, which were later added to the final expression
culture volume. On day 1, virus was added (1 mL virus/ 500 mL cells) to cells at 1.5×106
cells/mL, generating the ’short virus prep’. At the same time, cell cultures were expanded
to the desired culture volume, seeded at a density of 3× 105 cells/mL. Cell cultures and
the ’short virus prep’ were incubated at 27◦C, shaking at 140 rpm for 72 hours. The
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’short virus prep’ and cell cultures were counted before diluting the ’short virus prep’
into the expanded cells (25 mL short virus prep/ 500 mL expanded cell culture). The
cell cultures were incubated at 27◦C, shaking at 140 rpm, for 48 (Sf21) or 60 (Sf9) hours.
Final cell counts were measured and cells were harvested by centrifugation at 3400×g,
4◦C, 15 minutes. Cell pellets were stored at -80◦C until purifications were performed.
4.2.3 Purification of Cdc20WD40 protein
Purifications followed a general workflow as illustrated in Figure 4.2. The purification was
guided by details contained in previous publications [193, 195]. Due to multiple issues
during successive purifications, each attempt differed in its methodology to improve the
yield and purity of Cdc20. Buffers used in purifications are listed in Table 4.2.
Cell lysis and centrifugation
Immobilised Metal ion Affinity 
Chromatography and tandem desalting
Reverse-Immobilised Metal ion
Affinity Chromatography
Anion-exchange chromatography
Size-exclusion chromatography
TEV-cleavage/ His6-tag removal
Figure 4.2: General workflow of Cdc20 purifications.
Cell lysis
Cell pellets (pellet from 1 L of cell culture) were resuspended in 100 mL IMAC wash
buffer with SigmaFAST EDTA-free protease inhibitor tablets (Sigma) and crude DNaseI
(Sigma) or Basemuncher (Expedeon), using a serological pipette or a magnetic stirrer
until the lysate was homogenous. Lysis buffer volume scaled accordingly to the amount
of cell pellet purified. Resuspended cells were transferred into a resealable plastic bag or
aliquotted into 15 mL falcon tubes, frozen flat on dry ice or in liquid N2, respectively, and
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Table 4.2: Buffers used in Cdc20 purifications. Initial purifications began with first
generation buffers and gradually transitioned to second generation buffers by successive
optimisation.
Chromatography
step/ buffer
First generation Second generation
IMAC wash 50 mM Tris-HCl, 300 mM NaCl,
1 mM MgCl2, 30 mM imida-
zole, 5% (v/v) glycerol, 0.25 mM
TCEP, pH 7.5
50 mM Tris-HCl, 300 mM NaCl,
1 mM MgCl2, 10 mM imidazole,
5% (v/v) glycerol, 1 mM TCEP,
pH 8.5
IMAC elution 50 mM Tris-HCl, 300 mM NaCl,
1 mM MgCl2, 300 mM imida-
zole, 5% (v/v) glycerol, 0.25 mM
TCEP, pH 7.5
50 mM Tris-HCl, 300 mM NaCl,
1 mM MgCl2, 300 mM imida-
zole, 5% (v/v) glycerol, 1 mM
TCEP, pH 8.5
IEX LSB 25 mM Tris-HCl, 1 mM MgCl2,
0.25 mM TCEP, pH 7.5
25 mM Tris-HCl, 1 mM MgCl2,
5% (v/v) glycerol, 1 mM TCEP,
pH 8.5
IEX HSB 25 mM Tris-HCl, 1 M NaCl, 1
mM MgCl2, 0.25 mM TCEP, pH
7.5
25 mM Tris-HCl, 1 M NaCl, 1
mM MgCl2, 5% (v/v) glycerol,
1 mM TCEP, pH 8.5
SEC 25 mM Tris-HCl, 150 mM NaCl,
1 mM MgCl2, 5% (v/v) glycerol,
1 mM TCEP, pH 8.5
25 mM Tris-HCl, 150 mM NaCl,
1 mM MgCl2, 5% (v/v) glycerol,
5 mM TCEP, pH 8.5
then thawed in a room temperature water bath. Lysates were clarified by centrifugation
at 45,000×g, 4◦C for 45 minutes. Supernatants were pooled for subsequent IMAC.
IMAC
Supernatants were loaded onto a 5 mL HisTrap Excel column equilibrated in IMAC wash
buffer at 3 mL/min via the sample pump of an ÄKTA Pure chromatography system. The
column was washed using IMAC wash buffer at 7.5 mL/min for 20-30 CV. Proteins were
eluted as described in Section 2.3.2 into a 96 deep-well block, 50 mL falcon tubes (pre-
filled with IMAC wash buffer, no imidazole) or via the outlet valve into a duran bottle
(pre-filled with IMAC wash buffer, no imidazole) on a magnetic stirrer plate.
4.2. Methods 77
TEV cleavage
Pooled IMAC elution fractions were cleaved overnight at 4◦C with an approximate equimo-
lar concentration of His6-TEV protease (S219V) with agitation on a rotating wheel, rolling
platform or magnetic stirrer.
Reverse IMAC
The TEV-cleaved protein solution was either centrifuged briefly or filtered through a 0.80
µm syringe filter to remove precipitates formed during the overnight cleavage. In later
purification attempts, IMAC elution buffer was added to the protein sample to adjust the
solution to 5 mM imidazole. Supernatants were run over a 5 mL HisTrap Excel column
at 3 mL/min, collecting the flow through. The column was then washed with IMAC wash
buffer (0 mM or 5 mM imidazole) at 5 mL/min to collect residual cleaved protein that
was not specifically bound to the column.
Ion Exchange Chromatography (IEX)
Protein solutions from reverse IMAC were diluted 10-fold in IEX LSB to achieve a final
concentration of 30 mM NaCl. Proteins were loaded onto a MonoQ 10/100 GL column
at 6 mL/min via a sample line. Proteins were eluted from the column in a linear gradient
from 30 mM NaCl to 400 mM NaCl over 7.4 CV into 1 mL fractions at 4 mL/min. Protein
elutions were analysed by SDS PAGE prior to centrifugal concentration and subsequent
purification by size-exclusion chromatography.
Size Exclusion Chromatography (SEC)
Elution fractions containing Cdc20 protein were pooled and concentrated in a Vivaspin
20, 10 K MWCO centrifugal filter (Sartorius Stedim) at 8000×g, 10◦C in a fixed angle
rotor. A Superdex 75 Increase 10/300 GL column was equilibrated with SEC buffer and
proteins were injected onto the column using a 500 µL capillary loop. Samples were
separated at 0.75 mL/min over 1 CV. If the total sample volume after concentration was
> 0.5 mL, multiple runs were performed. Eluted proteins were analysed by SDS PAGE
prior to concentration. Protein was aliquoted, flash frozen in liquid N2 and were stored
at -80◦C until required.
4.2.4 Preparation of Cdc20 for SPR
His6-TEV-Cdc20 (161-477)
Protein eluted from the IMAC column were pooled and concentrated. Injections of 500 µL
were run on a Superdex 75 Increase 10/300 GL column at 0.75 mL/min in 25 mM HEPES,
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150 mM NaCl, 1 mM MgCl2, 0.5 mM TCEP, 5% (v/v) glycerol, pH 7.5. Elutions were
pooled and concentrated to 10 µM in Vivaspin 20, 10 K MWCO centrifugal concentrator
(Sartorius Stedim). The pooled and concentrated protein was analysed by SDS PAGE.
Cdc20 was then aliquoted and flash frozen in liquid N2 before storing at -80◦C, until
required.
Biotinylation of Cdc20 (161-477)
The protocol for the biotinylation of protein was adapted from [219]. Cdc20(161-477)
was thawed from -80◦C and centrifuged at 20,000×g, 4◦C for 10 minutes to remove any
precipitates. Cdc20 (40 µL, 48 µM) was diluted in biotinylation buffer (10 mM Tris-HCl,
150 mM NaCl, 1 mM MgCl2, 5% (v/v) glycerol, 1 mM TCEP, pH 7.3) to a final volume of
500 µL. A 1 mg aliquot of Sulfo-NHS-LC-LC-Biotin (Thermo Fisher Scientific, A35358)
was dissolved to a 1 mM stock solution in biotinylation buffer. The Sulfo-NHS-LC-LC-
Biotin solution was added to the protein to achieve a final molar ratio of 0.9:1 of biotin
reagent to Cdc20. The mixture was vortexed briefly and allowed to react on ice for 3
hours. The sample was then purified on a Superdex 75 Increase 10/300 GL column in
biotinylation buffer at 0.75 mL/min to remove the unreacted Sulfo-NHS-LC-LC-Biotin.
Elution fractions were pooled, aliquoted and flash frozen in liquid N2 before storing at
-80◦C.
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4.3 Results and Discussion
4.3.1 Test expressions
The over-expression of Cdc20 in each baculovirus infection was assessed using two metrics.
The cell count information provided qualitative information on successful viral infection
in conjunction with protein visualisation on a SDS PAGE gel. Two constructs lengths of
the Cdc20WD40 domain were explored. The first was the Tian et al. published construct
comprising residues 161-477 [193]. The second was a four amino acid truncation from the
N-terminus of this construct, i.e. 165-477, which corresponds to the residues observed and
modelled in the 4GGC PDB structure. Marginal Sf21 cell growth arrest was observed in
the viruses containing MBP-tags. In addition, these constructs showed similar viabilities
compared to the non-infected control, indicating poor infection. In contrast, cultures
infected with Cdc20 viruses without the additional MBP-tags showed cell growth arrest,
a drop in cell viability and cell swelling, indicating good viral infection and expression
as was observed with the positive control sample, YFP (Table 4.3). In addition, samples
from small-scale purifications using a PhyNexus instrument were analysed by SDS PAGE.
As can be seen in Figure 4.3, SDS PAGE gel analysis provided a more direct measure of
protein over expression. Viruses His6-TEV-Cdc20 (161-477) and His6-TEV-Cdc20 (165-
477), lanes 3 and 5 respectively, appear to have an additional protein expressed around
40 kDa, compared to the non-infected control sample. Proteins at this molecular weight
are in agreement with the expected molecular weight for the constructs (Table 4.1).
Table 4.3: Cell count information prior to harvesting and PhyNexus runs for each
virus construct. YFP is used as a postive control virus (provided by AstraZeneca).
Non-infected control gives baseline values for average cell diameter, % viability and
indication on cell growth arrest in positive samples.
Sample Final cell count % viability avg. diameter (µm)
His6-MBP-TEV-Cdc20 (161-477) 60.85× 105 92.5 21.83
His6-TEV-Cdc20 (161-477) 34.21× 105 87.4 22.74
His6-MBP-TEV-Cdc20 (165-477) 91.62× 105 92.5 19.74
His6-TEV-Cdc20 (165-477) 37.77× 105 87.0 24.01
YFP - positive control 29.85× 105 70.5 22.76
Non-infected - negative control 102.53× 105 94.2 19.61
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Figure 4.3: SDS PAGE gel of elutions fractions from Phynexus runs with Ni-NTA
tips. Lane 1: SeeBlue Plus2 marker, lane 2: His6-MBP-TEV-Cdc20 (161-477), lane
3: His6-TEV-Cdc20 (161-477), lane 4: His6-MBP-TEV-Cdc20 (165-477), lane 5: His6-
TEV-Cdc20 (165-477), lane 6: YFP, positive control, lane 7: Non-infected control,
lane 8: BSA standard. Protein band highlighted in the red boxes corresponds to the
expected molecular weight of the Cdc20 construct.
Due to unforeseen circumstances, the Cambridge insect cell culture facilities of As-
traZeneca were moved to Macclesfield during the final year of the PhD. This further
complicated the production of new insect cell pellets, since it was not possible to obtain
the AstraZeneca Sf21 cell line for work outside of AstraZeneca at a time when the expres-
sion protocols had already been optimised for this particular cell line. As a consequence
insect cell culture had to be performed within the Department of Pharmacology using
other insect cell lines. Test expressions were performed in Sf9 and Hi5 cell lines, using the
His6-TEV-Cdc20 (161-477), due to its higher expression in the Sf21 cell line (Figure 4.3),
compared to the His6-TEV-Cdc20 (165-477) virus. Cell growth in the Hi5 cells arrested,
but this did not appear to occur in the Sf9 cells. In addition, the Sf9 cell viability did
not drop to the same extent as in the Hi5 cells. However, the average diameter of the
Sf9 cells did increase significantly, whereas it appeared to decrease in the Hi5 cells (Table
4.4). The drop in average diameter in the Hi5 cells may be artefactual due to a change
in cellular morphology from circular to an elongated shape, which was often counted as
multiple smaller cells by the LUNA-II cell counter. Despite the initial appearance from
the cell count data, Figure 4.4 shows that the Sf9 cells are expressing the construct at
a higher level compared to the Hi5 cells. All large-scale expression cultures were then
performed with Sf9 cells.
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Table 4.4: Cell count information prior to harvesting and purification runs for Cdc20.
Non-infected control gives a baseline of average cell diameter, % viability and indication
on cell growth arrest in positive samples.
Sample Final cell count % viability avg. diameter (µm)
Sf9 - infected 3.89× 106 93.0 15.1
Sf9 - non-infected 4.68× 106 98.1 11.3
Hi5 - infected 1.71× 106 86.6 15.3
Hi5 - non-infected 3.35× 106 94.0 16.9
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Figure 4.4: SDS PAGE gel of purification fractions from 1 mL HisTrap Excel column.
Protein band highlighted at arrow indicator, correspond to proteins of the expected
molecular weight for the Cdc20 construct.
4.3.2 Purification of Cdc20WD40 protein
Every purification attempt differed in its protocol to some extent, where gradual improve-
ments were attempted at each iterative chromatography stage. The result was that no two
purifications were alike. Nevertheless, at each stage, progress was made and pure Cdc20
protein was obtained, but yield was often diminished. In each chromatography step, SDS
PAGE gels are shown, highlighting where chromatography was not optimal and how it
was improved accordingly.
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Cell lysis
It was assumed that optimal lysis could be performed using the C5-Emulsiflex as was
normally used for the lysis of E. coli cells. However, unlike E. coli, insect cells lysate is
very viscous causing air bubbles to be trapped during lysis that could not be removed
using high-speed centrifugation. The air bubbles and viscosity can create downstream
problems during liquid chromatography, as both air and high pressure due to very vis-
cous liquids could damage chromatography columns. However, unlike E. coli, insect cells
membranes are significantly weaker and can be lysed by a simple freeze-thaw cycle. The
supernatant from freeze-thaw lysis was considerably less viscous than when lysed using
the C5-Emulsiflex, and did not contain air trapped within it. Initially, freeze-thaw ly-
sis was performed using re-sealable bags on dry ice for total volumes of approximately
100 mL. However, in scaled-up protein purifications (cell pellets from 3.5 L of expression
culture) in which lysate volumes were around 300 mL, this process became less feasible.
Instead, resuspended lysates were aliquoted into 15 mL tubes and were freeze-thaw lysed
in liquid N2, due to ease of handling.
IMAC
Standard buffer compositions (Table 4.2, first generation) and protocols were used in early
IMAC purifications. Proteins bound to the 5 mL HisTrap Excel column were washed with
20 CV of IMAC wash buffer and eluted from the column. In early purification attempts,
the final wash fraction (wash 7 in Figure 4.5a) clearly indicates that the His6-TEV-Cdc20
(161-477) protein was eluting prematurely from the column. As a result, the yield from
this chromatography step was particularly poor. In subsequent purifications, the concen-
tration of imidazole in the IMAC wash buffer was decreased to 15 mM, however premature
elution from the IMAC column was still observed. To reduce this loss of protein, the con-
centration of imidazole was further reduced to 10 mM and the buffer pH was increased to
8.5 yielding the optimal second-generation buffers listed in Table 4.2. These alterations
resulted in a better overall yield from this chromatography step, but also came at a cost
of eluent purity, as can be seen in Figures 4.5b and 4.5c. Retrospectively, it must be
noted that the imidazole supplier was changed mid-way through these purifications. The
latter batch of imidazole was of lower purity than the previous batch, which could be
observed by its higher A280 signal and more distinct off-yellow colour compared to the
previous batch. Furthermore, other individuals in our laboratory had also observed their
His6-tagged constructs washing off at lower concentrations of imidazole than expected.
Thus, removal of protein contaminants was less efficient compared to purification using
higher purity imidazole. Unfortunately due to the limiting nature of reagents, it was not
possible to systematically determine what was the true cause of premature elution from
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the IMAC column.
Protein precipitation directly after IMAC elution into a 96 deep-well block was the
major source of protein loss. Precipitation would occur in a concentration-dependant
manner as could be observed when comparing the solution in the 96 deep-well block to
the ÄKTA chromatograms. Since samples were always taken for SDS PAGE gel analysis
after centrifugation, it was not possible to know how much Cdc20 was lost. However,
given the low yield often obtained, every step to improve the yield had to be explored.
In later IMAC purifications, alternative methods were employed to reduce precipitation.
Since protein precipitation appeared concentration-dependent, immediate dilution of the
IMAC eluent should be beneficial. The first attempt was to elute into 50 mL tubes
pre-filled with volumes of IMAC wash buffer (without imidazole). While the principle did
work and significantly less precipitation was observed, it was realised that physical mixing
was required during elution. Since this was not possible, using the fraction collector on
the ÄKTA, an alternative had to be developed. Elution via the outlet valve solved this
issue, where it was possible to directly connect the line from the outlet valve to a duran
bottle containing IMAC wash buffer (without imidazole) placed on a magnetic stirrer
plate. With gentle stirring during IMAC elution, no precipitation was observed.
TEV cleavage
An approximate equimolar amount of His6-TEV protease (S219V) was used for the
overnight cleavage of the His6-TEV-Cdc20 (161-477) protein. This high concentration
of TEV protease was used for two main reasons. The specific activity of the enzyme after
purification (Section 2.3.3) was never calculated. In addition, the following chromatog-
raphy step would remove all His6-tag containing proteins on the IMAC column, thereby
separating the excess TEV protein from the desired product. Since incomplete cleavage of
the Cdc20 construct would result in a significant loss of yield, an excess of TEV protease
was always added to ensure complete cleavage.
Reverse IMAC
IMAC purification from insect cells typically contains several contaminating proteins at
high molecular weights that bound non-specifically to the HisTrap column. These con-
taminants should be able to re-bind the IMAC column in the same manner, and this could
serve as an effective purification strategy. In all reverse IMAC purifications, re-binding
of contaminants was observed to varying degrees (Figure 4.5). In some instances, Cdc20
without the His6-tag was also observed to re-bind the IMAC column, likely due to its
low solubility and ‘sticky’ nature. In cases where this occured, it was possible to re-elute
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Figure 4.5: SDS PAGE gels of IMAC, TEV cleavage and reverse-IMAC purification
steps. (a) IMAC column was washed with using first-generation buffer (Table 4.2). (b)
IMAC column washed with 20 CV, second-generation IMAC buffer. (c) IMAC column
was washed with 30 CV second-generation buffer.
Cdc20 using IMAC elution buffer, however the eluent would inevitably be more contam-
inated and due to the high amount of impurities, it was not possible to further purify
this protein. In later purifications, non-specific binding of Cdc20 was prevented by the
addition of IMAC elution buffer into the TEV cleaved sample to a final concentration of
5 mM imidazole. This addition drastically improved the recovery of Cdc20 in the reverse
IMAC flow through fraction, but also came at a cost of purity since varying amounts of
the high molecular weight contaminants were also prevented from non-specific interaction
with the column (Figure 4.5).
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IEX
Ion exchange chromatography is often used to separate molecules of similar molecular
weights, with varying charge and is often employed as an intermediate purification step
between affinity chromatography and SEC. The theoretical isoelectric point (pI) of Cdc20
(161-477) was calculated at 6.58 using Protparam [202]. In all IEX buffer systems (Table
4.2), Cdc20 should be net negatively charged and able to bind anion exchange resins,
such as the MonoQ (GE Healthcare). Proteins were diluted 10-fold in MonoQ LSB to
achieve a concentration of 30 mM NaCl to enable proteins to bind the MonoQ 10/100
GL column (GE Healthcare). Due to the typically large elution volumes from the IMAC
column, the resulting volume to be loaded onto the anion exchange columns was typically
between 0.5 - 1.5 L. As a consequence proteins were loaded at the maximal flow rates
allowed for the column (dependant on the pre-column pressure limits) to reduce loading
times. Nevertheless, sample loading would often span hours.
All proteins loaded onto the MonoQ 10/100 GL column would elute before the gradient
reached 400 mM NaCl. Most contaminant proteins eluted from the column towards the
end of the gradient, while Cdc20 would elute earlier, resulting in highly pure Cdc20 from
the MonoQ column as monitored by SDS PAGE (Figure 4.6b). During IEX chromatog-
raphy proteins typically elute in a sharp peak. However, in the case of Cdc20, elution
was always observed to be biphasic with broad peaks occurring between 50 mM and 250
mM NaCl, of which Peak 1 was right-skewed and peak 2 was symmetric (Figure 4.6a).
This was observed regardless of the buffer pH used, i.e pH 7.5 or pH 8.5, and the presence
or absence of 5% glycerol. Despite the elution profile being non-standard for Cdc20, the
technique was still used as the sample purity would be increased. Due to the typically low
yields of protein, the two separate peaks were never investigated independently to look
at any functional differences.
In reverse IMAC purifications where Cdc20 was observed to non-specifically bind the
IMAC column, purification of this sample was attempted by IEX. However, due to the
increased number of contaminant proteins, only poor separation was observed (Figures
4.6c and 4.6d). This highlighted the necessity to first obtain the highest possible purity
of protein using IMAC.
4.3. Results and Discussion 87
Peak 1 Peak 2
(a)
260 kDa
15 kDa
25 kDa
35 kDa
40 kDa
50 kDa
70 kDa
100 kDa
140 kDa
B9 G2F5F2D7D3C12C9C7C3 C5C1
Cdc20
(161-477)
(b)
88 Production of Cdc20 for biophysical characterisation
(c)
B9 E5D7D4D2C12C9C7C5C3C1B11
260 kDa
15 kDa
25 kDa
35 kDa
40 kDa
50 kDa
70 kDa
100 kDa
140 kDa
Cdc20
(161-477)
(d)
Figure 4.6: ÄKTA chromatograms and their associated SDS PAGE gels of anion ex-
change chromatography purifications. (a, b) Sample from reverse IMAC flow through.
(c, d) Sample from reverse IMAC re-elutions.
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SEC
Due to the broad elution profiles from anion exchange chromatography, elution fractions
had to be concentrated prior to SEC. Centrifugal concentration would often take several
hours to achieve volumes ranging from 1 mL to 3 mL of protein. Slow concentration times
are indicative of protein precipitation occurring on the membrane. In order to reduce the
build up of concentration gradients within the concentrator, protein solutions were resus-
pended at regular intervals. Precipitates in solution was rarely observed, but it is possible
that they would remain bound to the concentrator membrane.
A Superdex 75 Increase 10/300 GL column (GE Healthcare) was used size exclusion
chromatography, due to the superior resolution and higher mechanical stability of the
Increase matrix compared to the standard Superdex matrix. This allowed the applica-
tion of flow rates of 0.75 mL/min, without losing significant resolution resulting in run
times of less than 30 minutes. Even with complex sample inputs, good separation could
be observed (Figure 4.7b). The column performed very well over multiple, consecutive
and non-consecutive runs, as is highlighted in the very reliable retention times for the
elution of Cdc20 (Figure 4.7a). This reliability aided the precise fraction collection and
monitoring the standard of protein purity between different preparations.
Purified Cdc20 was to be used in three main downstream experiments. Both meth-
ods for biophysical characterisation of peptide ligands (DSF and SPR) rarely required
any concentration after elution from the SEC column. However, for X-ray crystallog-
raphy, centrifugal concentration was necessary. In all instances, we observed similarly
long concentration times as described earlier, and protein from multiple preparations had
to be pooled in order to generate enough sample to prepare a single 96-well plate for a
crystallization trail.
4.3.3 Preparation of Cdc20 for SPR
Two ligand immobilisation techniques were explored for SPR. In both methods, an affin-
ity capture approach was preferred over standard amine coupling that requires pre-
concentration using low pH buffer, in which many proteins are unstable. The first method
utilised the affinity of His6-tagged Cdc20 construct to a Ni-NTA biosensor chip. The sec-
ond method utilised biotinylated-Cdc20 binding to a streptavidin-coated biosensor chip.
An in vitro biotinylated construct was considered utilising the Avi-tag and BirA biotin
ligase for biotinylation site specificity. However, given the need to clone and generate
new baculovirus it was considered unnecessary for the small scale of protein that would
inevitably be required for immobilisation onto the biosensor.
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Figure 4.7: (a) SDS PAGE gel of Cdc20 purification using a Superdex 75 Increase
10/300 GL column. Input sample run on gel shows contaminant proteins that are
separated from the Cdc20 in the elution fractions. (b) Overlay of multiple ÄKTA
chromatograms monitoring the A280 (solid line) and A260 (dashed line) of multiple
sample injections onto the column. Blue = run 1, orange = run 2, green = run 3.
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His6-TEV-Cdc20 (161-477)
Despite the normal Cdc20 purification requiring IEX chromatography, it was possible to
separate contaminant proteins present in a higher purity IMAC elution sample using the
Superdex 75 Increase 10/300 GL column equilibrated in HEPES buffer since the protein
would be amine coupled to the Ni-NTA biosensor after affinity capture. The purity of
this sample was confirmed by SDS PAGE of the pooled and concentrated protein and was
estimated to be >95% pure (Figure 4.5a, lane ‘SPR SEC’).
Biotinylation of Cdc20 (161-477)
The EZ-linkTM Sulfo-NHS-LC-LC-Biotin (Thermo Fisher Scientific) was used for chemical
biotinylation. This particular reagent was used due to the length of the linker provided
between the biotin group and Cdc20. Despite the commonly assumed principle that
NHS/EDC reactions should not be performed in buffers containing primary amines, Pa-
palia and Myszka present data that prove otherwise and show the reaction to work in
Tris-HCl buffer at a pH below the pKa of Tris. Due to the possibility of losing protein
during buffer exchange, Cdc20 was instead diluted in a buffer based on the results from
Papalia and Myszka [219]. The conjugation stoichiometry was determined as 1:1 of bi-
otin:Cdc20, and the yield was estimated to be ≈ 10% by ESI-MS on a Synapt G2-Si
(Waters), run by Dr. Christopher Stubbs at AstraZeneca. The predominant mass ob-
served corresponded to that of unconjugated Cdc20 (34847.1 ± 0.1 Da, Figure 4.8b),
which agrees with the predicted molecular weight (Table 4.1). A second mass correspond-
ing to Cdc20 coupled to a single Sulfo-NHS-LC-LC-Biotin molecule (35299.2 ± 0.4 Da)
was detected. This mass shift of 452.1 Da is in agreement with the expected addition of
452.6 Da [220].
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Figure 4.8: (a) m/z spectra of 25 nM Cdc20/ minimally biotinylated Cdc20. (b) Cal-
culation of derived total masses using the MassLynx, maximum entropy 1 (MaxENT1)
calculation from the m/z spectra.
4.4 Conclusions
This chapter discusses the production of Cdc20, which was used downstream to charac-
terise synthesised peptide ligands. First, a small series of Cdc20 constructs, based on
previously reported data described in the literature, was generated. For each construct,
recombinant baculovirus was produced by transfection in Sf21 insect cells. Out of the
four baculoviruses produced, the two viruses without the MBP-tags expressed the desired
proteins at levels detectable by SDS PAGE. Cdc20 (161-477), the literature precedent
construct published by Xuelian Luo’s lab [193, 195], was observed at a higher yield per
mL of Sf21 culture compared to the shorter construct.
One of the most challenging aspects of this project has been to produce suitable quan-
tities of Cdc20 for biophysical and structural characterisation. In order to obtain pure
protein in sufficient quantities, purification methods were iteratively adapted between
each purification attempt to improve the yield. Generating a good protocol for IMAC
was particularly important in obtaining highly pure protein, but precipitation at this step
was a significant issue and was likely the cause for reduction in the overall yield. IEX
chromatography was also a necessary step in the majority of purifications, however an op-
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timal elution profile in which Cdc20 would elute in a sharp peak from the MonoQ column
was never obtained. SEC using a Superdex 75 Increase 10/300 GL column was employed
as a final polishing step that resulted in highly pure protein. Solubility of Cdc20 was al-
ways an issue, particularly when attempting to concentrate the protein using centrifugal
concentrators in preparation for SEC or in achieving concentrations suitable for setting
up protein crystallisation plates.
Biotinylation of Cdc20 for use in SPR experiments was also explored. The amine
coupling reaction was performed in a buffer containing a primary amine (Tris), which is
contrary to what is standard in the field. Nevertheless, single-site biotinylation of Cdc20
was observed by ESI-MS and the final yield, although only 10%, was more than sufficient
for future SPR experiments.

Chapter 5
Design and synthesis of APC/CCdc20
peptide inhibitors
5.1 Introduction
This chapter will focus on the process of developing peptides against the APC/C and its
co-activator Cdc20. Here, the aim is give an overview of the peptides before describing
their binding activities in the following chapter. The design of peptides was based on
knowledge from consensus degron sequences in addition to structural data available from
EM and crystal structures of Cdc20 and Cdh1 bound to peptides derived from various
APC/C substrates. Only limited structural information is available for degron motifs
bound to Cdc20. However, Cdc20 and Cdh1 share a high degree of structural homology,
particularly around the WD40 domain containing the degron-binding sites. Therefore,
data from both Cdc20 and Cdh1 were used in the design process. Initially, a small subset
of peptide inhibitors were designed and synthesised targeting the binding sites for D-box,
KEN-box and ABBA motifs (Figure 5.1). Additionally, peptides were designed to inhibit
interactions between Cdc20 and the APC/C by mimicking the N-terminal C-box motif of
Cdc20.
5.2 Methods
5.2.1 Cryo-EM and X-ray crystal structure analysis
Models of Cryo-EM or X-ray crystal structures were analysed using PyMOL [204]. Analy-
sis of electron density maps (2Fo-Fc) was performed in some instances and map coefficients
file (.mtz) were downloaded from RCSB PDB [221, 222]. Coordinate (.pdb) and map co-
efficients files (.mtz) were loaded into Coot [213] to assess the 2Fo-Fc data in local areas,
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Figure 5.1: Overlay of the D-box (magenta, PDB:4BH6 [165], the KEN-box (yellow,
PDB:4GGD [193]) and the ABBA motif (grey, PDB:4BH6 [165]) with Cdc20 (cyan,
PDB:4GGD [193].
contoured at 1.5σ.
5.2.2 Solid-phase peptide synthesis (SPPS)
All peptides were synthesised using a vacuum manifold setup to aid the parallel syn-
thesis of multiple peptides simultaneously (Figure 5.2). Peptides were synthesised on
Ramage-ChemMatrix R© resin (Sigma Aldrich, 727792), using Fmoc-protected amino acids
(Sigma Aldrich). Fmoc-L-cBuAla-OH (CAS no: 478183-62-9), Fmoc-L-NptGly-OH (CAS
no: 139551-74-9) and (s)-Fmoc-2-amino-4,4,4-trifluoro-butryic acid (CAS no: 181128-
48-3) were purchased from Iris Biotech GmbH. Hexafluorophosphonate azabenzotriazole
tetramethyl uronium (HATU) and 1-Hydroxy-7-azabenzotriazole (HOAt) were purchased
from ApexBio and Sigma Aldrich, respectively. Peptides were synthesised using two pro-
tocols, of which the second protocol was optimised to increase the throughput of coupling
reactions and save reagents. The second method did not appear to compromise the yield
or purity of the crude sample.
Method 1
Synthesis was performed on a 0.1 mmol scale. Ramage-ChemMatrix R© resin (204 mg,
loading capacity of 0.49 mmol/g) was weighed into a Bio-rad Econo-Pac R© polypropylene
chromatography column with a nylon frit at the base. All swelling, coupling, de-protection
and washing steps of resins were performed with gentle bubbling using compressed air or
N2. Prior to coupling, resins were swelled for at least 30 minutes in DMF. The Fmoc-
protecting group from the previously coupled amino acid was de-protected in 20 % (v/v)
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Figure 5.2: SPPS using polypropylene columns on a vacuum manifold set up. Resins
are bubbled gently to ensure mixing from an inlet line of compressed air or N2, through
a series of 3-way luer-lock valves connected in parallel. Valve positions allow bubbling,
drainage or capping. Low vacuum pressure aids the drainage of solutions in the column.
piperidine in Dimethylformamide (DMF) for 15 minutes. Following de-protection, resins
were washed five times in DMF to remove residual piperidine. Meanwhile, Fmoc-L-amino
acids (5 molar equivalents (eq.)), HATU (5 eq.) and HOAt (5 eq.) were dissolved in 2
mL of N -Methyl-2-pyrrolidone (NMP). N ,N -Diisopropylethylamine (DIEA, 8.5 eq.) was
added to activate the resulting mixture for 7 minutes. Activated Fmoc-L-amino acids were
coupled for 1 hour to the resin were washed three times with DMF to remove uncoupled
amino acids. This process was repeated for each amino acid to be coupled to the peptide.
Finally, peptides were N-terminally acetylated in a 10 mL cocktail of acetic anhydride,
DMF and DIEA (2:2:1), respectively for 1 hour.
Method 2
Synthesis was performed on a 0.1 mmol scale using Ramage-ChemMatrix R© resin with
the following alterations to the protocol. Fmoc-L-amino acids (2 eq.), HATU (2 eq.),
HOAt (2 eq.) were dissolved in ≈ 2 mL of NMP. DIEA (3.4 eq.) was added to activate
the resulting mixture for 1 minute. Activated Fmoc-L-amino acids were coupled for 10
minutes. Coupling reactions of Fmoc-L-Arginine were performed with twice with 5 eq.
for 30 minutes each. In addition, the N-terminal acetylation reaction was reduced to 10
minutes.
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5.2.3 Ring-closing olefin metathesis
Resins were washed 4 times in DMF, 3 times in MeOH and twice in Et2O to clean
and dry the resins prior to ring-closing olefin metathesis (RCM). All RCM reactions
were performed in anhydrous dichloroethane (DCE). Resins were swelled in DCE while
bubbling with N2 gas before the reaction was intiated by the addition 3 mL of 10 mg/mL
Grubb’s 1st generation catalyst in DCE (Sigma Aldrich), bubbling in N2 gas for 2 hours.
The RCM reaction was repeated twice more with fresh reagent to increase the yield. The
resins were then washed four times in 50% DMF/DMSO and were soaked overnight in
the final wash solvent. An example of the RCM reaction is illustrated in Figure 5.3.
Grubb’s 1st
generation
catalyst
DCE
2h 
r.t.
Figure 5.3: Illustration of the RCM reaction for i,i+3, i,i+4 and i,i+7 staples in
α-helical peptides. Abbreviations: DCE - Dichloroethane, r.t. - room temperature,
S5 - S -2-(4’pentenyl) alanine, R5 - R-2-(4’pentenyl) alanine and R8 - R-2-(7’octenyl)
alanine. Figure adapted from Verdine and Hilinski [223]
5.2.4 Peptide cleavage
Resins were washed 4 times in DMF, 3 times in MeOH and twice in Et2O to clean and
dry the resins appropriately and were then transferred to a 50 mL falcon tube. For each
peptide, 8.6 mL of a cleavage cocktail containing 93% trifluoroacetic acid (TFA), 3.5%
ddH2O and 3.5% triisopropylsilane (TIPS) were added to the resin. Tubes were capped
and incubated with vigorous shaking for 1 hour to cleave the peptide from the resin.
Following this incubation, resins were separated from the cleaved peptide solution by
filtration through the polypropylene chromatography column used in the synthesis into a
fresh 50 mL falcon tube. Compressed air flow was then applied to the chromatography
columns through an adapted lid to remove residual peptide solutions from the resins.
Peptide solutions were triturated by the addition of 45 mL of Et2O and the resulting
peptide precipitate was isolated by centrifugation at 10,000 × g for 1 minute in a fixed
angle rotor before drying under a flow of N2. Peptides were then dissolved in a suitable
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ratio and volume of ddH2O/acetonitirile (MeCN) required to achieve full dissolution.
5.2.5 Analytical characterisation of peptides
Molecular weights of synthesised peptides were calculated using ChemDraw Ultra 12.0
software (CambridgeSoft, PerkinElmer). All peptide solutions were filtered through a
0.45 µm polytetrafluoroethylene (PTFE) syringe filter into a 250 µL polypropylene vial
(Agilent) for Liquid chromatography mass spectrometry (LCMS) and High-performance
liquid chromatography (HPLC) analyses.
Liquid chromatography-mass spectrometry (LCMS)
Chromatographs were recorded using a Waters ACQUITY H-Class UPLC with an ESCi
Multi-Mode Ionisation Waters SQ Detector 2 spectrometer using MassLynx 4.1 software.
Liquid chromatography runs separated on an ACQUITY UPLC R© CSH C18 (2.1 mm ×
50 mm, 1.7 µm, 130 Å) at 40◦C, with a PDA eλ detector 220 – 800 nm, interval 1.2 nm.
The following solvent and gradients were used for the runs. Solvent A: 2 mM NH4OAc
in 95% H2O, 5% MeCN; solvent B: 100% MeCN; solvent C: 2% formic acid. The linear
gradient was run from 5 - 95 % B with a constant of 5 % C over 1 minute, at a flow rate
of 0.6 mL/min.
Analytical High-performance liquid chromatography (HPLC)
Analytical HPLC chromatographic separations were obtained on an Agilent 1260 Infinity
system using a Supercosil ABZ+PLUS column (150 mm × 4.6 mm, 3 µm), eluting with
a linear gradient system (solvent A: 0.1% (v/v) TFA in H2O, solvent B: 0.05% (v/v)
TFA in MeCN) over 15 min at a flow rate of 1 mL/min. Eluents were monitored by UV
absorbance at 220 and 254 nm.
5.2.6 Semi-preparative HPLC
Semi-preparative HPLC was performed using an Agilent 1260 Infinity on a Supercosil
ABZ+PLUS column (250 mm × 21.2 mm, 5 µm) eluting peptides with a linear gradient
system (solvent A: 0.1% (v/v) TFA in H2O, solvent B: 0.05% (v/v) TFA in MeCN) over
20 min at a flow rate of 20 mL/min. Eluents were monitored by UV absorbance at 220
and 254 nm.
5.2.7 Quantification of peptide mass
Purified peptide solutions from semi-preparative HPLC were lyophilised using a -100◦C
freeze dryer (LaboGene, CoolSafe) in 50 mL falcon tubes. Solutions were frozen in liquid
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N2 and placed under vacuum for solvent sublimation to occur. Lyophilised peptides were
weighed using a 5 figure balance (0.01 mg resolution). Peptides were then dissolved to a
desired concentration (e.g 5 mg/mL) in an appropriate solution of H2O/MeCN to achieve
complete dissolution. Peptide solutions were then aliquoted in equal volumes into 1.5 mL
tubes and freeze-dried again to obtain multiple aliquots of a pre-determined mass.
5.3 Results
Peptides targeting degron-binding sites within Cdc20 or the Apc8 subunit of the APC/C
were designed using consensus degron sequences obtained from APC/C substrate proteins
(Figure 5.4) [165, 166, 224]. To aid the design process, X-ray crystal structure data of
proteins or small molecules bound to the degron-binding sites of Cdc20 [193, 195, 225]
and Cdh1 [165] were also used. Sequences, structures and analytical data relating to all
synthesised peptides are contained within Appendix B and are summarised later in Table
5.1.
Fx[ILV][FHY]x[DE]
D-box KEN-box ABBA motif
1 2 3 4 65
Figure 5.4: Consensus binding motifs derived from 68 APC/C substrates for the D-
box and KEN-box motifs (adapted from He J. et al. 2013), [165]. Consensus ABBA
motif adapted from Di Fiore et al. 2015, [166]. Numbers labelled in red describe amino
acids necessary for co-activator binding.
5.3.1 D-box peptide design
Sequences of the D-box peptide
The D-box peptide is comprised of nine amino acids, [165] and is the most studied of
all motifs in the literature with 119 D-box degrons experimentally validated across all
organisms [168, 169]. For all peptides the canonical nine-residue motif was used. The mi-
totic checkpoint complex (MCC) is a multi-subunit complex that binds to the APC/C to
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prevent premature anaphase onset, if chromosomes have not fully attached to the mitotic
spindle [173, 224, 225]. The structure of fission yeast MCC (PDB:4AEZ) was determined
at 2.3 Å resolution as a heterotrimer of Cdc20, Mad2 and Mad3. Mad3 interacts with
the D-box and KEN-box binding sites of Cdc20 simultaneously [225]. Figure 5.5a illus-
trates how the C-terminus of Mad3 from one MCC heterotrimer (magenta) binds to the
D-box-binding site of Cdc20 contained within the other MCC heterotrimer (cyan, surface
representation) in the same asymmetric unit. This inter-MCC interaction is believed to be
a crystallographic artefact of packing, and Chao et al. detail how the Mad3 C-terminus
provides a D-box peptide mimetic [225]. Nonetheless, this structure provided the first
atomistic detail of how a D-box peptide may interact with the Cdc20WD40 domain. The
C-terminal residues of Mad3 appear to be better resolved in one heterotrimer (cyan) and
Coot was used to further examine the local architecture, contoured at 1.5σ in the 2Fo-Fc
map (Figure 5.5b). The electron density of amino acids C-terminal to Leu216 within the
Mad3 D-box peptide mimic are well defined. However, it is unclear whether this is a true
representation of the interactions that may occur in natural D-box degrons, or whether it
is a crystal packing artefact, in which the residues appear to be wedged tightly between
the Cdc20WD40 domain and Mad2 of the adjacent asymmetric unit.
In addition to the MCC, the structure of the S. cerevisiae Cdh1-APC/C modulator
1 (Acm1) complex was determined at 2.9 Å resolution (PDB:4BH6) [165]. Acm1 is a
natural inhibitor of Cdh1, that interacts through three peptide motifs resembling ABBA,
KEN-box and D-box degrons. This unique structure supported the architecture of D-box
degron binding observed in the MCC. As can be seen in Figure 5.6, the Cdh1-Acm1 struc-
ture provided additional evidence for the binding of the canonical arginine at position 1
of the degron, in addition to a plausible binding pose for a leucine at position 7 of the
degron (numbering according to Figure 5.4). However, the binding position of L125 is
non-standard for non-polar aliphatic amino acids: the hydrophobic side chain is solvent
exposed and appears to stack against the aliphatic atoms of D256 of Cdh1. Although an
interaction between the two side chains would not normally be expected, the model is well
supported by the electron density well and densities for other possible rotamers were not
observed. Since L125 is not surrounded by any neighbouring proteins within the crystal
lattice, this interaction is unlikely to be an artefact of crystal packing.
In addition to the atomistic detail provided by the above crystal structures, a D-
box degron derived from the Hsl1 protein sequence, termed the ’super D-box’, was
reported to be the most optimal binding sequence for the D-box degron binding site
[164, 168, 169, 226]. This made the Hsl1-derived peptide an ideal starting point for
peptide D1 (Ac-GRAALSDITN-NH2) in addition to the consensus sequence, peptide D2
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Mad3
Cdc20
Mad3
Cdc20
(a)
Mad3
Mad2
Cdc20A
Cdc20B
L216
(b)
Figure 5.5: Structural representations of the D-box binding site in fission yeast Cdc20
in the MCC (PDB:4AEZ [225]). (a) C-terminus of Mad3 in the MCC heterotrimer (ma-
genta, stick representation) mimics D-box peptide binding to Cdc20WD40 domain (cyan,
surface representation). The black box highlights the area further explored with elec-
tron density maps. (b) The Mad3 pseudo D-box degron (cyan, stick representation) is
bound to Cdc20A (magenta, cartoon representation) is wedged between Cdc20B (ma-
genta, cartoon) and Mad2 (orange, cartoon) of the adjacent asymmetric unit. Electron
density map (blue mesh) is contoured at 1.0σ in the 2Fo-Fc map.
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E537
D256
R119
L125
Figure 5.6: Structural analysis of the D-box binding site of Cdh1 bound to Acm1
(PDB:4BH6, 119RIALKDL125) [165]. R119 of Acm1 forms two hydrogen bonds (yel-
low, dashed lines) with Cdh1 with the carboxylic acid side chains of D256 and E537.
Aliphatic side chain atoms of Acm1 L125 and Cdh1 D256 stack in a planar orientation.
Electron density map (blue mesh) is contoured at 1.0σ in the 2Fo-Fc map.
(Ac-RLPLGDVSN-NH2). However, due to the evidence of residue 2 remaining solvent
exposed (observed in PBD:4AEZ [225] and PDB:4BH6 [165]), a large aliphatic amino
acid such as leucine would likely be energetically unfavourable while also reducing the
solubility. Therefore, leucine at position 2 was replaced by alanine in subsequently syn-
thesised peptides, similar to the Hsl1-derived peptide sequence. In addition a negative
control D-box peptide with the key binding residues removed was synthesised (D13: Ac-
GDAAASDGTN-NH2).
Exploring non-natural amino acids
The X-ray crystal structure of CdC20 bound to the small molecule Apcin was used for
the design of further D-box peptides. Apcin interacts with Cdc20’s D-box binding site,
specifically docking into the pocket where the leucine sidechain at position 4 would dock
(formed by L176, D177, A178, P179, V200, L202, Y207, W209 and I217, Figure 5.7b).
The structure of Apcin bound to Cdc20 provides evidence that a larger chemical moiety
compared to a leucine sidechain can bind this pocket, (Figure 5.7). To further gauge
what size moiety may bind this pocket, the bond lengths of the CCl3 moiety of Apcin
were measured. Whereas the typical bond length of an aliphatic chain C-C bond is ≈
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1.52 Å, the C-Cl bond of Apcin is slightly longer, at 1.73 Å. The total diameter and
thus volume of the CCl3 moiety fills more space within the degron-binding pocket. Addi-
tionally, halogenated ligands are typically more hydrophobic and ’drug-like’ compared to
their carbon-substituted counterparts. Given this analysis, non-natural amino acids with
bulkier side chains than leucine were considered with the aim to increase binding affinity
(Figure 5.8), and thus peptides D6 (Ac-RAPcBuAlaGDISN-NH2), D7(Ac-RAPC3GDISN-
NH2) and D20 (Ac-RAPC3SDITN-NH2) were produced. The synthesis of Fmoc-protected
(S )-2-amino-4,4,4- trichlorobutanoic acid (Figure 5.8d was tasked to an external company,
as there were no literature reports of its synthesis. Unfortunately, over 10 months, the
synthesis of this amino acid was unsuccessful, and therefore it was not possible to intro-
duce it into D-box peptides at position 4.
(a)
D177
W209
V200
I216
Y207
L202
P179
A178
L176
(b)
Figure 5.7: Structural analysis of the D-box-binding site in human Cdc20 bound to
Apcin, (PDB:4N14) [195]. (a) Apcin (stick representation, magenta) bound to human
Cdc20 (surface representation, cyan) in the leucine-binding pocket of the D-box-binding
site. (b) Cdc20 (cartoon representation, cyan) with amino acid side chains of leucine
binding pocket forming residues illustrated (stick representation, orange).
Designing hydrocarbon peptide constraints
Hydrocarbon constraints of D-box peptides were considered under guidance from Dr. Yaw
Sing Tan (Bioinformatics Institute, A*STAR, Singapore) and Dr. Fernando Ferrer (p53
laboratory, A*STAR, Singapore). Although many different chemistries exist for peptide
stapling, only olefin-metathesised hydrocarbon staples were considered since Dr. Ferrer
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(a) C3
NH O
(b) cBuAla
NH O
F F
F
(c) F3
NH O
Cl Cl
Cl
(d) Cl3
Figure 5.8: Non-natural amino acids considered for position 4 in D-box peptides. (a)
(S )-2-amino-4,4-dimethylpentanoic acid. (b) (S )-2-amino-3-cyclobutylpropanoic acid.
(c) (S )-2-amino-4,4,4-trifluorobutanoic acid. (d) (S )-2-amino-4,4,4- trichlorobutanoic
acid.
had extensive experience with this chemistry. Although stapling chemistries are more
commonly used for the constraint of α-helical structures (peptides and peptoids), the
constraining of loop structures [227], intrinsically disordered regions [228] and extended
interfaces [102] has been explored also. Therefore it was thought to be reasonable to ex-
plore the constraint of D-box peptides. Due to the small number of residues in the peptide,
only two stapling positions were explored (Figure 5.9). Peptide D9 (Ac-GRS5ALR8TN-
NH2) contains a longer hydrocarbon between the S -2-(4’-pentenyl) alanine (S5) and R-
2-(7’-octenyl) alanine (R8) residues at positions 2 and 7 respectively, which are typically
used in the stapling of α-helices. Although the aliphatic amino acid at position 7 was
replaced, it was assumed that this loss could be overcome by confining the peptide to-
wards a favourable binding conformation. Peptides D16 (Ac-RR5ALS5DISN-NH2), D17
(Ac-RR5AcBuAlaS5DISN-NH2) and D18 (Ac-RR5AC3S5DISN-NH2) were designed us-
ing a shorter constraint with S5 and S5 amino acids at positions 2 and 5, respectively.
This staple position was considered to be more optimal compared the positions used in
peptide D9, since the aliphatic residue at position 7 in maintained. The distances be-
tween the Cα atoms of residues 2 and 5 are approximately 5.4 Å, which is akin to the i,
i + 3 stapling of α-helices [229], although the geometries are very different. Despite an
unproblematic synthesis, the RCM efficiency was very low for all three peptides. Kim et
al. [229] also described poor RCM efficiency of the i, i + 3 stapled α-helices. Despite
this, semi-preparative HPLC purification was attempted, however the samples were too
low in purity and yield.
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(a) D9
(b) D16
Figure 5.9: Models of stapling positions in D-box peptides. (a) Model of peptide D9
bound to Cdh1. (b) Model of peptide D16 bound to Cdh1. Models were built using
the PyMOL builder function. All models were constructed using PDB:4BH6, using
base coordinates for the Cdh1 (cyan, surface representation) and the Acm1 D-box
peptide. D-box peptide shown as stick representation in magenta, with hydrocarbon
staple amino acids coloured orange.
5.3. Results 107
5.3.2 KEN-box peptide design
Unlike other WD40 or similar β-propeller domain proteins that bind their partners at the
bottom-inner groove of the donut-like structure, the binding surface for the KEN-box is
on the opposite face of the WD40 domain. This results in a very flat surface without
any pockets to drive a small molecule drug discovery effort. Binding of the KEN-box
motif to Cdc20 and Cdh1 is entirely driven by polar interactions, illustrated in Figure
5.10 [193]. The amino acids K, E and N of the KEN-box motif adopt a 310 helix, which
can be observed across all X-ray crystal structures of KEN-box peptides bound to Cdc20
(PDB:4GGD, 4AEZ) [193, 225] and Cdh1 (PDB:4BH6) [165] (Figure 5.11).
R445
T377
Q401
A357
N331
N329
Y186
E2
K1
L(-2)
R445
N3Q401
Y185
Y186
Figure 5.10: KEN-box peptide motif interactions with human Cdc20, PDB:4GGD.
Polar interactions between the BubR1-derived KEN-box peptide (yellow, stick represen-
tation) and Cdc20 (cyan, cartoon and stick representation). Hydrogen bonds (dashed
yellow lines) are formed between several side chain and backbone atoms between both
molecules. Images are approximately a 180◦ rotation around the z-axis to show all
intermolecular hydrogen bonds.
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The first KEN-box peptide motif synthesised was based on the BubR1 sequence bound
to Cdc20 from by Tian et. al from BubR1 [193]. However, the peptide used in their
co-crystallisation experiment was significantly longer (CDEWELSKENVQPLRQGRIM-
STLQ) compared to the residues observed. Therefore, a minimal motif (peptide K1,
Ac-ELSKENV-NH2) was designed based on the resolved residues in the hope that this
motif would be sufficient for binding Cdc20. However, it is unlikely that the 310 helix
appearing in all KEN-box structures would be energetically favourable in the context of
a minimal peptide. Therefore, hydrocarbon-constrained peptides were also designed and
synthesised in an attempt to overcome this potential energetic barrier. Constraints were
designed at positions 2 and 7, relative to the K1 peptide sequence and illustrative models
of the constrained KEN-box peptides are shown in Figure 5.12. The synthesis of the
hydrocarbon-constrained peptides, K7 (Ac-ER5SKENS5-NH2) and K8 (Ac-ES5SKENS5-
NH2) with R-2-(4’-pentenyl) alanine (R5)-S5 and S5-S5 amino acids, respectively did not
appear problematic, as evident from masses corresponding to the non-stapled peptide.
However, similar to observations in D16, D17 and D18, the RCM reaction did not go
to completion. Due to time constraints, further stapling chemistries and positions were
not explored. A negative control KEN-box peptide with the key residues substituted
for alanine was synthesised (K9: Ac-ELSAAAV-NH2), however due to its insolubility in
H2O/MeCN, we were unable to purify this peptide.
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(a) BubR1-Cdc20
(b) S. pombe MCC
(c) Acm1-Cdh1
Figure 5.11: The KEN-box forms a strained α-helix turn motifs from three X-ray
crystal structures of (a) BubR1 bound to Cdc20 (PDB:4GGD), (b) the S. pombe MCC
(PDB:4AEZ), and (c) Acm1 bound to Cdh1 (PDB:4BH6). Proteins/peptides con-
taining KEN-box motifs are shown in yellow with cartoon and stick representations.
Cdc20/ Cdh1 are shown in cyan, cartoon representation.
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(a) K7 model
(b) K8 model
Figure 5.12: Models of stapled KEN-box peptides bound to Cdc20 based on coor-
dinates from PDB:4GGD. (a) Model of peptide K7 with i, i + 5, R5-S5 hydrocarbon
staple. (b) Model of peptide K8 with i, i + 5, S5-S5 hydrocarbon staple. KEN-box
peptides are shown in yellow with hydrocarbon staple residues in orange. Cdc20 is
shown in cyan as a surface representation.
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5.3.3 ABBA motif peptide design
In contrast to the D-box and KEN-box degron motifs, there is only limited information
on the ABBA motif as its discovery in S. cerevisiae Acm1 by Burton et al. is compara-
tively recent [230]. At present, only Acm1 [165, 230], Bub1 [166], Bub1B [151, 166, 167],
Clb5 [231] and Cyclin A [166] are known to bind co-activators via ABBA motif degron
sequences. As for the D-box and KEN-box peptide design, ABBA motif peptides were
based on data from X-ray crystal structures [165] (Figure 5.13a and were kept minimal in
length for ease of synthesis as well as to create a more ‘drug-like’ molecule. The ABBA
motif relies on two hydrophobic interactions at positions 1 and 3, an aromatic ring at
position 4 and a negatively charged residue at position 6 (numbering according to Fig-
ure 5.4). Peptide A1 (Ac-FGLYEE-NH2, Figure 5.13b) was almost entirely based on the
peptide motif from Acm1 [165, 230], apart from a methionine to glycine substitution at
position 2. The methionine residue is solvent exposed and therefore unlikely to contribute
to binding. Methionine also complicates the synthesis process, as peptide cleavage under
acid conditions (TFA cleavage cocktail) yields would typically yield an oxidised methion-
ine residue. Although protocols exist for the cleavage of methionine-containing synthetic
peptides, it was decided to avoid the complication altogether. Since the ABBA motif
adopts an extended conformation, hydrocarbon constraints would likely reduce the affin-
ity and hence were not explored. A negative control peptide was also synthesised (A9:
Ac-AGAAEE-NH2), however due to insolubility issues this peptide could not be purified.
(a) Acm1 ABBA motif
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(b) A1 model
Figure 5.13: (a) Binding pose of the Acm1 ABBA motif (residues 61-66) to S. cere-
visiae Cdh1. PDB:4BH6 [165]. (b) Model of peptide A1 bound to S. cerevisiae Cdh1
based on PDB:4BH6.
5.3.4 C-box peptide design
In addition to targeting the degron-binding sites of Cdc20, peptides were designed to
mimic the C-box motif contained within the N-terminal IDR of co-activators, which is
partially responsible for binding to Apc8 of the APC/C [161, 232–234]. In addition to the
C-box motif, co-activator association is mediated by the C-terminal Isoleucine-Arginine
tail (IR-tail) at a structurally homologous binding site on Anaphase-promoting complex
subunit 3 (Apc3) of the APC/C, (Figure 5.14) [162].
Peptide C1 (Ac-GDRYIPSR-NH2), was designed using both human Cdc20 (GDRYIPHR)
and Cdh1 C-box motifs (GRDFIPSR). Due to the smaller side chain, the serine in the
Cdh1-bound peptide (Figure 5.15a) appeared to be more favourable than the histidine in
the Cdc20-bound peptide, where intramolecular steric clashing could occur in alternative
rotamers of the histidine side chain. Conversely, tyrosine at position 4 in the Cdc20-bound
peptide (Figure 5.15b) appeared to be preferred over phenylalanine due to the potential
ability to form an additional hydrogen bond. Peptide C5 (Ac-GDAAIPSA-NH2) served
as a negative control peptide with the key binding residues substituted for alanine residues.
Given that the C-box forms a tight loop comprising residues Y/F3 and R4, constrain-
ing this motif should be favourable for binding. Peptide C6 was designed with guidance
from Dr. Yaw Sing Tan (Bioinformatics Institute, A*STAR, Singapore) who performed
MD simulations to investigate an optimal hydrocarbon staple position and length. A
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Figure 5.14: (Top) Schematic of co-activator domain topology with IDRs flanking
the WD40 domain (Cdc20, PDB:4GGC [193]). (a) The Cdh1 IR-tail, (b) Apc10 IR-tail
and (c) C-box motifs bind structurally homologous sites of Apc3 subunit A (Apc3A),
Apc3 subunit B (Apc3B) and Apc8 subunit B (Apc8B), respectively. Panels (a, b and
c) were adapted from Alfieri et al. [162].
model of the peptide is shown in Figure 5.15c. Peptide C6 (Ac-S5DRYIPS5R-NH2) was
then synthesised. Serendipitously, the semi-preparative HPLC provided sufficient separa-
tion of the cis and trans isomers produced during RCM. These peptides are labelled as
’C6e’ (early isomer) and ’C6l’ (late isomer) in Appendix B according to their analytical
HPLC retention times. Further characterisation was not performed to identify the early
or late peaks to the cis and trans isomers due to the difficulty of determining such isomers
by proton nuclear magnetic resonance (1H NMR) in the context of several hydrogen atoms
within a peptide molecule.
Since the binding sites of Apc8 and Apc3 are homologous, it was hypothesised that
peptide C6 might also bind to Apc3. Alignment of the C6 peptide was performed against
Cdc20 R499 of the IR-tail, using residues R3 and R8 (Figure 5.16).
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(a) Cdh1 C-box
(b) Cdc20 C-box
(c) C6 trans isomer model
Figure 5.15: C-box peptides of (a) Cdh1 (PDB:4UI9) [150] and (b) Cdc20
(PDB:5LCW) [151] bound to the TPR superhelix structure of Apc8. (c) Model of
C6 stapled peptide bound to Apc8. PDB:5LCW. C-box peptide motifs are shown in
lime green and stick representation with hydrocarbon staple amino acids in blue. Apc8
is shown in orange, cartoon representation with stick representation for amino acids
forming polar interactions. Polar interactions are indicated by yellow dashed lines.
5.3. Results 115
(a) Cdc20 IR-tail
(b) R3 alignment
(c) R8 alignment
Figure 5.16: (a) Cryo-EM model of Cdc20-IR tail (cyan, stick representation) bound
to the Apc3 subunit (magenta, cartoon representation). (b) Structural alignment of
peptide C6, residue R3 to Cdc20 R499. (c) Structural alignment of peptide C6, residue
R8 to Cdc20 R499. C6 peptides are shown in lime green, stick representation with
hydrocarbon staples coloured in blue with Apc8 in magenta cartoon representation.
(PDB:5LCW) [151].
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5.4 Discussion
Four series of peptide inhibitors targeting the three degron-binding sites (degrons: D-box,
KEN-box and ABBA motif) of APC/C co-activator Cdc20 and the C-box-binding groove
of Apc8 were produced. Primarily, sequences of all peptides were designed based on X-
ray crystal structures and Cryo-EM datasets as well as consensus sequence information.
However, consensus sequences are only reliable for D-box and KEN-box degrons, as there
are many of these degrons that have been identified in natural substrates. Contrastingly,
only a limited number of ABBA motifs are currently reported in the literature (due to its
recent discovery as a degron motif) and likewise little information exists for the C-box.
All peptide sequences are listed at the end of this chapter (Table 5.1). In SPPS, cou-
pling of Fmoc-amino acids was initially performed for 1 hour per residue. This resulted in
very low throughput, particularly at times when only one or two peptides were synthesised
in parallel. Since the formation of the amide bond occurs very rapidly, an improvement
to the solid phase synthesis was implemented whereby coupling reaction times were re-
duced to 10 minutes with no apparent loss of yield or generation of side products, which
typically resulted in full peptide sequences synthesised in less than 2 days. The 0.1 mmol
synthesis scale would normally result in around 50-100 mg of crude product. Following
semi-preparative HPLC purification, 30-60 mg of purified peptide were typically obtained.
Although no more than 1-2 mg of peptide were required for downstream biophysical anal-
ysis, the larger scale preparations were necessary in order accurately work with a known
concentration of peptide. This was particularly important as amino acid analyses were
previously conducted by Dr. Peter Sharrat (formerly PNAC facility, Biochemistry de-
partment, University of Cambridge). However since his retirement, this service was no
longer available. Although commercial services exist, the amount of sample they required
and cost of the service was prohibitive for concentration determination of peptides.
Due to the need to focus on a small number of peptides, the KEN-box and ABBA
motif peptide series were relinquished early on, in favour of the D-box peptides. However,
despite ceasing to work on these two motifs further, there is still plenty of scope for both
peptides to optimise the length and amino acid sequences, incorporate non-natural amino
acids similar to those explored in the D-box peptide and to further explore the constraint
of the peptide. Indeed, one may also consider to make macrocyclic small molecules and
even small molecules based on the ABBA motif, however these were considered beyond
the scope and time constraints of the project.
For three out of the four peptide series, hydrocarbon constraints were explored. The lit-
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erature is well defined in the design of hydrocarbon constraints in the context of α-helices.
However, in the context of loop (D-box and C-box) or 310-helix (KEN-box) structures that
comprise different geometries, no information exists. In addition, the short sequences that
were designed also limit the number of stapling positions and so only a few hydrocarbon
staples were designed and synthesised through a rational approach. Unfortunately, poor
RCM efficiencies were observed in five out of seven hydrocarbon-contrained peptides.
However, RCM reactions of peptides D9 and C6 went to completion. In addition, the iso-
mers produced at the carbon-carbon double bond were efficiently separated in C6, which
allows for the downstream biophysical characterisation of two distinct peptides. This was
not possible for D9 as the crude yields after RCM were too low. The increased chro-
matographic separation of the two isomers appears unique to these loop-like structures,
since the α-helical peptides do not separate efficiently. Despite the low success rate of
producing stapled peptides, exploring this in more detail was outside the scope of the
project due to time constraints. However, several different methods to constrain peptide
structures including click-chemistry, lactam bridging and thioether formation among oth-
ers (reviewed by Lau et al. [93]) exist and could be considered in future works.
Although a rational design approach is valuable and interesting for a PhD student,
the throughput is low. Library-selection methods, such as phage and ribosome display,
offer a significantly larger chemical space. However, at the beginning of this project and
indeed till the end, generating purified Cdc20 was a limiting factor so these techniques
were not explored.
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Table 5.1: Summary of synthesised APC/C-targeting peptides. % purity is calculated
using the integral of the peptide peak monitored by absorbance at 220 nm. Abbrevia-
tions of unnatural amino acids: C3 - (S )-2-amino-4,4-dimethylpentanoic acid, cBuAla -
(S )-2-amino-3-cyclobutylpropanoic acid, F3 - (S )-2-amino-4,4,4-trifluorobutanoic acid,
S5 - S -2-(4’-pentenyl) alanine, R8 - R-2-(7’-octenyl) alanine, R5 - R-2-(4’-pentenyl)
alanine. Full details of structures, HPLC chromatographs and LCMS data can be
observed in Appendix B.
Name Sequence % purity Synthesis outcome
D1 Ac-GRAALSDITN-NH2 97.0
D2 Ac-RLPLGDVSN-NH2 92.4
D3 Ac-RAPLGDVSN-NH2 95.9
D4 Ac-RAPLGDISN-NH2 89.6
D5 Ac-RAPLGDLSN-NH2 89.9
D6 Ac-RAPcBuAlaGDISN-NH2 97.3
D7 Ac-RAPC3GDISN-NH2 97.6
D9 Ac-GRS5ALR8TN-NH2 90.3 Mix of early and late isomers
D10 Ac-RAALGDISN-NH2 99.7
D11 Ac-RAAcBuAlaGDISN-NH2 - Insoluble; not purified
D12 Ac-RAAC3GDISN-NH2 98.6
D13 Ac-GDAAASDGTN-NH2 97.0
D16 Ac-RR5ALS5DISN-NH2 - Poor RCM yield; impure
D17 Ac-RR5AcBuAlaS5DISN-NH2 - Poor RCM yield; impure
D18 Ac-RR5AC3S5DISN-NH2 - Poor RCM yield; impure
D19 Ac-RAPLSDITN-NH2 99.2
D20 Ac-RAPC3SDITN-NH2 98.4
D21 Ac-RAPF3SDITN-NH2 98.4
K1 Ac-ELSKENV-NH2 91.0
K7 Ac-ER5SKENS5-NH2 - Poor RCM yield; impure
K8 Ac-ES5SKENS5-NH2 - Poor RCM yield; impure
K9 Ac-ELSAAAV-NH2 - Insoluble; not purified
A1 Ac-FGLYEE-NH2 97.3
A9 Ac-AGAAEE-NH2 - Insoluble; not purified
C1 Ac-GDRYIPSR-NH2 98.2
C5 Ac-GDAAIPSA-NH2 84.9
C6e Ac-S5DRYIPS5R-NH2 87.7 Early isomer
C6l Ac-S5DRYIPS5R-NH2 87.7 Late isomer
Chapter 6
Biophysical characterisation of
APC/CCdc20 peptide inhibitors
6.1 Introduction
Several methods for characterising ligand binding exist, although they differ in their sensi-
tivity, sample requirements, throughput and measured parameters. Here, it was purified
Cdc20WD40 that was the limiting factor. With this constraint in mind, methods such
as isothermal titration calorimetry (ITC) and fluorescence polarisation (FP) were not
considered feasible. Although FP experiments often require little protein, the amount
is strongly dependent on the affinity of the fluorescent-labelled ligand for the protein. If
ligand binding is weak, FP will require higher protein concentrations to obtain the 50-80%
of the protein in the ligand-bound state at equilibrium, suitable for competition experi-
ments. Therefore, differential scanning fluorimetry (DSF) and surface plasmon resonance
(SPR) experiments were explored as alternative methods, since both have low protein
requirements and are also high-throughput thereby allowing multiple peptide ligands to
be tested in parallel.
6.2 Methods
6.2.1 Differential scanning fluorimetry
Experiments were conducted using a Roche Lightcycler 480 I or Biorad CFX Connect
in 96-well plate format. Cdc20 (161-477) was prepared at a final concentration of 750
nM in 25 mM Tris-HCl, 150 mM NaCl, 1 mM MgCl2, 5% (v/v) glycerol, 1 mM TCEP
and 1% (v/v) DMSO, 5× Sypro Orange, pH 8.5 in the absence or presence of varying
ligand concentrations in a final volume of 20 µL. Plates were sealed with a transparent
film. Thermal melt curves were acquired using temperature ramps from 25◦C to 95◦C
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at a rate of 0.03◦C/sec and data were collected at a frequency of 20 points/◦C for the
Roche Lightcycler 480 I. Thermal melts on the Biorad CFX Connect were acquired using
a temperature ramp from 25◦C to 95◦C with a step ramp of 0.5◦C/step with a 20 second
equilibration before reading each new temperature. An excitation wavelength of 483± 35
nm was used for the Sypro Orange dye and fluorescence was detected at an emission
wavelength of 568± 20 nm.
Data analysis
Melting temperatures (Tm), were determined using the in-built ’Tm calling’ function of the
Roche LightCycler 480 I software. Briefly, the software calculates the negative derivative
of the melt curve, where the minimum then corresponds to the Tm of the sample. Melting
temperatures were derived separately for each well, averaged over triplicate well samples
and are reported with the standard error of the mean (SEM). Data from the Biorad CFX
Connect is automatically exported with the raw and negative derivative data.
6.2.2 Surface plasmon resonance
All experiments were conducted using a Biacore T200 instrument (GE healthcare) at
AstraZeneca under the guidance of Dr. Christopher Stubbs.
Ligand immobilisation - Ni-NTA biosensor
Experiments on the Ni-NTA biosensor chip were conducted using His6-TEV-Cdc20 (161-
477) protein (see lane ‘SPR SEC’ in Figure 4.5a) in running buffer (10 mM HEPES, 150
mM NaCl, 0.1 mM TCEP, 0.05% (v/v) Tween 20 and 1% (v/v) DMSO) at 25◦C. The
His6-TEV-Cdc20 (161-477) protein was diluted in running buffer to ≈ 20 µg/mL in 500
µL. The Ni-NTA biosensor was docked and primed three times in running buffer. Each
flow cell was processed in succession. All steps were performed with a flow rate of 30
µL/min. First, flow cells were stripped of Ni2+ with 500 mM EDTA, followed by re-
equilibration with running buffer. The flow cell was then recharged with 500 µM NiSO4.
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide and N -hydroxysuccinimide were mixed
and immediately flown over to activate the surface for covalent coupling. His6-TEV-
Cdc20 (161-477) was flown over Fc 2, 3 and 4 for increasing lengths of time, respectively,
or with increasing RU capture targets between flow cells. All flow cells were blocked using
1 M Ethanolamine, pH 8.5. Non-covalently bound ligands were removed with an injection
of 500 mM EDTA.
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Ligand immobilisation - Streptavidin biosensor
The Streptavidin (SA) biosensor chip was prepared in a similar manner, but using biotiny-
lated Cdc20 (161-477) protein (Figure 4.8) and the following alterations. The biotinylated
Cdc20 (161-477) protein was diluted in running buffer 2-fold. Flow cells were washed three
times with 50 mM NaOH, 1 M NaCl. Protein was then flowed at 5 µL/min for 5, 10 and
20 minutes over Fc 2, 3 and 4, respectively. All flow cells were then blocked with an injec-
tion of 50 µM amine-PEG4-Biotin and detectors were then normalised with an injection
of 70% (v/v) glycerol as per the manufacturers recommendation.
Analyte binding experiments
Compounds were diluted to a top concentrations of 100, 50 or 10 µM in running buffer
maintaining 1 % (v/v) DMSO in the final solution, and used to created a 7-point 2-fold
serial dilution in a 96-well plate. A running buffer blank was included as the first sample
for each ligand. Vials for solvent correction were prepared using 0.2, 0.8, 1.4 and 2.0 %
(v/v) DMSO and were run before and/or after all analyte binding experiments. Within a
particular analyte sample, each series were run from low to high concentrations to reduce
the chance of slow dissociation times effecting the next injection cycle. Injection cycles
were set at 60 seconds of association and 60 or 120 seconds of dissociation at 30 µL/min.
Between different analytes, a minimum of four running buffer injections were performed
to ensure all analyte was removed prior to the injection of the next analyte.
Data analysis
The reference flow cell (Fc 1) was subtracted from all sensorgrams and the 0 µM blank
belonging to the analyte dilution series to better account for any loss of ligand activity over
the course of an experiment. Steady-state affinities were calculated from the concentration
series of each analyte. Observed response units (RU) were calculated from a 5-second
average, 12 seconds prior to the analyte injection end-point of each injection cycle and
are relative to the RU at t = 0 sec of analyte injection. Since buffer blank subtractions
were performed, all data were fitted using
RUanalyte =
RUmax × [analyte]
(Kd + [analyte])
, (6.1)
where RUanalyte is the observed response units at a given analyte concentration at equilib-
rium, [analyte] is the molar concentration of the analyte, Kd is the dissociation constant
for the analyte and ligand interaction and RUmax is the theoretical maximum response of
the analyte with a fixed ligand immobilised. RUmax is further defined by
RUmax =
MWanalyte ×RUligand × valencyligand
MWligand
, (6.2)
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where RUligand is the response units immobilised onto the biosensor chip, valencyligand
is the stoichiometry of the interaction, MWanalyte is the molecular weight of the analyte
and MWligand is the molecular weight of the ligand. The percentage of functional ligand
immobilised onto the biosensor chip, % Ligandfunctional, was calculated using
% Ligandfunctional =
RUmax
RUligand
× MWligand
MWanalyte
× 100. (6.3)
All values are reported as the mean and standard error calculated from the fits of reference
and blank subtracted flow cells, Fc 2-1, Fc3-1 and Fc 4-1. Since RU artefacts often occur
upon valve switching from running buffer to sample injection, and vice-versa, data at
the beginning of these valve transitions are excluded from the raw data. These data are
outside of the raw sensorgram data used for calculation of steady-state affinity and thus
their exclusion does not affect the calculation of binding affinities as described above.
6.2.3 Cellular Thermal Shift Assays
CETSA of endogenous protein
HEK 293T cells were cultured in DMEM (Gibco) + 10% FBS (Sigma Aldrich) at 37◦C,
5% CO2, in a humidified environment. Cells were cultured in multiple T75 flasks to gen-
erate sufficient quantities of cell lysates for downstream applications. Cells were grown to
confluency, washed in PBS and trypsinised from the culture vessel for 5 minutes at 37◦C,
before quenching with medium. Cell suspensions were pooled and centrifuged at 500 ×
g for 3 minutes to pellet the cells. Cell pellets were washed twice in PBS with repeated
centrifugation. The washed and pelleted cells were resuspended in NET-2 buffer (50 mM
Tris-HCl, 150 mM NaCl, 1 mM MgCl2, 0.5 % (v/v) NP-40, 0.5 mM DTT, 2 mM NaVO3,
5 mM NaF, 1 mM PMSF and 1 × SigmaFAST EDTA-free protease inhibitor cocktail
(Sigma Aldrich), pH 7.4). The lysate was incubated at 4◦C for 1 hour on a rotating wheel
to lyse. The lysate was clarified by centrifugation at 21,000 × g, 4◦C for 20 minutes and
the supernatant was transferred to a fresh microfuge tube. The total protein concentra-
tion was determined as described in Section 2.3.1, yielding 2.27 mg/mL. Lysates were
aliquoted in 100 µL, flash frozen in liquid N2 and stored at -80◦C.
For each experimental condition, a single 100 µL aliquot was thawed on ice. Apcin,
TAME or DMSO were added to a final concentration of 100 µM compound and 1% DMSO,
samples were mixed immediately by vortexing and returned to ice to incubate for 1 hour.
All subsequent steps were performed on PCR machines. Incubated lysates were aliquoted
into 11 PCR strip tubes at 4◦C. Each strip tube was heated at a different temperature
between 40 and 60◦C, in 2◦C steps for 3 minutes before returning to 4◦C. Tubes were then
centrifuged at 20,000 × g, 4◦C for 10 minutes to pellet precipitated proteins. The super-
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natant was added to an equal volume of 2× SDS PAGE loading buffer and samples were
loaded onto an 8% SDS PAGE gel cast using ProtoGel buffers and acrylamide (National
diagnostics), with SpectraTM Multicolour Broad Range protein ladder (Thermo Fisher
Scientific) in both outside lanes. Gels were run in TGS buffer at 60 V for 30 minutes fol-
lowed by 120 V for 90 minutes. Gels were then transferred onto 0.45 µm PVDF membrane
in transfer buffer using a semi-dry transfer system (Pierce Power blotter, Thermo Fisher
Scientific). PVDF membranes were then cut (if necessary) and incubated in western blot
blocking buffer for 1 hour at room temperature on a rocking platform. The respective
membranes were incubated with 1:1000 dilutions of anti-Cdc20 (D6C2Q, #14866, Cell
Signalling Technologies), anti-Apc8 (D5O2D, #15100, Cell Signalling Technologies) or
anti-Apc3 (D3I1V, #12530, Cell Signalling Technologies) Rabbit monoclonal antibodies
(mAbs) in western blot blocking buffer overnight at 4◦C. The following day, primary an-
tibodies were decanted and membranes were washed 3 × in PBST. Blots were incubated
with a 1:10000 dilution of Swine anti-Rabbit HRP-linked polyclonal antibody (DAKO)
in western blot blocking buffer for 1 hour at room temperature on a rocking platform.
Secondary antibody was removed and membranes were washed three times with PBST.
Amersham ECL western blotting substrate was prepared according to the manufacturers
instructions and incubated with the blot for 5 minutes. Membranes were imaged using
a BioSpectrum R© 810 imaging system (UVP) with a cumulative integration of data over
time. A white light image was also taken for reference. Data were analysed by preparing
a box of fixed dimension around each band and calculating the integral of the signal peak
using ImageJ [235]. The integrands were normalised relative to the highest observed sig-
nal in a thermal melt curve, plotted in GraphPad Prism 7.0 and fitted using a Boltzman
equation to detemine the apparent melting temperature (Tm) [236]:
Y = Ymin +
Ymax − Ymin
1 + e(
Tm−X
slope
)
(6.4)
where Y is the normalised fraction of protein at temperature X. Ymin and Ymax are
the minimum and maximum plateaus of normalised signal, and slope is the gradient of
the melt transition. The midpoint of the transition defines apparent melting temperature,
Tm.
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CETSA of exogenous protein
High-throughput CETSA experiments with exogenous proteins were based on protocols
described by N. Martinez et al. [237]. HEK 293T cells were cultured in DMEM (Gibco)
+ 10% FBS (Sigma Aldrich) at 37◦C, 5% CO2, in a humidified environment. Cells were
seeded on day 1 to reach 70% confluency on the following day. Transfection reagents were
prepared by mixing 10 µg of plasmid DNA (see Table 6.1 and Appendix A for construct
information) with 30 µL of Lipofectamine 2000 (Thermo Fisher Scientific) in 1 mL of
OptiMEM (Gibco). The transfection complexes were incubated at room temperature for
5 minutes prior to their addition to the cell culture flask. Cell cultures were incubated
for a further 48 hours, before washing in PBS and trypsinisation. Cell suspensions were
washed and centrifuged as described above, and were resuspended in lysis buffer (PBS
(Gibco), 5 mM NaF, 2 mM NaVO3 and 1 × SigmaFAST EDTA-free protease inhibitor
cocktail (Sigma Aldrich). Cells were lysed by freeze-thawing in liquid N2 and the lysates
were clarified by centrifugation at 21,000 × g, 4◦C for 20 minutes. Supernatants were
transferred to a fresh microfuge tube and the total protein concentration was determined
in each lysate. Supernatants were aliquoted in 100 µL aliquots, flash frozen in liquid N2
and stored at -80◦C.
After initial pilot experiments, only the Cdc20 (1-499)-HiBiT and Apc8 (1-591)-HiBiT
transfected lysate was carried forward to analyse ligand binding. Cdc20 (1-499)-HiBiT
and Apc8 (1-591)-HiBiT lysates were diluted to 0.2 mg/mL and 0.25 mg/mL, respectively
in lysis buffer and aliquoted into separate tubes according to the number of experimental
samples. To probe binding to exogenous Cdc20, Apcin, D21, D20, D19, D7 or DMSO (1
µL of 10 mM compound in 100% DMSO) were added to a final concentration of 100 µM
compound, 1% DMSO. To probe binding to Apc8, TAME, C1, C5, C6e, C6l or DMSO (1
µL of 10 mM compound in 100% DMSO) were added to a final concentration of 100 µM
compound, 1% DMSO Tubes were mixed immediately by vortexing and returned to ice
to incubate for 1 hour. Thermal melts were conducted as described above. The heated
lysate samples were aliquoted (2 µL/well) into an AlphaPlate light-grey 384-well plate in
triplicate at 4◦C. Lysis buffer and a non-transfected cell lysate control were included as
negative control samples. The Nano-Glo R©HiBiT lytic detection system (Promega) was
prepared according to the manufacturers’ instructions and 10 µL were added to each well.
The plate was incubated on a shaking platform (1000 rpm) to ensure sample homogeneity.
The plate was then read in a CLARIOStar microplate reader (BMG labtech) with the
focal height and gain adjusted to 10.5 cm and 2000, respectively, and with the detector
set to read the luminescence signal at 460 ± 80 nm. Data were normalised with respect
to the first temperature of the thermal melt curve (40◦C). Normalised data were then
plotted in GraphPad Prism 7.0 and fitted using Equation 6.4.
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Table 6.1: Cdc20, Apc3 and Apc8, HiBiT-tagged constructs used for transfection into
HEK 293T cells for CETSA experiments with D-box and C-box-targeting ligands.
Construct Tag terminus MW (Da)
HiBiT-Cdc20 (1-499) N 56444.6
Cdc20 (1-499)-HiBiT C 56588.8
HiBiT-Apc3 (1-824) N 93590.3
Apc3-HiBiT (1-824) C 93459.1
HiBiT-Apc8 (1-591) N 70007.6
Apc8-HiBiT (1-591) C 69876.4
6.2.4 In vitro ubiquitination assays
In vitro ubiquitination experiments were performed by Dr. Thomas Tischer in the Barford
laboratory at the MRC LMB, Cambridge, UK. Experiments were performed using APC/C
and Cdc20 purified from insect cells as described by Zhang et al. [28]. 60 nM APC/C,
30 nM Cdc20, 90 nM UBA1, 300 nM UbcH10, 300 nM Ube2S, 35 µM ubiquitin, 1 µM
cyclin B1, 5 mM ATP, 10 mM MgCl2 were mixed in a buffer containing 40 mM HEPES,
80 mM NaCl, 0.6 mM DTT, pH 8.0. Reactions were incubated for 30 minutes at 23◦C
in the presence of ligands or DMSO as the vehicle control. Reactions were stopped by
the addition of one volume of 2× concentrated NuPAGE LDS loading buffer (Invitrogen).
All antibodies used and western blotting procedures are consistent with the previously
published data from the Barford laboratory [28].
6.2.5 X-ray crystallography
Crystallisation
Cdc20 (161-477) from multiple protein purification attempts were combined for crystalli-
sation trials. Proteins were concentrated using an Amicon Ultra 0.5 mL 10 K MWCO
centrifugal filters (Merck) at 4◦C, 14,000 × g. Proteins were concentrated to ≈ 0.4 mg/mL
before peptide D21 was added to a final concentration of 100 µM, 1% DMSO, to stabilise
the protein during further concentration and eventually yielding 1.9 mg/mL. A custom
crystallisation grid screen was designed around conditions described by Tian et al. [193]
(Figure 6.1). The solutions were dispensed into a 96-well 2-drop MRC crystallisation plate
(Swissci, Molecular Dimensions) using a Dragonfly crystal instrument (TTP Labtech) and
mixed for 5 minutes using a MXone instrument (TTP Labtech). The Cdc20 (161-477)-
D21 complex was then dispensed using a Mosquito HTS (TTP Labtech). Drops in 5%
glycerol well solutions were prepared using the 0% glycerol counterpart well solution. For
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example, drop A4 was prepared from 100 nL protein complex and 100 nL of well solution
from well A1. The crystallisation plate was sealed with Crystal clear sealing tape (Hamp-
ton Research) and stored at 20◦C in a Rock Imager (Formulatrix). Visible light and UV
images were collected to monitor each drop during the incubation period.
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Figure 6.1: Setup of 96-well plate for crystallisation trials. All wells contain a fixed
concentration of 0.1 M MES pH 6.5, varying concentrations of Polyethylene glycol
(PEG) 6000 from 6-20 % (w/v), 0, 5 or 10% (v/v) 2-Methyl-2,4-pentanediol (MPD), 0
or 5% (v/v) glycerol and 1:1 or 2:1 ratios of protein to well solution in crystallisation
drops.
Ligand soaking and crystal harvesting experiments
Ligand soaking experiments were performed by Dr. Marianne Schimpl at AstraZeneca
using an adapted protocol from Sackton et al. [195]. Crystals were looped and washed
through 3 × 0.5 µL drops of MPD-washout solution (0.1 M MES pH 6.5 and 20% PEG
6000) and were incubated in the final wash drop for 30 minutes at 20◦C. Peptides were
diluted to 2.5 mM (5% (v/v) DMSO) or 5 mM (10% (v/v) DMSO) in the MPD-washout
solution. Crystals were passed through one drop (0.5 µL) of the peptide-containing so-
lution and were incubated in a second drop (0.5 µL) of the peptide-containing solution
for 4 hours at 20◦C. For each peptide-soaked crystal, 3µL of cryo-protectant solution
(0.1 M MES pH 6.5, 20% (w/v) PEG 6000 and 10% (v/v) glycerol) was mixed with
the first peptide-containing soak solution. Crystals were looped and passed through the
soak/cryo-protectant solution and were flash frozen in liquid N2.
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X-ray diffraction
Crystals were diffracted on beamline I04 at Diamond Light Source (Oxford, UK) by Dr.
Jason Breed (AstraZeneca). The beam wavelength and size were fixed to 0.9795 Å and 32
µm × 20 µm, respectively. Crystals were manually centred and 1350 diffraction images
were collected using an Eiger2 XE 16M detector (Dectris) over 270◦, with 0.2◦ oscillations
between each image (50 ms exposure time) at 100 Kelvin.
Structure determination
Diffraction images were processed using autoPROC-STARANISO [206, 238–242]. Criteria
used in the determination of diffraction limits were set by a local I/σI ≥ 1.20. Structures
were solved by molecular replacement using Phaser [209] with the Apo-Cdc20 (161-477)
structure, PDB: 4GGC [193] followed by iterative model building in Coot [213] and refine-
ment in Refmac5 [210] using 4.9% of reflections as an Rfree test set. Restraint dictionary
files for non-natural amino acids, (S )-2-amino-4,4-dimethylpentanoic acid (PDB ligand
ID: 0JY) and (S )-2-amino-4,4,4-trifluorobutanoic acid (PDB ligand ID: 3EG) were gen-
erated using Grade v1.105 [243]. Ligands were built into the models after proteins and
water molecules were refined and added.
Subsequent refinement of all structures were performed using BUSTER version 2.10.3
[211], with additional use of Local Similarity Structural Restraints (LSSR) for refinement
the Cdc20-D7 complex [212]. Results pertaining to structural data are updated using
newly refined datasets.
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6.3 Results
6.3.1 Method development and initial screens of screens of degron
peptides
Setting up DSF experiments
Differential scanning fluorimetry (DSF) was used to identify ligand-dependant stabilisa-
tion of recombinant Cdc20, in which the fluorescence intensity of the Sypro Orange dye
molecule increases upon interacting with hydrophobic regions of a protein that are ex-
posed during the unfolding of of Cdc20. Initial pilot experiments were performed at 1.5
µM of Cdc20 using the Biorad CFX Connect instrument, however, the data quality was
not ideal. By serendipity around a similar time to developing this assay, our laboratory
acquired a Roche Lightcycler 480 I, which can also be used for the same experiment.
This allowed us to make a comparison of the data obtained from both instruments, where
the results of Apo and vehicle control (1% DMSO) were used to make this comparison
(Figure 6.2). Between the two machines, there are several noticeable differences. The
first is the absolute Tm value for both Apo and vehicle control samples, which are 50.5◦C
and 50.2◦C for the Biorad CFX connect and 53.8◦C and 53.6◦C, respectively. There is
also more noise in the raw data and the density of collected data is approximately ten
times less from the Biorad CFX connect compared to the Lightcycler 480 I, which has a
direct impact on the calculation and peak height of the negative differential plot. This
introduces a greater amount of uncertainty when determining the minimum. In addition,
it was possible to use half the concentration of Cdc20 to 750 nM, and still retain high
quality data. These differences may be due to multiple factors inherent to the individual
instrument hardware and the differing protocols that can be used as a result of this. The
Lightcycler 480 I is able to read all wells, simultaneously in a continuous manner, whereas
the Biorad CFX Connect can only read single wells and thus must scan the entire plate at
a fixed temperature. This results in longer runs and effectively slower ramp rate, which
may alter the kinetics of protein unfolding and the rate of Sypro Orange dye association/
dissociation from the unfolded protein. In addition to the inherent hardware differences,
it is also possible that the quality of proteins between batches could also be a causative
factor of data quality. Unfortunately, given the limited amount of protein purified, it was
not possible to compare this factor on one machine.
In the pilot experiment using the Biorad CFX connect, a small group of ligands in-
cluding Apcin, D1, D9, A1 and K1 were also tested, in addition to the apo and vehicle
controls (Figure 6.3). Data for D9, A1 and K1 were not re-tested using the Roche Light-
cycler 480 I and thus may account for the poorer data quality comparatively to D1 and
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(b) Roche Lightcycler 480 I
Figure 6.2: Thermal melt curves of Cdc20 (161-477) with vehicle control (1% DMSO,
black) or without (apo, purple). Each trace represents an individual well. Raw and
negative derivative data are represented in top and bottom panels, respectively. (a)
Data acquired using the Biorad CFX Connect, with 1.5 µM Cdc20 (161-477), three
technical replicates. (b) Data acquired using Roche Lightcycler 480 I using 750 nM
Cdc20 (161-477), three technical replicates for Apo, six technical replicates for 1%
DMSO. Black dashed lines indicate the Tm as calculated by the average of the minimum
from the negative differential plots.
Apcin, which were re-collected as additional positive controls in subsequent experimental
runs. Apcin produced a large concentration-dependant change in the Tm of Cdc20 (Fig-
ure 6.3a), whereas the Hsl1-derived ’Super D-box’ peptide D1 produced a much smaller
change in the Tm of Cdc20 (Figure 6.3b), indicating a weaker binding affinity to Cdc20
compared to Apcin. Additionally, the raw data for Cdc20 melt curves with Apcin show
a dose-dependant fluorescent intensity baseline of the pre-unfolding transition, which is
likely due to the Sypro Orange dye binding to Apcin, which then dissociates with increas-
ing temperature. This is likely due to the low aqueous solubility of the Apcin molecule.
In contrast, D1 does not show a similar trend, whereby the pre-unfolding transition base-
line is consistent between the concentrations of D1. Peptides D9, A1 and K1 were only
screened at the highest concentration of 100 µM initially, due to a lack of Cdc20 material.
In all three cases the change in Tm was around 2-3 fold lower than D1 and similar in
melting temperature to 1% DMSO, indicative of very weak to no binding. Based on these
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Figure 6.3: Raw and negative derivative data from melt curves of 750 nM Cdc20
(161-477) in the presence of (a) Apcin and (b) D1, at 100 µM (blue), 50 µM (green)
and 25 µM (red). Data in (c) D9, (d) A1 and (e) K1 are from melt curves with
1.5 µM Cdc20 (161-477) with 100 µM of the indicated ligand using the Biorad CFX
connect instrument. Black dashed lines indicate the average Tm of Cdc20 for the given
concentration of ligand. Each trace represents an individual well. (f) Bar charts of
the change in melting temperature (∆Tm) in the presence of different ligands at the
indicated concentrations (relative to 1% DMSO). All data are relative to the 1% DMSO,
vehicle control data collected from the Biorad CFX connect.
data, and together with the greater wealth of information of D-box degron motifs present
in the literature, the ABBA motif and KEN-box peptide inhibitor series were not pursued
further.
Developing an SPR assay
Since DSF can only provide rough affinity trends, Cdc20-SPR assays were developed
alongside. First, Cdc20 was immobilised using Ni-NTA chips since further modification
of the protein was not required for this approach. However, given the poor activity of the
Cdc20 ligand in this immobilisation strategy, an alternative was explored. The Biotin-
Streptavidin interaction is of such high affinity, that subsequent amine coupling, as used
in the Ni-NTA immobilisation strategy, is not required. Despite immobilising similar RU
of ligand onto both chips (5427 and 4638 RU for the Ni-NTA and SA chips on Fc 4, re-
spectively), the data quality and signal between the two are very different (Figure 6.4 and
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Table 6.2). Whereas Ni-NTA captured ligand produced only poor quality sensorgrams,
the SA-captured ligand exhibited clean association and dissociation phases.
0 1´10 -5 2´10 -5 3´10 -5 4´10 -5
0
2
4
6
8
[Apcin] (M)
R
e
s
p
o
n
s
e
U
n
it
s
(R
U
)
0 60 120
-5
0
5
10
Time (sec)
R
e
s
p
o
n
s
e
U
n
it
s
(R
U
)
(a) Ni-NTA capture: Apcin Fc4-1
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(b) SA capture: Apcin Fc4-1
Figure 6.4: Difference in raw data quality between ligand immobilisation using (a)
Ni-NTA capture or (b) SA capture. Steady state affinity fits and sensorgrams are shown
for Fc 4-1 for the small molecule Apcin. Results from data fitting are listed in Table
6.2.
Furthermore, an approximate 3-fold increase of signal is observed using the SA chip
compared to the Ni-NTA chip. Although dissociation constants are somewhat similar,
the fit from SA immobilised protein is more reliable due to the increase raw data quality.
The amount of functional Cdc20 ligand on the Ni-NTA chip is very low, indicating that
the ligand is either binding incompetent while remaining folded, e.g. by being attached to
the surface in an orientation that occludes the binding site, or that it has lost its native
fold during the immobilisation procedure. For example, due to multiple freeze-thaw cycles
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Table 6.2: Results from data fitting of steady-state affinity measurements of Apcin
using a Ni-NTA or SA chip.
Biosensor chip Ni-NTA SA
RUmax (RU) 7.2 19.8 ± 0.6
Kd (nM) 634 ± 96 418 ± 53
% Ligandfunctional 11.9 34.4
and sample preparation, aggregates or misfolded monomers could accumulate that may
still bind the chip but are unable to interact with the analyte. However, if around 60%
of the protein was not folded correctly, DSF melt curves would exhibit an altered transi-
tion profile. Since abnormal thermal shifts were not observed, it is more likely that the
protein remains largely folded correctly, but can simply not bind the analyte for various
reasons. All dissociation constants quoted in the following sections were generated using
biotinylated Cdc20 ligand immobilised onto the SA chip.
6.3.2 Exploring position 7 of the D-box motif
The amino acids found at position 7 of the D-box peptide motif tend to be aliphatic (va-
line, isoleucine and leucine, Figure 5.4) [165]. Peptides D3 (Ac-RAPLGDVSN-NH2), D4
(Ac-RAPLGDISN-NH2) and D5 (Ac-RAPLGDLSN-NH2) were designed and synthesised
incorporating point mutations of valine, isoleucine and leucine at position 7, respectively.
In addition, the consensus D-box motif, peptide D2 (Ac-RLPLGDVSN-NH2) was synthe-
sised and tested as well. Peptides were initially screened for binding by DSF (Figure 6.5).
DSF results for all four peptides are shown in Figure 6.5, with Apcin included as a
positive control molecule that can also serve as an internal standard between different
sets of experiments. However, the Tm shift of Cdc20 with 100 µM Apcin appeared to
be higher in the first run (+10.08 ± 0.05 ◦C, Figure 6.3f) than in the second run (+8.08
± 0.08◦C, Figure 6.5). Indeed, subsequent DSF experiments show the second result to
be more representative of the average, and the higher observed Tm initially could be a
result of poor sample dilution. Thermal shifts due to D1 appear more consistent than
for Apcin between the first and second experiments (2.99 ± 0.37◦C and 2.89 ± 0.06◦C,
respectively). Surprisingly, little to no evidence of binding is observed for peptide D2, the
consensus sequence. Peptides D3, D4 and D5 show dose-dependent Tm shifts, which are
all smaller than that of D1 at the same concentrations. As was shown for Apcin and D1
in Figures 6.3a and 6.3b, the raw data for D4 is shown for a subsequent experiment where
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Figure 6.5: Raw and negative derivative data from melt curves of 750 nM Cdc20 (161-
477) in the presence of (a) D2 and (b) D3, (c) D4 and (d) D5 at 100 µM (blue), 50
µM (green) and 25 µM (red). Black dashed lines indicate the average Tm of Cdc20 for
the given concentration of ligand. Each trace represents an individual well. Raw data
for D4 is representative from a subsequent experiment, where the overall quality was
improved. (e) Bar charts of the change in melting temperature (∆Tm) in the presence
of different ligands at the indicated concentrations (relative to 1% DMSO). All data
are relative to the 1% DMSO, vehicle control data collected on the Roche Lightcycler
480 I.
generated better quality data, whereas peptides D2, D3 and D5 were not subsequently
repeated due to lack of sufficient purified Cdc20. Since DSF data did not provide suitable
resolution for the relatively small changes in Tm of Cdc20, these experiments were not
entirely sufficient to determine which residue at position 7 was optimal.
All peptides except D2, for which there was no clear evidence of binding (Figure 6.5),
were further analysed by SPR. The data presented in Figure 6.6 and Table 6.3 show a
clear preference for longer aliphatic side chains: isoleucine and leucine gave higher affinities
than the shorter side chain of valine. In addition, isoleucine is better than leucine and it
was therefore incorporated into all subsequently synthesised D-box peptides at position
7. Peptides D1 and D4 have very similar dissociation constants, and this similarity is also
apparent in the DSF data (Figure 6.5).
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(c) Fc4-1, D4: Ac-RAPLGDISN-NH2
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(d) Fc4-1, D5: Ac-RAPLGDLSN-NH2
Figure 6.6: Representative data from Fc 4-1 of SPR steady state affinity fit plots (left
panels) and sensorgrams (right panels) of peptides D1, D3, D4 and D5. Results from
data fitting are listed in Table 6.3.
Table 6.3: SPR analysis of Cdc20 binding to D3, D4 and D5. Kd values are reported
as the average of all three reference-subtracted flow cells, with the standard error of
the mean. RUmax and % Ligandfunctional are reported for Fc4-1 only.
Peptide D1 D3 D4 D5
RUmax (RU) 65.29 54.5 58.25 56.9 ± 0.6
Kd (µM) 18.59 ± 0.22 54.37 ± 0.74 19.58 ± 0.22 27.12 ± 1.04
% Ligandfunctional 47.0 42.8 45.1 44.0
6.3.3 Exploring position 3 of the D-box motif
The consensus sequence of D-box peptides has a strong preference for either proline or
alanine at position 3, with proline being observed at a higher frequency. To investigate
which of the two amino acids at position 3 were optimal for binding, a derivative of peptide
D4 (Ac-RAPLGDISN-NH2) was synthesised to introduce alanine in its place, resulting
in peptide D10 (Ac-RAALGDISN-NH2). Indeed, the inclusion of alanine at position 3
of the D-box peptide is not favourable as evident from the reduced thermal stabilisation
of Cdc20 compared to peptide D4 (Figures 6.7a and 6.7b) and a 3.5-fold weaker binding
affinity as measured by SPR (69.56 ± 3.39 µM Figure 6.7c).
6.3.4 Exploring positions 5 and 8 of the D-box motif
The remaining differences between peptides D1 (Ac-GRAALSDITN-NH2) and D4 (Ac-
RAPLGDISN-NH2), excluding the solvent-exposed N-terminal glycine residue of D1, are
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(c) Fc4-1, D10: Ac-RAALGDISN-NH2
Figure 6.7: (a) Raw and negative derivative data from melt curves of 750 nM Cdc20
(161-477) in the presence of D10 at 100 µM (blue), 50 µM (green) and 25 µM (red).
Black dashed lines indicate the average Tm of Cdc20 for the given concentration of
ligand. Each trace represents an individual well. (b) DSF analysis of D10 compared to
D1 and D4 and Apcin binding to Cdc20. (c) Representative SPR data of D10 binding
to Cdc20 on Fc4-1. Steady state affinity (left) and sensorgram (right).
positions 5 and 8 (highlighted in red). Due to a lack of time to explore both positions
independently, peptide D19 (Ac-RAPLSDITN-NH2) was synthesised, incorporating both
residues from D1 into the D4 sequence. Only 25 µM of D19 produces a similar response
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in DSF compared to 100 µM of D1 or D4 alone (Figure 6.8b), and D19 can be observed
to bind with a dissociation constant of 5.87 ± 0.11 µM by SPR (Figure 6.8c). Despite
deriving an optimal sequence comprising natural amino acids, it was evident that the
affinity of a natural peptide was not comparable to Apcin (Table 6.2).
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(c) Fc4-1, D19: Ac-RAPLSDITN-NH2
Figure 6.8: (a) Raw and negative derivative data from melt curves of 750 nM Cdc20
(161-477) in the presence of D19 at 100 µM (blue), 50 µM (green) and 25 µM (red).
Black dashed lines indicate the average Tm of Cdc20 for the given concentration of
ligand. Each trace represents an individual well. (b) DSF analysis of D19 compared to
D1 and D4 and Apcin binding to Cdc20. (c) Representative SPR data of D19 binding
to Cdc20 on Fc4-1. Steady state affinity (top) and sensorgram (bottom).
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6.3.5 Incorporating non-natural amino acids at position 4
Initially, (S )-2-amino-3-cyclobutylpropanoic acid (cBuAla), which had previously been
used in the context of the p53 peptide [105], and (S )-2-amino-4,4-dimethyl-pentanoic
acid (C3) were explored as functional derivatives of the leucine side chain (for structures
see Figure 5.8). It was hypothesized that burial of a slightly bulkier side chain into the
D-box pocket may increase the affinity. Both amino acids were incorporated into the
scaffold of D4, resulting in the synthesis of peptides D6 (Ac-RAPcBuAlaGDISN-NH2)
and D7 (Ac-RAPC3GDISN-NH2). Although substitution of cBuAla did not yield an im-
proved ligand, peptide D7 showed significant improvement over peptide D4, with a change
in melting temperature of 4.13 ± 0.03◦C versus 1.51 ± 0.03◦C, respectively (Figure 6.9).
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Figure 6.9: Raw and negative derivative data from melt curves of 750 nM Cdc20 (161-
477) in the presence of (a) D6 and (b) D7 at 100 µM (blue), 50 µM (green) and 25 µM
(red). Black dashed lines indicate the average Tm of Cdc20 for the given concentration
of ligand. Each trace represents an individual well. (b) Representative SPR data of
D7 binding to Cdc20 on Fc4-1. Steady state affinity (left) and sensorgram (right). (c)
DSF analysis of D6 and D7 compared to Apcin and the parental peptide sequence, D4,
binding to Cdc20.
These results indicated that the higher affinity could be driven by the leucine-binding
pocket of Cdc20. The C3 amino acid was substituted into peptides D10 and D19 (creating
D12 and D20, respectively) to see if it could improve the binding of both the lower- and
higher-affinity peptide scaffolds to Cdc20. In all three C3-containing derivative peptides,
increases in Cdc20 thermal stability and binding affinity were observed compared to their
leucine-containing parental sequences (Figures 6.9 and 6.10 and Table 6.4). Surprisingly,
the 6-fold increase in affinity upon incorporating (S )-2-amino-4,4-dimethylpentanoic acid
appeared to be independent of the parental sequence. Attempts to make the peptide
more similar to Apcin by incorporation of a halogenated amino acid were also pursued. As
mentioned in Chapter 5, Fmoc-(S )-2-amino-4,4,4-trichlorobutanoic could not be produced
by a commercial vendor. The closest halogenated alternative, Fmoc-(S )-2-amino-4,4,4-
trifluorobutanoic acid, is commercially available and was used to synthesise peptide D21
(Ac-RAPF3SDITN-NH2), which exhibits the tightest binding to Cdc20 of all peptides by
producing an 11-fold increase in affinity (Figure 6.10 and Table 6.4).
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(g) Fc4-1, D21: Ac-RAPF3SDITN-NH2
Figure 6.10: Biophysical characterisation of peptide derivatives containing a
substitution of (S )-2-amino-4,4-dimethylpentanoic acid (C3) and (S )-2-amino-4,4,4-
trifluorobutanoic acid (F3), for leucine at position 4. Raw and negative derivative data
from melt curves of 750 nM Cdc20 (161-477) in the presence of (a) D12, (b) D20 and
(c) D21 at 100 µM (blue), 50 µM (green) and 25 µM (red). Black dashed lines indicate
the average Tm of Cdc20 for the given concentration of ligand. Each trace represents
an individual well. (d) DSF analysis of D12, D20 and D21 compared to Apcin and their
respective parental peptide sequences, binding to Cdc20. SPR steady state affinity fits
(Left) and sensorgrams (Right) for peptides (e) D12, (f) D20 and (g) D21.
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Table 6.4: Fitting outputs of steady-state affinity measurements Fc 4-1 of D4, D7,
D10, D12, D19, D20 and D21. Kd is the average of all three reference-subtracted flow
cells with the standard error of the fits.
Peptide RUmax (RU) Kd % Ligandfunctional Fold Kd increase
D4 58.25 19.58 ± 0.22 µM 45.1 -
D7 63.31 3.10 ± 0.10 µM 48.3 6.3
D10 55.22 69.56 ± 3.39 µM 43.9 -
D12 58.88 13.30 ± 0.10 µM 46.1 5.2
D19 65.24 5.87 ± 0.11 µM 48.3 -
D20 67.55 902 ± 14 nM 49.4 6.5
D21 62.07 524 ± 14 nM 44.9 11.2
Most notably, the thermal stabilisation of Cdc20 by Apcin, is now almost achieved by
both the D20 and D21 peptides (Figure 6.10d). For the first time, we can directly make
a qualititative comparison on the correlation of thermal stabilisation by a Cdc20 ligand
with affinities derived from SPR steady-state equilibrium fits. Though it could also be
inferred similarly with the weaker ligands, such as D1, D3, D4 and D5, the resolution and
clarity of this was more difficult to observe, hence the defined the necessity for the SPR
experiments. Indeed, from the DSF data there is a clear discrepancy for order of thermal
stabilisation with Apcin > D21 > D20. This trend observed by DSF also follows for their
calculated affinities of 419 ± 53 nM, 524 ± 14 nM and 902 ± 14 nM, respectively. This
observation, particularly in the higher affinity regime demonstrates that DSF can be a
high-throughput and reliable method for screening ligands targeting Cdc20.
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6.3.6 Cellular Thermal Shift Assays
Cellular Thermal Shift Assays (CETSA), a relatively new technique similar to DSF, relies
on the fact that ligand binding will influence the melting temperature (Tm) of a protein.
CETSA has the benefit of working in a more physiological context, such as mammalian
cells or even tissues [244], instead of being reliant on recombinant protein in aqueous
buffers. Here, the stabilisation of both endogenous and exogenous target proteins was
explored in the background of HEK 293T lysates. Working with endogenous protein has a
major biological advantage over transiently transfected (exogenous) protein. First, protein
levels are reflective of the natural system instead of being overexpressed. Second, it is
not clear that exogenous protein will have the same functional capability as endogenous
protein. However, detection of endogenous protein levels and changes therein can be
difficult, whereas exogenous proteins can be modified to include small tags for various
detection methods.
CETSA of endogenous proteins
Since changes in melting temperature observed in DSF experiments were sufficiently large,
it was hypothesised that a ligand would also stabilise endogenous Cdc20 in the cell as
measured by CETSA. Additionally, it was thought that a similar approach could be used
to investigate ligand binding to Apc8 and Apc3, for which it was not feasible to establish
assays using purified protein. A dilution series of endogenous HEK 293T lysate was
analysed to probe the linearity of the densitometric analysis and was which was found to
be approximately linear for Apc3, Apc8 and Cdc20 (Figure 6.11). Sackton et al. [195]
performed an isothermal melt using a titration of ligand to induce increased stabilisation
of Cdc20. However, attempts to recapitulate the isothermal CETSA data by western blot
were unsuccessful (data not shown) and therefore a thermal melt curve approach was used
instead. The addition of 100 µM Apcin was sufficient to stabilise Cdc20, whereas 100 µM
TAME induced stabilisation of Apc3 but not Apc8 (Figure 6.12 and Table 6.5).
Table 6.5: Melting temperatures of Apc3, Apc8 and Cdc20 from endogenous HEK
293T lysates, with small molecule compounds.
Protein
Melting temperature (◦C)
1% DMSO TAME Apcin
Apc3 46.88 ± 0.27 48.07 ± 0.26 -
Apc8 48.88 ± 0.37 48.57 ± 0.29 -
Cdc20 48.88 ± 0.29 - 51.09 ± 0.21
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Figure 6.11: (a) Dilution of HEK 293T lysate from 11 to 1 µg of protein loaded onto
each lane. (b) Densitometric analysis of the HEK 293T dilution series.
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Figure 6.12: Thermal melt curves of proteins from endogenous HEK 293T lysates.
(a) Apc3 with 100 µM TAME (green) or vehicle control (orange) (b) Apc8 with 100
µM TAME (green) or vehicle control (orange). (c) Cdc20 with 100 µM Apcin (blue)
or vehicle control (orange). Data represent the average of biological duplicates.
CETSA of exogenous Cdc20
Quantitative western blotting is particularly low in throughput and, therefore, a split-
luciferase detection method was implemented [237]. This approach utilises the LgBiT
protein and the HiBiT tag, a high-affinity complementing peptide (VSGWRLFKKIS)
that is able to reconstitute the NanoLuc luciferase (Promega). The HiBiT-tag (with ad-
ditional GS-linkers appended to both ends of the tag) was added to full-length Cdc20
(1-499) at either the N- or C- terminus. In a preliminary experiment, the signal for the
Cdc20 (1-499)-HiBiT (C-terminal) construct was found to be significantly better than the
N-terminally tagged protein and therefore all future experiments were conducted using the
C-terminally tagged variant. The 1% DMSO control sample was used to examine whether
the removal precipitated protein after heating by centrifugation had a significant impact
on data quality (Figure 6.13a). Cdc20 in the centrifuged sample showed a Tm of 49.56 ±
0.70◦C, whereas Cdc20 in the non-clarified sample showed a Tm of 48.98 ± 0.43◦C. Since
these values are the same within error, the centrifugation step could be omitted to speed
up sample processing, highlighting one major advantage of the split-luciferase CETSA
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method compared to western blot detection. Furthermore, melting temperatures of ex-
ogenous protein were similar to the Tm of endogenous Cdc20 and this provided confidence
that the protein was not behaving significantly differently when overexpressed (Table 6.5).
Next, Apcin and the top four D-box peptides (D7, D19, D20 and D21) were tested to see
if they stabilised (i.e. bound to) the exogenous Cdc20 protein (Figure 6.13b-f) and Table
6.6).
With all novel D-box peptide ligands, we observed a significant stabilisation of Cdc20
relative to the vehicle control. However, the weakest ligand, D19, produces only a marginal
positive shift of 0.9◦C, highlighting that ligands in the low-to-mid micromolar affinity
range are those at the detection limit of the developed system. Additionally, despite
D21 and Apcin having very similar affinities as measured by SPR and DSF, there is a
larger discrepancy in the relative melting temperature shift of both compounds in this
experiment. Sackton and co-workers demonstrated Apcin’s specificity to binding Cdc20
in comparison to other WD40 domain proteins, including the Cdc20 homologue protein,
Cdh1 [195]. Due to a lack of time, experiments to this extent were not performed and it
is indeed very likely that these D-box ligands will also have similar affinities to Cdh1.
Table 6.6: Melting temperatures of Cdc20 (1-499)-HiBiT in transfected HEK 293T
lysates, with D-box ligands.
Ligand Melting temperature (◦C)
1% DMSO 48.98 ± 0.43
100 µM Apcin 56.06 ± 0.70
100 µM D7 50.94 ± 0.40
100 µM D19 50.88 ± 0.31
100 µM D20 53.06 ± 0.44
100 µM D21 53.42 ± 0.37
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Figure 6.13: Thermal melt curves of exogenous Cdc20 (1-499)-HiBiT in the presence
of vehicle control (1% DMSO), Apcin, D7, D19, D20 or D21. (a) Impact of centrifuga-
tion as determined by comparing centrifuged (lime-green) and non-centrifuged (orange)
samples of 1% DMSO control. Ligand-induced stabilisation of Cdc20 using (b) 100 µM
Apcin, (c) 100 µM D7, (d) 100 µM D19, (e) 100 µM D20 or (f) 100 µM D21. All sam-
ples are overlaid with the 1% DMSO control . Data represent the average of triplicate
experiments.
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CETSA of exogenous Apc8
Although we had demonstrated that we could observe binding of TAME to endogenous
Apc3 by the western blotting methodology (Figure 6.12), it still suffers from the same
low-throughput and low sensitivity as was seen with CETSA experiments with Cdc20.
Due to this fact, developing the same high-throughput split-luciferase assay format was
desirable for both Apc3 and Apc8. However, for reasons that were not clear, very poor
expression of the HiBiT-Apc3 (1-824) and Apc3 (1-824) constructs were observed, which
were only 7-fold greater than the background signal observed of untransfected lysates.
It is possible that the introduction of the HiBiT tag at either terminus of Apc3 hinders
its’ incorporation into the APC/C complex and thus may be very unstable as a result,
as indicated from personal communication with our collaborator, Prof. David Barford,
an expert in the structural biology of the APC/C. Unperturbed by the poor signal from
the HiBiT-tagged Apc3 constructs, we explored HiBiT-tagged Apc8 constructs. In the
preliminary experiments, the C-terminally tagged construct showed approximately twice
the raw luminescence values compared to the N-terminally tagged construct. Here, we
observed greater than 100-fold signal change over the background of untransfected cell
lysates indicating a more stable construct that is assumed to be incorporated in the
APC/C complex. First, we demonstrated that the Apc8 (1-591)-HiBiT construct would
also behave similarly as we could see with the Cdc20 constructs, whereby it was possible
to remove the centrifugation step without significantly affecting the melting temperature
of Apc8 (Figure 6.14a). Having established that the Tm of the non-centrifuged and cen-
trifuged samples were 45.3 ± 0.5 and 44.3 ± 0.3, (Table 6.7), respectively as an average
from experimental triplicates. While the difference here is greater than the standard de-
viation from the experimental triplicates, curve fitting of the centrifuged samples is more
erroneous given the larger error between technical replicates of each temperature point,
where it is believed that the centrifugation step in this process leads to increased hetero-
geneity across the technical replicates in each assay plate.
The focus then turned to testing the TAME small molecule alongside the C-box pep-
tides to observe if they would stabilise Apc8. Observing the TAME small molecule in
this split-luciferase assay format (Figure 6.14b) is in agreement with what was observed
in the initial western blotting experiments looking at TAME against endogenous Apc8
(Figure 6.12b). In both experiments, no thermal stabilisation of Apc8 was observed and
this provided some confidence that TAME was indeed a poor inhibitory ligand as has
been described in the literature, when used on it’s own [194, 195]. Observing both the
linear, C1, and Alanine-mutant knockout peptide, C5, we similarly observe little to no
change in the melting temperature of the reporter construct. While we expected the neg-
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ative control peptide, C5, to do exactly this, the same was not expected for the linear
peptide. Since this assay format is the only way that has been explored to provide a
semi-biophysical interpretation of ligand binding to the target protein, it may well be
possible that the affinity is too low to be detectable. Indeed, as was the case with Cdc20
and D-box ligands, the mid-single digit micromolar range appeared to be the cut-off of
detectable thermal stabilisation in those CETSA experiments. However, in stark contrast
to the other ligands, both the early and later isomers of the hydrocarbon-stapled pep-
tide ligand, C6e and C6l, produced a significant destabilising effect to exogenous Apc8.
Although rarely observed in drug discovery high-throughput screening campaigns, both
ligands that produce thermal stabilisation or destabilisation are of interest. Destabilis-
ing ligands may offer mechanisms of allosteric inhibition by shifting the global protein
structure and thereby reducing the free energy required to unfold the protein. However,
in this specific case, since we are working in a non-purified system, it is perhaps more
likely that we have a element of competition for the C-box binding site. In the cell lysate,
either Cdc20 or Cdh1 is likely to be bound and indeed the total binding interface spans
more than just the the C-box motif. Therefore, relative to either Cdc20 or Cdh1 bound
to Apc8, our C-box ligands offer a smaller binding interface that is unable to stabilise
Apc8 to the same extent as either co-activating protein.
Table 6.7: Melting temperatures of Apc8 (1-591)-HiBiT in transfected HEK 293T
lysates, with C-box ligands.
Ligand Melting temperature (◦C)
1% DMSO 44.3 ± 0.3
100 µM TAME 44.1 ± 0.4
100 µM C1 44.4 ± 0.6
100 µM C5 44.6 ± 0.2
100 µM C6e 42.0 ± 0.5
100 µM C6l 41.9 ± 1.0
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Figure 6.14: Thermal melt curves of exogenous Apc8 (1-591)-HiBiT in the presence
of vehicle control (1% DMSO), TAME, C1, C5, C6e and C6l. (a) Impact of centrifuga-
tion as determined by comparing centrifuged (lime-green) and non-centrifuged (orange)
samples of 1% DMSO control. Ligand-induced destabilisation of Apc8 using (b) 100
µM TAME, (c) 100 µM C1, (d) 100 µM C5, (e) 100 µM C6e or (f) 100 µM C6l.
All samples are overlaid with the 1% DMSO control. Data represent the average of
triplicate experiments.
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6.3.7 In vitro ubiquitination assays
Binding of a ligand to its target receptor is merely a starting point to generating an in-
hibitory molecule. The ligand of interest must also be able to produce a functional effect
as a result of receptor binding. Until this point, characterisation of novel D-box and C-box
ligands has revolved around investigating their binding affinities to the target protein and
their abilities to engage their target in a cellular context using CETSA assays. However,
determining whether these ligands can behave as functional inhibitors of the APC/C is far
more complicated as a matter, owing to the unique and complex biology that the APC/C
performs and is indeed regulated by. To make matters more challenging in this regard,
functional output of cell cycle control protein would ideally be investigated in living cells.
However, peptide ligands on their own are typically impermeable to the cell membrane
due to their hydrophilic nature, which was discussed previously in Section 1.2.1. To over-
come this and also vastly simplify the complex nature of the APC/C function that occurs
in a cellular context, in vitro ubiquitination assays that had previously been established
by the Barford laboratory were employed to investigate the inhibitory action of the lead
ligands (Figure 6.15).
The first iteration of this experiment utilised very high concentrations in the millimo-
lar range since previous characterisation of TAME could only achieve inhibitory effects
at concentrations in this range (Figure 6.15a) [28]. Indeed, poor inhibitory activity of
TAME was observed in this experiment, whereby only marginal effect is observed at 3
mM concentrations. In stark comparison, both D-box peptides are significantly more po-
tent at inhibiting Cyclin B1 poly-ubiquitination at the same concentrations. At 300 µM
concentrations of D20 and D21, band intensity of each band in the poly-ubiquitinated
Cyclin B1 ladder is less intense compared to the vehicle control. At the highest concen-
trations of 3 mM, the ladder intensity is further reduced, in addition to the extent of
poly-ubiquitin laddering where only 2-3 bands in the ladder can be observed. However,
it should be noted that TAME does not serve as the correct positive control molecule in
this experiment due to its mechanism to deplete Cdc20 from the APC/C, whereas D-box
peptides directly compete for the D-box degron binding site of Cdc20. As such, it was
imperative to repeat these experiments with the appropriate controls. In addition, such
high concentrations of ligands are physiologically irrelevant and as such, lower concentra-
tions were used in further experiments.
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Figure 6.15: Ubiquitination assays probing Cyclin B1 poly-ubiquitination in the
presence or absence of TAME, Apcin, D-box peptides and C-box hydrocarbon stapled
peptides at varying concentrations or vehicle control. (a) Preliminary experiment prob-
ing TAME, D20 and D21. (b) Experiments to probe the C-box stapled peptides and
a combination dosage with C6e and D21. (c) Experiments to comparing D20 and D21
against Apcin. Cyclin B1 and Apc2 serve as loading controls for each experiment. (d)
Structures for C6e and C6l, which vary by cis and trans isomerisation at the carbon-
carbon double bond of the hydrocarbon staple (circled in red) Further information of
each peptide is described in Appendix B.
154 Biophysical characterisation of APC/CCdc20 peptide inhibitors
This pilot experiment was followed up with two experiments. Since the C-box sta-
pled peptides produced a destabilising effect in the CETSA experiments (Figures 6.14e
and 6.14f), it was believed that this may translate into a functional change of APC/C
activity. The two ligands were tested at two concentrations of 30 µM and 300 µM, where
both ligands produced surprisingly opposing functional effects. The stapled peptide, C6e,
produces an apparent inhibitory effect on Cyclin B1 ubiquitination in comparison to the
vehicle control lane (0.7% DMSO), which supports the hypothesis that Cdc20 could be
displaced by the ligand as initially designed. In contrast, C6l produces the opposing
effect, where increasing concentrations of ligand appear to further activate the APC/C
and induce greater amounts of Cyclin B1 poly-ubiquitination compared to the vehicle
control (Figure 6.15b). Given the high structural similarity of the two stapled peptides,
which only differ by the cis and trans isomers at the carbon-carbon double bond of the
hydrocarbon staple linker (Figure 6.15d), this result was highly surprising. In addition to
single ligand dosing, as was done for all ligands, it was hypothesised that dual inhibitor
action may result in a synergistic effect, as was observed by Sackton et al. [195]. When
co-drugging with C6e and D21, which both produce inhibitory function in these assays,
we observed quite the opposite when drugged in conjunction. Although at 15 µM of both
ligands, inhibitory function is observed compared to the vehicle control, increasing of both
doses 10-fold to 150 µM results in apparent lack and perhaps even further activation of
APC/C ubiquitination.
Lastly, we conducted experiments to directly compare the lead D-box peptides, D20
and D21 against the small molecule, Apcin. Although Apcin had not been previously
assayed by the Barford laboratory, a dose-dependent inhibitory profile for the ligand was
expected as seen in Figure 6.15c. Both D20 and D21 also produce similar inhibitory
profiles for the 300 µM concentrations between Figures 6.15a and 6.15c, which provides
confidence in the results observed. Curiously, despite the measured affinities of each
ligand that were determined against Cdc20 in the SPR assays (Tables 6.2 and 6.4), which
indicate that D21 and Apcin are very similar in affinity, and D20 is approximately 2-fold
weaker than Apcin and D21, both peptide ligands appear to produce a greater inhibitory
response, which can be most evidenced at the 30 µM concentration of each ligand. This
result was highly intriguing and provides evidence that ligand affinity does not necessarily
equate to a good inhibitor.
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6.3.8 X-ray crystal structures of D-box peptides bound to Cdc20
To obtain a more detailed understanding of the interaction between D-box peptides and
Cdc20, structural information was thought to be necessary. However, due to the produc-
tion of recombinant Cdc20 being a limiting factor, only one crystallisation grid screen
was prepared and the Cdc20 concentration of 1.9 mg/mL was significantly lower than
previously reported (7-8 mg/mL [193] and 4-5 mg/mL [195]). Despite this apparent dis-
advantage, cuboidal crystals were observed in multiple wells that grew to maximum size
within 2-3 days of incubation at 20◦C (Figures 6.16a and 6.16b). This surprising success
elicited a serious emotional perturbation, the symptoms of which were excessive dancing
and singing (of the human, not Cdc20). The MPD molecule contained in the mother
liquor binds in the leucine-pocket of the D-box-binding site (Figure 6.16c) [193]. There-
fore, it was thought unlikely that crystals would contain any D21 peptide even though
it was used for concentrating the protein stock originally. Indeed, crystals that were not
soaked in peptide did not have D21 bound.
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Figure 6.16: (a) Crystallisation hits are marked by a cross (X) in their corresponding
wells. Red crosses (X) indicate wells containing crystals that were sent for data col-
lection. (b) A representative image of cuboidal Cdc20 (161-477) crystals in drop E9,
grown in 0.1 M MES pH 6.5, 14% (w/v) PEG 6000, 10% (v/v) MPD, 2:1 protein to
well solution. A scale bar of 200 µm is shown as a reference for crystal size. (c) MPD
binds the D-box binding site (PDB:4GGC) [193].
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Crystals were soaked in solutions containing four D-box peptides: D21, D20, D7 and
D19. Since, D7 and D19 are relatively weak ligands in the field of drug discovery, with
dissociation constants in the low micromolar range, soaking was performed using these
peptides at higher concentrations. The crystals did not appear to dissolve in the soaking
conditions over the 4-hour incubation period. Structures containing D-box peptides were
solved for the three highest-affinity D-box peptides (D21, D20 and D7) and the corre-
sponding structure refinement statistics are summarised in Table 6.8. Densities for the
D19 peptide were very poor, and it was not possible to build meaningful models. All
structures solved, were found in the space group P21, as was observed previously [193].
Interestingly, the observed density in the omit maps (Figures 6.17a, 6.17c and 6.17e)
correlates with ligand affinity. Due to the packing geometry, in which the next asymmet-
ric unit is observed in very close proximity to the peptide binding site, densities for the
C-terminal three residues (I[T/S]N-NH2) of each peptide ligand could not be observed.
Table 6.8: Data collection, phasing and BUSTER refinement statistics for Cdc20-D-
box structures.
Parameters and statistics
Crystal
Cdc20-D21 Cdc20-D20 Cdc20-D7
Data collection
Space group P21 P21 P21
Unit cell, a, b, c (Å), 35.49, 87.55, 48.57 35.34 87.34 48.51 35.00 86.87 48.03
α, β, γ (◦) 90.00, 109.71, 90.00 90.00 110.14 90.00 90.00 109.60 90.00
Resolution range, Å 45.73 - 1.51 (1.66 - 1.51) 45.55 - 1.46 (1.60 - 1.46) 45.24 - 1.92 (2.09 - 1.92)
Total reflections 162715 (6076) 184416 (10465) 76640 (3657)
Unique reflections 32820 (1641) 35450 (1772) 14979 (750)
Multiplicity 5.0 (3.7) 5.2 (5.9) 5.1 (4.9)
Completeness (spherical), % 74.7 (14.5) 74.5 (16.0) 71.8 (15.4)
Completeness (ellipsoidal), % 90.4 (41.9) 92.9 (60.1) 90.5 (57.6)
I/σI 13.1 (1.6) 13.6 (1.4) 7.6 (1.5)
Rmerge 0.050 (0.598) 0.048 (1.000) 0.132 (1.161)
CC1/2 0.999 (0.714) 0.999 (0.635) 0.996 (0.536)
Refinement
Rwork/Rfree, % 0.175/0.194 0.165/0.184 0.207/0.231
Unique reflections used 32820 35450 14966
R.m.s deviations:
bond lengths, Å 0.008 0.008 0.008
bond angles, ◦ 1.01 1.02 1.00
Ramachandran analysis:
Favoured, % 97.10 98.06 97.33
Allowed, % 2.58 1.61 2.33
Outliers, % 0.32 0.32 0.33
Number of atoms
(average B-factor, Å2):
Protein 2452 (24.31) 2434 (25.80) 2340 (29.68)
Solvent 236 (39.17) 240 (44.08) 72 (32.96)
Peptide 46 (37.72) 46 (46.88) 25 (48.49)
Mean/Wilson B-factor, Å2 25.8/22.9 27.8/23.9 30.0/27.8
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(a) D21 omit map (b) D21 model
(c) D20 omit map (d) D20 model
(e) D7 omit map (f) D7 model
Figure 6.17: X-ray crystal structure data of D-box peptides in complex with Cdc20.
(Left panels) Omit maps of refined structures showing Fo-Fc map (green mesh) con-
toured at 2.5σ for peptides (a) D21, (c) D20 and (e) D7. (Right panels) Models of pep-
tides built into the electron density map showing 2Fo-Fc map (blue mesh) contoured
at 1.0σ for peptides (b) D21, (d) D20 and (f) D7. Peptides in stick representation are
coloured in cyan. Cdc20 represented in cartoon is shown in white.
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Next, the structures were compared to previously published Cdc20 structures (Figure
6.18) [193, 195], resulting in an alignment with a negligible root mean squared deviation
(rmsd) of 0.228 Å between all residues and atoms of the Cdc20 protein in PDB:4GGC and
the Cdc20-D21 structure, proving that these Cdc20 structures are highly similar. Minor
shifts were only observed around a loop comprising residues 340 - 344 and could be due
to a the poor density and consequently modelling of these local residues. In the case of
the Cdc20-D7 structure, it was not possible to build convincing residues for this region.
D-box binding site
Residues 340-344
Figure 6.18: Alignment of published Cdc20 structures with the structures of Cdc20
bound to D-box peptides. The colouring is as follows: PDB:4GGC - green, PDB:4N14
- violet, Cdc20-D21 - cyan, Cdc20-D20 - magenta, and Cdc20-D7 - yellow. All water
molecules were omitted for clarity.
In all three structures, peptides bound the canonical binding site and formed the same
set of inter-molecular hydrogen bonds (H-bonds), as can be seen in Figures 6.19a, 6.19c
and 6.19e. The guanidino group of R1 of peptides interacts through H-bonding with the
carboxylic acid side chains of D177 and E465 of Cdc20. The nitrogen backbone atom of
the F3/C3 non-natural amino acids also form a hydrogen bond with the carbonyl of D177.
Additionally, the D177 nitrogen backbone atom forms an interaction with the carbonyl
group of S5/G5 of the peptide. Lastly, D6 forms inter-molecular H-bonds with R174. This
network of H-bonding appears to be identical to the H-bond network described previously
for homologous residues in the Acm1-Cdh1 structure [165].
In addition to the inter-molecular H-bonding network, the incorporation of S5 in D21
and D20 instead of glycine results in an unique intra-molecular H-bond formed between
the hydroxyl groups of the serine side chain with the carbonyl group of A2. A second
intra molecular H-bond is formed between the nitrogen backbone atom of either residue
at position 5 and the carbonyl of A2, although this is likely to be a weaker given its longer
range (3-3.1 Å).
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D177
E465
R174
R1
D6
(a) D21 inter-H-bond
A2
S5
(b) D21 S5 intra-H-bond
D177
E465
R174
R1
D6
(c) D20 inter-H-bond
A2
S5
(d) D20 S5 intra-H-bond
D177
(e) D7 inter-H-bond
A2
G5
(f) D7 intra H-bond
Figure 6.19: X-ray crystal structure data of D-box peptides in complex with Cdc20.
Left panels: Inter-molecular hydrogen bonding (yellow-dashed lines) between Cdc20
(R174, D177, E465) and D-box peptides (a) D21, (c) D20 and (e) D7. Right pan-
els: Intra-molecular hydrogen bonding (yellow-dashed lines) between position 5 amine
group group and A2 carbonyl group for peptides (b) D21, (d) D20 and (f) D7. D21
and D20 contain serine at position 5, which contributes a second intramolecular H-bond
between the serine hydroxyl group and A2 carbonyl group.
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6.4 Discussion
Biophysical assay development
The development of assays to assess peptide binding were mindful of the limitations in-
volved with producing purified Cdc20. We found DSF to be very efficient in terms of
sample use, requiring a concentration of only 750 nM to produce sufficient signal from
Sypro Orange binding upon the unfolding of the WD40 domain. Indeed, this often requires
protein concentrations in the range of 5-20 µM to produce a sufficient signal-to-noise ratio.
Although it is possible to derive affinity constants from DSF data, either by extrapola-
tion of thermodynamic parameters [245] or by fitting isothermal data from a titration of
ligand concentrations [246], these routes were not explored. Firstly, the method of ex-
trapolating thermodynamic parameters requires defining the specific heat capacity of the
protein, which can be experimentally determined using differential scanning calorimetry
(DSC). Although, it is possible to estimate this value based on the molecular weight of
the protein, this may result in a large and unknown error. Secondly, DSF was used only
as a preliminary screening method, in which the titration was only performed over three
ligand concentration points. This was sufficient to provide confidence that the change in
melting temperature was due to the stabilisation of Cdc20 without using larger amounts
of protein which would be required for a titration that can be used to determine an affinity.
The phenomenon that a given binding ligand can raise the Tm of a protein, even in
vast excess of the apparent stoichiometry and exceeding the ligand’s KD to the target is
one that is often observed [245, 247]. Although these authors have dedicated a significant
amount of time in the development of mathematical models to describe differential scan-
ning fluorimetry data, they do not answer why this phenomenon occurs.However, it is
clear that this phenomenon is independent of the protein class, whether it is a reversibly
folding protein or not and indeed what kind of ligand it may be. The only common
characteristic is that the ligands are reversible binding partners to the protein target.
Though detailed models and descriptions describing this could theoretically be pursued,
it is certainly beyond the scope of this PhD. However, one way to briefly rationalise the
phenomenon may be by thinking about the change in KD of a ligand as a function of
temperature. Indeed, with higher temperatures, 10-fold weaker binding affinities can be
observed, between 6◦C and 37◦C [248]. Most physiological experiments will not exceed
temperatures greater than 37◦C, but here the goal is to fully induce thermal denaturation
of the target protein. A key question in the context of thermal denaturation assays is
how weak is the KD at the Tm of the target protein. In addition to this, it may also be
important to consider the kinetics of protein unfolding in relation to the kinetics of ligand
association and dissociation and also as a function of temperature.
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To further characterise each peptide, SPR experiments were performed. The Ni-NTA
immobilisation strategy displayed poor activity of the immobilised Cdc20 protein. This
may be due to the subsequent amine coupling required to ensure the RUligand remains
sufficiently stable over the course of an experiment. It nevertheless proved worthwhile
to develop a SAR for for peptides in the early stages of the project. Minimally biotiny-
lated Cdc20 was significantly more active on the SA biosensor, observing ligand activities
around 45% for D-box peptides. Although this activity is still far from 100%, it may be
attributed to subjecting the Cdc20 protein to multiple freeze-thaw cycles between purifi-
cation, biotinylation and SPR experiments. In addition, the data observed for Apcin, D21
and D20 would be sufficient for kinetic fit analysis, given less bulk RI shift upon valve
switching at the beginning and end of the analyte association phases. However, this would
likely require thorough cleaning of the Biacore instrument prior to experimentation and
good sample preparation to avoid DMSO mismatching. Ideally, an orthogonal technique
to measure binding affinities of peptides would have been developed, such as competi-
tion fluorescence polarisation assays. However, this technique uses high concentrations
of protein dependent on the Kd of the fluorescent-labelled tracer peptide. Therefore, we
were unable to develop a tracer peptide of sufficient affinity early in the project to aid our
screening approach.
At present, no biophysical characterisation of Apcin binding to Cdc20 has been ex-
plored, except the CETSA and X-ray crystal structure datasets published by Sackton et
al. [195]. However a review by Schapira et al. [249] claim Apcin to have a KD > 10
µM, without providing further citation. This value is in fact an error that relates to the
Ki of the ligand instead. The SPR data presented here show that the Kd is much closer
to 500 nM, a 20-fold difference to the previously claimed value. Given this high affinity,
Apcin was the ideal positive control molecule during the peptide screens in addition to
providing an aim to design a peptide of at least as good an affinity if not better. Moreso,
the development of robust DSF and SPR assays provide opportunities for further studies
to develop inhibitors against all Cdc20 degron-binding sites, a key advancement for the
scientific community.
Although assays to generate reliable data to build a SAR for D-box, KEN-box and
ABBA motif peptides were developed, it was not as simple to develop a method for the
assessment of C-box peptides. The target of the C-box peptide was primarily Apc8,
with a potential to interact further with Apc3 due to strong homology of C-box and
IR-tail binding pockets, respectively. Both proteins are essential components of the core
APC/C structure [158] and therefore the proteins themselves (or truncated subdomains)
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can not be purified without their interaction partners (communications with David Bar-
ford, unpublished). Therefore, CETSA assays were explored for Apc8, Apc3 and Cdc20,
simultaneously, using the small molecules, Apcin and TAME as initial ligands in early
experiments. The approach using quantitative western blotting was beneficial since the
readout was from endogenous protein. However, the generation of data was cumbersome
and prone to error at multiple stages. These errors could arise from unequal transfer
efficiencies as well as the amount of endogenous Cdc20 not being sufficient to create a
significant signal and resolution, as could be observed from the relatively small thermal
shifts upon addition of the small molecules. The initial results also suggested that this
method was unlikely to provide sufficient resolution to understand the SAR of D-box,
KEN-box, ABBA motif or C-box peptides. However, a subset of the highest affinity D-
box peptides were tested in a split-luciferase CETSA experiment, which was considerably
higher throughput and generated data that were in support of the affinity trends observed
by DSF and SPR. Yet, small differences in the melting temperatures of Cdc20 with 100
µM Apcin were detected between the split-luciferase and the western blot assays. This
may be due to the significantly lower concentration of total protein and therefore lower
concentrations of Cdc20 used in the split-luciferase CETSA (0.2 mg/mL total protein)
compared to the Western blot (2.27 mg/mL total protein). Further experiments would
be required to prove this hypothesis.
Similarly to split-luciferase CETSA assays for Cdc20-binding ligands, constructs were
generated to assess ligand binding to Apc8 using the split-luciferase assay. It is believed
this is the first semi-biophysical method to observe ligand binding to any core component
of the APC/C. This provides a particular challenge since true physiological relevance
requires Apc8 to be in complex with the APC/C. In this work, experiments to evidence
this have not been explored due to a lack of time. Whilst it was possible to setup the split-
luciferase CETSA assay for Apc8, attempts to do similar for the IR-tail-binding subunit,
Apc3, were not successful. Preliminary experiments showed very low raw luminescence
signal, only between 6-8-fold greater than the background signal. Comparatively, Apc8
and Cdc20 produce greater than 100-fold and up to 400-fold increased signal compared to
the background, respectively. The reason that split-luciferase based Apc3 CETSA assay
development was unsuccessful in our hands could be two-fold. Firstly, the HiBiT-tag,
irrespective of which terminus it is located, could be buried within the native protein
and therefore unable to complement the LgBiT protein to reconstitute the NanoLuc.
Secondly, and perhaps the more likely case is that incorporation of the HiBiT-tag on
either end hinders the incorporation of the Apc3 subunit into the larger APC/C complex.
Based on our previous communications with Prof. David Barford, this cellular protein is
likely to be highly unstable and could therefore be rapidly degraded by the cell as it is
expressed.
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The CETSA data suggests that peptides can bind full-length Cdc20 and Apc8 within
a cellular context. However, CETSA experiments can be performed in live cells and whole
tissues, but since it was unlikely that the peptides would traverse the cell membrane and
subsequently reach their intracellular targets, experiments were limited to cell lysates and
therefore are not a true representation of a living cell. Furthermore, the peptides are
likely to be cleaved by broad specificity cellular proteases, so the inclusion of protease
inhibitors were key for retaining intact ligand for the course of the experiment.
Structure-activity-relationships of the D-box peptide
Through iterative design, synthesis and characterisation of D-box peptides it was possible
to deconvolve the structural determinants corresponding to affinity. Early in the develop-
ment, isoleucine at position seven was identified as the optimal residue of three aliphatic
side chain amino acids (valine, isoleucine and leucine). Following this, proline at position 3
was believed to provide optimal peptide-backbone geometry for the turn between residues
2-5. Subsequent incorporation of S5 and T8 from D1 into the D4 backbone generated the
lead natural amino acid-containing D-box peptide (D19, Ac-RAPLSDITN-NH2) with an
affinity of 5.87 ± 0.11 µM. Although the D19 peptide did not exhibit sufficient density in
crystallo, the X-ray datasets of D20- and D7-bound Cdc20 provide some insight into why
S5 is preferred over G5. The formation of a hydrogen bond between the hydroxyl side
chain of serine and carbonyl group of alanine provides an intra-molecular stabilisation of
the bound peptide. One would therefore expect that this is only important in the bound
state of the ligand and so may have an affect on the koff rate, rather than the kon rate.
Although this could be explored by SPR, the dataset collected was not of sufficient quality
for kinetic fitting.
The addition of C3 or F3 non-natural amino acids at position 4 improved the peptide
affinity 6- or 11-fold, respectively, resulting in affinity of peptide D21 (Ac-RAPF3SDITN-
NH2, 524 ± 14 nM) that is comparable to Apcin (418 ± 53 nM). It was highly unfortunate
that the Fmoc-(S )-2-amino-4,4,4- trichlorobutanoic acid could not be synthesised. Due
to the evidence from the binding of Apcin, which contains a CCl3 group, we expect the
affinity of a peptide with the sequence (Ac-RAPCl3SDITN-NH2) to further improve and
perhaps reach the double-digit nM range. Indeed, molecules with binding affinities in this
range become successful drug candidates.
In vitro ubiquitination assays
The use of functional assays to determine whether both D-box and C-box ligands could
inhibit the E3 ubiquitin ligase function of the APC/C was invaluable to this project.
164 Biophysical characterisation of APC/CCdc20 peptide inhibitors
With these few experiments, it was demonstrated that the extent of poly-ubiquitination
of a bait substrate, Cyclin B1, could be greatly reduced in the presence of D-box peptides
D20 and D21 at concentrations ranging from 30 µM up to 3 mM. Most notably, both
peptides appear to provide greater reduction of Cyclin B1 ubiquitination by the APC/C
compared to Apcin at equivalent concentrations. Since both D20 and D21 are less potent
binders than Apcin, this suggests a role beyond the standard affinity dogma of inhibition.
Indeed, D-box degron recognition by Cdc20 and Cdh1 is deemed to require an Arginine
at position 1 of the degron sequence (Figure 5.4, [165]) for effective recognition. How-
ever, Apcin as a ligand primarily competes for the Leucine binding pocket at position 4
of the D-box degron (Figure 5.7, [195]). This begs the question whether D-box degrons
contained within Cyclin B1, in our assays can still interact and be poly-ubiquitinated by
the APC/C despite Apcin being bound to Cdc20. In contrast, since our D-box peptides
contain the Arginine residue at position 1, and indeed even more of the designated D-box
degron towards the C-terminus, it is believed that any transient and/ or weak interactions
of Cyclin B1 with Cdc20 in the presence of Apcin are not feasible with D20 or D21 given
their larger extended binding interfaces. This is also particularly interesting since more
recently following the submission of this thesis, a further publication relating to Apcin’s
mechanism of action were published by Randall King’s laboratory [199]. Briefly, given the
right cellular conditions, where the spindle assembly checkpoint activity is high, Apcin
can increase the rate of mitotic exit thus producing the opposite desired phenotypic effect.
Whether the novel D-box peptides would act similarly is a question that would still need
to be answered.
In addition to the D-box ligands, stapled C-box peptides were also tested in these
assays. These two ligands, C6e and C6l, corresponding to the early and later isomers
(determined by analytical HPLC) of the hydrocarbon staple are particularly interesting
due to their apparent opposing functions in the in vitro ubiquitination assay. C6e’s
dose-dependent inhibition on Cyclin B1 ubiquitination fits the model of an inhibitory
peptide that acts to deplete Cdc20 from the APC/C, by competing for the C-box binding
site of Apc8. On the other hand, C6l, produces the opposing effect, whereby Cyclin B1
ubiquitination is vastly increased in a dose-dependent manner. Why exactly this occurs is
currently unknown and would require extensive characterisation using multiple techniques
to determine its mechanism of action. When considering that these two peptides only
differ by the orientation of the carbon-carbon double bond in the cis or trans isomer,
these results are even more surprising and fascinating.
Alongside looking at C6e and C6l as inhibitors in their own right, it was hypothesised
that co-treatment of our lead D-box peptide, D21, and the stapled peptide C6e, that
produces an inhibitory effect as a singular treatment could produce a synergistic effect on
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Cyclin B1 ubiquitination. This principle had been established with the TAME and it’s
prodrug analogue proTAME with Apcin by Sackton et al. [195]. Initially, it was envisaged
that since both D21 and C6e outperform their small molecule counterparts, an even greater
reduction of Cyclin B1 ubiquitination would be observed. However, as observed in Figure
6.15b, the opposite was evident. Although at the lower concentrations tested, the overall
ubiquitination is less than the vehicle control, increased drug concentrations result in more
ubiquitination, akin to the observations with C6l. Why this is occurs, is still unknown and
is highly puzzling. However, it very succinctly demonstrates the difficulty and complexity
of effectively inhibiting large complexes, such as the APC/C.
X-ray crystal structures of D-box peptides bound to Cdc20
These datasets presented in this chapter are the first known structures of designed D-box
peptide inhibitors bound to Cdc20. Although the overall molecular architecture of binding
is highly similar to the D-box peptide in the Acm1-Cdh1 structure [165], subtle differences
can be detected. We observed very strong evidence for the binding of the F3 and C3 amino
acids in the leucine-binding pocket. In addition, the data suggest why serine at position 5
may improve the affinity of the peptide due to geometry of hydrogen bonding between the
hydroxyl group of serine to the carbonyl group of alanine at position 2. Unfortunately,
residues 7-9 remain unresolved due to steric clashing between the peptide C-terminus and
the protein in the neighbouring asymmetric unit. Since the peptide can only bind through
its six N-terminal residues, the binding affinities of the whole peptide in the context of
the crystal lattice are likely to be impaired and this may be the reason why it was not
possible to build convincing models for D19. Currently, all Cdc20 structures (without
additional proteins) are solved in the space group P21 or P212121 [193]. However, even
in the alternative space group, Cdc20 from the neighbouring asymmetric unit partially
occludes the D-box binding area. Unless the protein is crystallised in a different space
groups, it is unlikely that the entire peptide will ever be resolved.
In addition to the asymmetric unit clashing with the C-terminus of the peptides, there
is also another possible explanation to the lack of density for these residues. It has been
proposed that one of the core subunits of the APC/C, Apc10, acts as a co-receptor for
D-box degrons contained within substrate proteins [250–252]. Da Fonseca et al. show an
overall shift of Cdh1 towards the Apc10 subunit in the presence of substrates containing
a D-box degron. More recent higher resolution cryo-EM structures from the Barford lab-
oratory indicate that the C-terminal residues comprising the D-box degron are directly
involved in forming the Apc10 co-receptor, as shown in Figure 6.20. This raises the ques-
tion whether the final two residues, i.e. TN-NH2 could be observed without hindrance
from the asymmetric unit.
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Cdc20
Apc10
Hsl1 D-box
degron
Figure 6.20: Cryo-EM model of Hsl1 D-box peptide (cyan, stick representation) in
complex with Cdc20 (magenta) and Apc10 (orange). Black arrows refer to the amino
acids that interact with Apc10 at the C-terminus of the D-box degron sequence. PDB
ID: 5G04, [28].
Following the defence of this thesis, and in preparation of the data for publication,
it was realised that an undesirably large Rwork/Rfree gap had emerged in the Cdc20-D7
structure. In addition, the electron density maps for this structure were of less quality
compared to the other two, taking into account the difference in resolution. Following
investigation, it was found that this gap would occur immediately after the first round of
refinement in Refmac 5.0, following the molecular replacement solution by Phaser. Al-
though it was never understood why this occurred, it was decided to redo the refinement
using BUSTER (Global Phasing), as suggested by Dr. Marianne Schimpl at AstraZeneca.
Refinement in BUSTER resulted in better map quality, containing less large areas of neg-
ative density. In addition, the Rwork/Rfree gap closed up towards acceptable values for
publication and altogether there was better confidence in the modelled peptide residues.
For consistency between the three structures, it was decided that all datasets would be
refined using BUSTER instead. In all cases, the Rwork/Rfree gap was smaller, the root
mean square bond lengths and bond angles were improved and the overall quality of maps
were better as colleagues at AstraZeneca had often observed with BUSTER refinements.
Previous attempts by Tian et al. to co-crystallise a D-box peptide derived from Securin
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(CDAPPALPKATRKALGTVNRATEKS) were noted as being unsuccessful despite ob-
taining high resolution data (1.35 Å). Note that the amino acids pertinent to the D-box
degron are highlighted in bold. With the blend of knowledge gained from various aspects
of this project, it is possible to understand why this might have occurred in their hands.
Firstly, to dissect the structural determinants of D-box degron binding, the presence of
Alanine at position 3 results in an approximately 3-fold weaker ligand compared to Pro-
line at the equivalent position. It is also noted that Glycine at position 5 was weaker
due to the loss of an intramolecular hydrogen-bond compared to its serine-containing
counterpart. Position 6 also has Threonine in place of Aspartic acid in our synthesised
ligands, which produced additional salt bridges between R174 of Cdc20. While threonine
could potentially form hydrogen bonds via the hydroxyl group, the overall length of the
side chain is also different and it therefore may not be within close proximity to form
this bond. Lastly, position 7 contains a Valine residue, which was discovered early in our
biophysical characterisation to be the worst of the three aliphatic residues for binding to
Cdc20, approximately 2-fold weaker than an isoleucine-containing peptide. In addition,
soaking experiments of the D21, D20, D7 and D19 ligands provided evidence of decreasing
ligand density, which clearly correlated to the overall affinity of the ligand, as measured by
SPR. The density around the expected binding site of the D19 peptide was so poor that it
was not possible to build even a single residue of the peptide. The gained understanding
of an approximate binary affinity for the securin D-box peptide used by Tian et al. is
almost certainly in the range of 10-100 µM, if not even weaker. Given that D19 binds
with 5.87 ± 0.11 µM, and no credible ligand density was observed for this peptide, it is
not surprising that ligand density was absent using peptides that are undoubtedly weaker
affinity in their attempts.
Altogether, these datasets provide evidence for the molecular architecture of binding
between a designed D-box peptide and Cdc20. Originally, functional experiments were out
of the scope of the initial project due to time constraints, lack of cell permeability/delivery
methods and limited in-house expertise in this area of cell biology. However, the data
presented here can now form a basis for further D-box peptide development and their
characterisation in functional assays, such as the inhibition of the E3 ubiquitin ligase
APC/C and consequently mitotic exit.

Chapter 7
Final conclusions and future work
The work described in this PhD thesis focuses on the development of peptide inhibitors
against two tandem-repeat proteins whose over-expression is associated with cancer. For
both targets, small molecule therapeutics are of limited efficacy, or have not yet been iden-
tified, and therefore peptide-based alternatives were explored using a rational structure-
based design approach.
7.0.1 Development of Tankyrase inhibitors
The sub-project conducted in the first year of the PhD focused on the improvement of pep-
tide inhibitors of the substrate-binding ARC domains of Tankyrase that were previously
developed in the Itzhaki lab [102]. The original peptides had sub-micromolar affinities
and, after conjugation with cell-penetrating peptides, they were shown to be able to in-
hibit tankyrase, however their IC50 values were not sufficiently efficacious for further drug
development. Therefore, our primary goal was to further increase their binding affini-
ties and thereby improve their cellular efficacy utilising the same delivery approach with
CPPs. First an expanded suite of biophysical assays was developed, including FP, DSF,
SPR and ITC. However, we found that SPR did not provide suitable data quality due
to unknown reasons. Multiple approaches were explored to improve peptide affinity to
the TNKS ARC domains. First, point mutations at position 5 of the peptide sequence
were introduced to exploit an adjacent pocket of the surface that was observed in ARC2
and ARC5 domains compared to ARC1 and ARC4 domains. Although this approach did
not yield improved affinities, this highlighted a degree of previously unknown specificity
between the different ARC domains, where preferential, but weak binding was observed to
TNKS1 ARC2-3 compared to TNKS2 ARC4. In addition, we explored a novel macrocycle
design that yielded peptide T1-1, which bound with 3.41 ± 0.08 µM affinity to TNKS2
ARC4. Unfortunately, attempts to co-crystallise the TNKS2 ARC4-T1-1 complex were
unsuccessful. Therefore, without an understanding of the macrocycle pose and why it re-
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duced the affinity compared to the consensus sequence, no further structure-based design
was possible.
Although peptides with higher affinities were not obtained as a result of these efforts,
there is considerable scope to expand the project to include alternative methods. Although
a consensus binding motif was described by Guettler et al. [131], it may not necessarily be
the highest affinity ARC-binding peptide. First, library techniques such as phage, mRNA
or ribosome display may produce a higher affinity peptide than the current consensus
sequence, which was developed through matrix screen approach [131]. Second, different
macrocyclisation chemistries could be explored, which are likely to sample alternative
chemical space resulting in a more potent ligand. Third, the ability of Tankyrases to
bind their substrates through four independent ARC domains allows the development
of multi-valent inhibitors as a strategy increase cellular efficacy (ongoing work in the
Itzhaki lab and publications to be submitted). Fourth, peptides could be designed that
go beyond traditional competitive inhibition. For example, covalent peptide inhibitors can
exploit the reactivity of lysine or cysteine side-chains surrounding the substrate-binding
site. Lastly, peptide inhibitors of Tankyrase can potentially be used in combination with
degradation-targeting moieties to harness the ubiquitin-proteasome system (UPS) and
drive the degradation of Tankyrase to reduce its oncogenic activity of the various pathways
that it can act upon such as the β-catenin/WNT signalling pathway [112]. Such work is
currently underway in the Itzhaki lab.
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7.0.2 Development of APC/CCdc20 inhibitors
The greater focus of this thesis has revolved around the development of peptide inhibitors
to target the oncogenic activity of the Anaphase Promoting Complex/Cyclosome with
the Cdc20 co-activating protein. Cdc20 in stark contrast to it’s homolog protein Cdh1,
is known to be an oncoprotein. Unfortunately, the number of drug discovery campaigns
has been limited to a high-throughput screen of over 100,000 small molecule compounds
by Verma et al. [197]. In this screen, a number of compounds were found to stabilise the
Cyclin B1-luciferase reporter used, but only three of these hits were found to be specific
competitive inhibitors against the APC/CCdc20 [194, 195, 198]. This equates to approx-
imately 0.003% hit success rate. As such, we focused our studies on the development
of peptide-based inhibitors to target the APC/CCdc20’s oncogenic activity. Initially, four
peptide series were designed, consisting of peptides based on the three degrons (D-box,
KEN-box and ABBA motif) with the fourth being based on the C-box motif required for
Cdc20 to bind the Apc8 subunit of the APC/C.
We began our studies by attempting to setup a robust system in which to quantify
the binding affinity of designed and synthesised ligands to Cdc20. For this, recombi-
nant Cdc20 comprising the WD40 domain had to be expressed in baculovirus expressions
systems and purified using a three-step chromatography protocol based on procedures
described by [193, 195]. Obtaining pure Cdc20 presented a significant challenge to the
project as a result of problems at multiple stages including expression, solubility and
purification. Therefore, biophysical techniques were carefully selected that would be suf-
ficiently sensitive with small sample requirements. DSF relies on a signal change when
a fluorescent reporter molecule binds to hydrophobic residues that are exposed as the
protein unfolds. The WD40 domain of Cdc20 contains high percentage of hydrophobic
amino acids, which resulted in a large signal change at lower protein concentrations than
are commonly used in this type of experiment. DSF proved to be an ideal method to
screen a large number of peptide ligands relatively rapidly. This allowed us to initially
screen our synthesised ligands to be ranked in order of affinity, of which the best were
selected for further characterisation. The binding affinities were then quantified by SPR
using biotinylated Cdc20 protein, and the results were in agreement with the rankings
obtained by DSF. While this approach worked with probing binding to Cdc20, develop-
ing a method to explore the binding of the C-box peptides to Apc3 and Apc8 was not
straightforward. We first utilised CETSA with endogenous protein to probe binding of
the published small molecules Apcin and TAME to Cdc20 and Apc3/Apc8, respectively.
However, using quantitative western blotting to detect thermal stabilisation of endogenous
proteins was low-throughput and was not sufficiently sensitive. We therefore invested into
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developing a more high-throughput method in 384-well plate format for CETSA assays
using split-luciferase detection rather than western blotting. This allowed us to develop
the first high-throughput experiments for screening Cdc20 and Apc8-targeting ligands,
which can be utilised downstream by the drug discovery community.
Initial sets of the four peptide series, including a subset of D-box, KEN-box and C-
box hydrocarbon-stapled derivatives, were synthesised in Singapore with the help of Dr.
Fernando Ferrer (A*STAR). The designs were supported with modelling and MD simula-
tions conducted by Dr. Yaw Sing Tan (A*STAR). Early in the biophysical analysis, the
KEN-box and ABBA motif peptides were not observed to bind to Cdc20, and therefore
these degrons were not explored further. However, the Hsl1-derived ’super D-box’ pep-
tide (D1: Ac-GRAALSDITN-NH2) provided promising initial results, and further D-box
peptides were designed and synthesised to establish a SAR. This iterative design process
revealed the optimal natural sequence to be Ac-RAPLSDITN-NH2 (D19), which bound
with an affinity of 5.87 ± 0.11 µM to Cdc20. In the process of determining this high
affinity natural amino acid peptide, we uncovered structural determinants that result
in improved D-box degron affinity to Cdc20. Examples of this include the P3A muta-
tion resulting in approximately 3-fold improvement of affinity; G5S mutation resulting
in around 3-fold improvement in affinity and Isoleucine being the most efficient residue
at position 7 for binding, compared to the other two aliphatic amino acids, Valine and
Leucine. In addition, the use of tri-methylated (C3) and tri-fluorinated (F3) non-natural
amino acids in place of the canonical leucine residue resulted in a remarkable improve-
ment in the resulting peptides: D7, D12, D20 and D21. These modifications resulted in
binding affinities of 902 ± 14 and 524 ± 14 nM for D20 (Ac-RAPC3SDITN-NH2) and
D21 (Ac-RAPF3SDITN-NH2), respectively which are approximately 6-fold and 11-fold
improved from the Leucine-containing parental peptide, D19.
It was then demonstrated that the highest affinity D-box peptides: D21, D20, D7
and D19 were able to bind exogenous full-length Cdc20 in a split-luciferase CETSA assay
indicating that these peptides are able to engage Cdc20 within the context of the cellu-
lar environment. We were also able to demonstrate that the C-box hydrocarbon-stapled
ligands, C6e and C6l were potent destabilising peptides against the Apc8 subunit of the
core APC/C. This result, in conjunction with the in vitro ubiquitination experiments
performed by Dr. Thomas Tischer in Prof. David Barford’s laboratory demonstrated
for the first time that these peptides could also function as potent inhibitors against
APC/CCdc20-mediated substrate ubiquitination. These ligands were significantly more
potent than the current alternative, TAME and have the potential to be further devel-
oped either rationally or through focused screening. In addition, our lead D-box ligands,
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D20 and D21, which were weaker in affinity as determined by SPR, also outperformed
the small molecule Apcin in their ability to inhibit Cyclin B1 ubiquitination. Lastly, we
successfully crystallised and determined the co-crystal structures of three D-box peptides
(D7, D20 and D21) bound to Cdc20 with resolutions of 1.92 Å, 1.46 Å and 1.51 Å, re-
spectively. These data provide evidence of the binding mode and confirmed the SAR and
the models established throughout the design process during their development. Notably,
these are the first human Cdc20 crystal structures with D-box peptides bound, despite
extensive attempts previously in the literature.
Overall, the rational design approach has proved to be able to develop potent D-box
and C-box peptide inhibitors, which target the Anaphase Promoting Complex/Cyclo-
some. These first in-class peptide inhibitory molecules have the potential to be further
explored, modified and developed to answer countless further questions pertaining to
the overall efficacy of suitability these molecules may have as therapeutic candidates to
eventually treat a wide range of cancers. Until then, these initial molecules may serve a
useful role modulating the APC/CCdc20 ubiquitination activity in the context of further
understanding APC/C function in the cell.
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7.0.3 Future work
Due to the high homology between Cdc20 and Cdh1, it is very likely that the D-box pep-
tides, which were optimised for binding to Cdc20, could also bind to Cdh1. However, in
the context of cancers in which Cdc20 is highly over-expressed [163] and Cdh1 expression
is down-regulated [253], such off-target effects of D-box peptides may be negligible or even
irrelevant for the overall efficacy of the ligand. Although Cdh1 is the obvious secondary
target, probing other off-target effects is also worthwhile and necessary to assess possible
negative side-effects that may occur as a result. The combination of CETSA with pro-
teomic profiling could be used identify proteins that are stabilised due to the inhibition
of the APC/C [254–256]. At present, a joint PhD student between the Itzhaki and Lin-
don labs is investigating the sequence and structural requirement of the degrons of the
APC/CCdh1, and she will examine whether the peptides presented here can act as Cdh1
inhibitors. She is also exploring whether more potent peptide-based inhibitors can be
developed by incorporating multiple degrons in a single protein to function as multivalent
biologic inhibitors.
With the advent of the in vitro ubiquitination experiments providing evidence of in-
hibitory actions for peptides D20, D21 and C6e, further functionalisation of these ligands
to traverse the cell membrane would be highly worthwhile. If we can achieve this, these
molecules could be further characterised to examine their functional output, i.e. whether
they can inhibit mitotic exit. In addition, the curious results of the C-box ligands in
particular could be further examined using negative stain electron microscopy or even
cryogenic electron microscopy to determine whether these ligand binding events cause
broader structural re-arrangements of the APC/C. This would be particularly interesting
in the case of C6l, which produced the increased levels of Cyclin B1 ubiquitination.
Similar to what was described above for Tankyrase peptides, library display ap-
proaches could also be used to generate higher affinity ligands for Cdc20 and simulta-
neously counter-screen against Cdh1, if Cdc20-specific inhibitors are desired. This could
result in more potent ligands that target the D-box, KEN-box and ABBA motif degrons
that adhere towards the known consensus sequences, but it could also possibly generate
new and diverse ligands and binding conformation for use as tools or further development
towards therapeutics. However, library-based methods are unlikely to be successful for
the development of peptide inhibitors based on the C-box peptide, given that the Apc8
and Apc3 subunit cannot be produced outside the context of the APC/C. Instead the
split-luciferase CETSA approach could potentially be combined with peptide libraries to
screen for stabilising or indeed as we observed, destabilising Apc8 and Apc3 ligands.
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In these studies, only a limited set of hydrocarbon staples and non-natural amino acids
were investigated during the PhD. However, the possibilities of expanding the chemical
space are vast and may include alternative chemical constraints and modifications that
could lead to more potent ligands, improved efficacy and future drug candidates. Utilis-
ing our new crystal structure data, models were generated for a Lanthionine-containing
peptide to constrain between position 2 to position 5 7.1. This new chemistry might be
more amenable given the longer bond lengths of the C-S bonds compared to C-C bonds,
that are adopted in the hydrocarbon-stapled peptides.
Figure 7.1: Models generated for possible lanthionine based chemistries to explore
new chemical space to staple between position 2 and 5 of D-box peptides. Cdc20 in
magenta surface, the D21 parental peptide coloured in cyan, stick representation with
the new staple modelin green. PDB: Cdc20-D21 structure from this work.
Lastly, the field of targeted protein degradation (TPD) is rapidly evolving and like
discussed at the during the introduction, the pharmaceutical industry rapidly became
limited in the scope of possible degradation mechanisms. Of the >600 predicted E3
ubiquitin ligases that could be used for TPD, very few are commonly used, such as
Cereblon, VHL, IAPs and Mdm2 have been utilised [257]. The APC/C offers a unique
position to be utilised for TPD application due to its already wide range of (>60) known
substrates that it can degrade. This characteristic could be highly valuable for these
applications and the new ligands and knowledge based from these studies could pave the
way for utilising this E3 ubiquitin ligase for a variety of pathological diseases.

Appendix A
Protein sequences
Key:
Affinity tags = X
Protease cleavage site = X, | indicates site of peptide bond cleavage.
His6-TEV protease (S219V)
MGHHHHHHGESLFKGPRDYNPISSTICHLTNESDGHTTSLYGIGFGPFIITNKHLF
RRNNGTLLVQSLHGVFKVKNTTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFREP
QREERICLVTTNFQTKSMSSMVSDTSCTFPSSDGIFWKHWIQTKDGQCGSPLVST
RDGFIVGIHSASNFTNTNNYFTSVPKNFMELLTNQEAQQWVSGWRLNADSVLW
GGHKVFMVKPEEPFQPVKEATQLMNELVYSQ
His6-TEV-Mdm2 (6-125)
MRGSHHHHHHNNNNNNNNNNENLYFQ|GGSMSVPTDGAVTTSQIPASEQETLVR
PKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLG
DLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSEN
His6-thrombin-TNKS1 ARC2-3 (315-662)
MRGSHHHHHHGLVPR|GSGKSALDLADPSAKAVLTGEYKKDELLEAARSGNEEK
LMALLTPLNVNCHASDGRKSTPLHLAAGYNRVRIVQLLLQHGADVHAKDKGGLV
PLHNACSYGHYEVTELLLKHGACVNAMDLWQFTPLHEAASKNRVEVCSLLLSHG
ADPTLVNCHGKSAVDMAPTPELRERLTYEFKGHSLLQAAREADLAKVKKTLALE
IINFKQPQSHETALHCAVASLHPKRKQVTELLLRKGANVNEKNKDFMTPLHVAA
ERAHNDVMEVLHKHGAKMNALDTLGQTALHRAALAGHLQTCRLLLSYGSDPSII
SLQGFTAAQMGNEAVQQILSESTPIRTSDVDYRLLEASKAGD
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His6-thrombin-TNKS2 ARC4 (488-649)
MAHHHHHHSDLSDLVPR|GSGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDI
EGRQSTPLHFAAGYNRVSVVEYLLQHGADVHAKDKGGLVPLHNACSYGHYEVA
ELLVKHGAVVNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTP
LDLVKDGDTDIQDLLRGDAAL
GST-thrombin-TNKS2 ARC4 (488-649)
MMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP
NLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRI
AYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVV
LYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHP
PKSDLVPR|GSGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDIEGRQSTPLH
FAAGYNRVSVVEYLLQHGADVHAKDKGGLVPLHNACSYGHYEVAELLVKHGAV
VNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTPLDLVKDGDT
DIQDLLRGDAAL
GST-thrombin-TNKS2 ARC4 (488-649, G558D)
MMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP
NLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRI
AYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVV
LYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHP
PKSDLVPR|GSGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDIEGRQSTPLH
FAAGYNRVSVVEYLLQHGADVHAKDKDGLVPLHNACSYGHYEVAELLVKHGAV
VNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTPLDLVKDGDT
DIQDLLRGDAAL
GST-thrombin-TNKS2 ARC4 (488-649, G558S)
MMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP
NLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRI
AYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVV
LYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHP
PKSDLVPR|GSGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDIEGRQSTPLH
FAAGYNRVSVVEYLLQHGADVHAKDKSGLVPLHNACSYGHYEVAELLVKHGAV
VNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTPLDLVKDGDT
DIQDLLRGDAAL
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GST-thrombin-TNKS2 ARC4 (488-649, G558T)
MMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP
NLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRI
AYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVV
LYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHP
PKSDLVPR|GSGNSEADRQLLEAAKAGDVETVKKLCTVQSVNCRDIEGRQSTPLH
FAAGYNRVSVVEYLLQHGADVHAKDKTGLVPLHNACSYGHYEVAELLVKHGAV
VNVADLWKFTPLHEAAAKGKYEICKLLLQHGADPTKKNRDGNTPLDLVKDGDT
DIQDLLRGDAAL
His6-MBP-TEV-Cdc20 (161-477)
MSYYHHHHHHDYDIPTTKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTV
EHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYP
FTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSA
LMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIK
NKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQ
PSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE
EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALK
DAQTNSSSNNNNNNNNNNENLYFQ|GASRKTCRYIPSLPDRILDAPEIRNDYYLNL
VDWSSGNVLAVALDNSVYLWSASSGDILQLLQMEQPGEYISSVAWIKEGNYLAVG
TSSAEVQLWDVQQQKRLRNMTSHSARVGSLSWNSYILSSGSRSGHIHHHDVRVAE
HHVATLSGHSQEVCGLRWAPDGRHLASGGNDNLVNVWPSAPGEGGWVPLQTF
TQHQGAVKAVAWCPWQSNVLATGGGTSDRHIRIWNVCSGACLSAVDAHSQVCS
ILWSPHYKELISGHGFAQNQLVIWKYPTMAKVAELKGHTSRVLSLTMSPDGATV
ASAAADETLRLWRCFELD
His6-MBP-TEV-Cdc20 (165-477)
MSYYHHHHHHDYDIPTTKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTV
EHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYP
FTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSA
LMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIK
NKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQ
PSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYE
EELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALK
DAQTNSSSNNNNNNNNNNENLYFQ|GACRYIPSLPDRILDAPEIRNDYYLNLVDWS
SGNVLAVALDNSVYLWSASSGDILQLLQMEQPGEYISSVAWIKEGNYLAVGTSSA
EVQLWDVQQQKRLRNMTSHSARVGSLSWNSYILSSGSRSGHIHHHDVRVAEHHV
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ATLSGHSQEVCGLRWAPDGRHLASGGNDNLVNVWPSAPGEGGWVPLQTFTQH
QGAVKAVAWCPWQSNVLATGGGTSDRHIRIWNVCSGACLSAVDAHSQVCSILWS
PHYKELISGHGFAQNQLVIWKYPTMAKVAELKGHTSRVLSLTMSPDGATVASAA
ADETLRLWRCFELD
His6-TEV-Cdc20 (161-477)
MSYYHHHHHHDYDIPTTNSSSNNNNNNNNNNENLYFQ|GASRKTCRYIPSLPDRIL
DAPEIRNDYYLNLVDWSSGNVLAVALDNSVYLWSASSGDILQLLQMEQPGEYISS
VAWIKEGNYLAVGTSSAEVQLWDVQQQKRLRNMTSHSARVGSLSWNSYILSSGS
RSGHIHHHDVRVAEHHVATLSGHSQEVCGLRWAPDGRHLASGGNDNLVNVWPS
APGEGGWVPLQTFTQHQGAVKAVAWCPWQSNVLATGGGTSDRHIRIWNVCSG
ACLSAVDAHSQVCSILWSPHYKELISGHGFAQNQLVIWKYPTMAKVAELKGHTS
RVLSLTMSPDGATVASAAADETLRLWRCFELD
His6-TEV-Cdc20 (165-477)
MSYYHHHHHHDYDIPTTNSSSNNNNNNNNNNENLYFQ|GACRYIPSLPDRILDAPE
IRNDYYLNLVDWSSGNVLAVALDNSVYLWSASSGDILQLLQMEQPGEYISSVAWI
KEGNYLAVGTSSAEVQLWDVQQQKRLRNMTSHSARVGSLSWNSYILSSGSRSGH
IHHHDVRVAEHHVATLSGHSQEVCGLRWAPDGRHLASGGNDNLVNVWPSAPGE
GGWVPLQTFTQHQGAVKAVAWCPWQSNVLATGGGTSDRHIRIWNVCSGACLS
AVDAHSQVCSILWSPHYKELISGHGFAQNQLVIWKYPTMAKVAELKGHTSRVLSL
TMSPDGATVASAAADETLRLWRCFELD
HiBiT-Cdc20 (1-499)
MGSVSGWRLFKKISGSMAQFAFESDLHSLLQLDAPIPNAPPARWQRKAKEAAGP
APSPMRAANRSHSAGRTPGRTPGKSSSKVQTTPSKPGGDRYIPHRSAAQMEVAS
FLLSKENQPENSQTPTKKEHQKAWALNLNGFDVEEAKILRLSGKPQNAPEGYQN
RLKVLYSQKATPGSSRKTCRYIPSLPDRILDAPEIRNDYYLNLVDWSSGNVLAVA
LDNSVYLWSASSGDILQLLQMEQPGEYISSVAWIKEGNYLAVGTSSAEVQLWDVQ
QQKRLRNMTSHSARVGSLSWNSYILSSGSRSGHIHHHDVRVAEHHVATLSGHSQE
VCGLRWAPDGRHLASGGNDNLVNVWPSAPGEGGWVPLQTFTQHQGAVKAVA
WCPWQSNVLATGGGTSDRHIRIWNVCSGACLSAVDAHSQVCSILWSPHYKELISG
HGFAQNQLVIWKYPTMAKVAELKGHTSRVLSLTMSPDGATVASAAADETLRLW
RCFELDPARRREREKASAAKSSLIHQGIR
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Cdc20 (1-499)-HiBiT
MGSMAQFAFESDLHSLLQLDAPIPNAPPARWQRKAKEAAGPAPSPMRAANRSHS
AGRTPGRTPGKSSSKVQTTPSKPGGDRYIPHRSAAQMEVASFLLSKENQPENSQT
PTKKEHQKAWALNLNGFDVEEAKILRLSGKPQNAPEGYQNRLKVLYSQKATPG
SSRKTCRYIPSLPDRILDAPEIRNDYYLNLVDWSSGNVLAVALDNSVYLWSASSGD
ILQLLQMEQPGEYISSVAWIKEGNYLAVGTSSAEVQLWDVQQQKRLRNMTSHSA
RVGSLSWNSYILSSGSRSGHIHHHDVRVAEHHVATLSGHSQEVCGLRWAPDGRHL
ASGGNDNLVNVWPSAPGEGGWVPLQTFTQHQGAVKAVAWCPWQSNVLATGG
GTSDRHIRIWNVCSGACLSAVDAHSQVCSILWSPHYKELISGHGFAQNQLVIWKY
PTMAKVAELKGHTSRVLSLTMSPDGATVASAAADETLRLWRCFELDPARRRER
EKASAAKSSLIHQGIRGSVSGWRLFKKISGS
HiBiT-Apc3 (1-824)
MGSVSGWRLFKKISGSMTVLQEPVQAAIWQALNHYAYRDAVFLAERLYAEVHSE
EALFLLATCYYRSGKAYKAYRLLKGHSCTTPQCKYLLAKCCVDLSKLAEGEQILS
GGVFNKQKSHDDIVTEFGDSACFTLSLLGHVYCKTDRLAKGSECYQKSLSLNPFL
WSPFESLCEIGEKPDPDQTFKFTSLQNFSNCLPNSCTTQVPNHSLSHRQPETVLTE
TPQDTIELNRLNLESSNSKYSLNTDSSVSYIDSAVISPDTVPLGTGTSILSKQVQNKP
KTGRSLLGGPAALSPLTPSFGILPLETPSPGDGSYLQNYTNTPPVIDVPSTGAPSK
KSVARIGQTGTKSVFSQSGNSREVTPILAQTQSSGPQTSTTPQVLSPTITSPPNALP
RRSSRLFTSDSSTTKENSKKLKMKFPPEIPNRKTKSKTNKGGITQPNINDSLEITK
LDSSIISEGKISTITPQIQAFNLQKAAAEGLMSLLREMGKGYLALCSYNCKEAINILS
HLPSHHYNTGWVLCQIGRAYFELSEYMQAERIFSEVRRIENYRVEGMEIYSTTLW
HLQKDVALSVLSKDLTDMDKNSPEAWCAAGNCFSLQREHDIAIKFFQRAIQVDP
NYAYAYTLLGHEFVLTEELDKALACFRNAIRVNPRHYNAWYGLGMIYYKQEKFS
LAEMHFQKALDINPQSSVLLCHIGVVQHALKKSEKALDTLNKAIVIDPKNPLCKFH
RASVLFANEKYKSALQELEELKQIVPKESLVYFLIGKVYKKLGQTHLALMNFSWA
MDLDPKGANNQIKEAIDKRYLPDDEEPITQEEQIMGTDESQESSMTDADDTQLH
AAESDEF
Apc3 (1-824)-HiBiT
MTVLQEPVQAAIWQALNHYAYRDAVFLAERLYAEVHSEEALFLLATCYYRSGK
AYKAYRLLKGHSCTTPQCKYLLAKCCVDLSKLAEGEQILSGGVFNKQKSHDDIV
TEFGDSACFTLSLLGHVYCKTDRLAKGSECYQKSLSLNPFLWSPFESLCEIGEKP
DPDQTFKFTSLQNFSNCLPNSCTTQVPNHSLSHRQPETVLTETPQDTIELNRLNL
ESSNSKYSLNTDSSVSYIDSAVISPDTVPLGTGTSILSKQVQNKPKTGRSLLGGPA
ALSPLTPSFGILPLETPSPGDGSYLQNYTNTPPVIDVPSTGAPSKKSVARIGQTGT
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KSVFSQSGNSREVTPILAQTQSSGPQTSTTPQVLSPTITSPPNALPRRSSRLFTSDS
STTKENSKKLKMKFPPEIPNRKTKSKTNKGGITQPNINDSLEITKLDSSIISEGKIS
TITPQIQAFNLQKAAAEGLMSLLREMGKGYLALCSYNCKEAINILSHLPSHHYNT
GWVLCQIGRAYFELSEYMQAERIFSEVRRIENYRVEGMEIYSTTLWHLQKDVAL
SVLSKDLTDMDKNSPEAWCAAGNCFSLQREHDIAIKFFQRAIQVDPNYAYAYTL
LGHEFVLTEELDKALACFRNAIRVNPRHYNAWYGLGMIYYKQEKFSLAEMHFQ
KALDINPQSSVLLCHIGVVQHALKKSEKALDTLNKAIVIDPKNPLCKFHRASVLFA
NEKYKSALQELEELKQIVPKESLVYFLIGKVYKKLGQTHLALMNFSWAMDLDPK
GANNQIKEAIDKRYLPDDEEPITQEEQIMGTDESQESSMTDADDTQLHAAESDE
FGSVSGWRLFKKISGS
HiBiT-Apc8 (1-591)
MGSVSGWRLFKKISGSMVPVAVTAAVAPVLSINSDFSDLREIKKQLLLIAGLTRER
GLLHSSKWSAELAFSLPALPLAELQPPPPITEEDAQDMDAYTLAKAYFDVKEYDR
AAHFLHGCNSKKAYFLYMYSRYLSGEKKKDDETVDSLGPLEKGQVKNEALRELR
VELSKKHQARELDGFGLYLYGVVLRKLDLVKEAIDVFVEATHVLPLHWGAWLE
LCNLITDKEMLKFLSLPDTWMKEFFLAHIYTELQLIEEALQKYQNLIDVGFSKSSY
IVSQIAVAYHNIRDIDKALSIFNELRKQDPYRIENMDTFSNLLYVRSMKSELSYLAH
NLCEIDKYRVETCCVIGNYYSLRSQHEKAALYFQRALKLNPRYLGAWTLMGHEY
MEMKNTSAAIQAYRHAIEVNKRDYRAWYGLGQTYEILKMPFYCLYYYRRAHQL
RPNDSRMLVALGECYEKLNQLVEAKKCYWRAYAVGDVEKMALVKLAKLHEQL
TESEQAAQCYIKYIQDIYSCGEIVEHLEESTAFRYLAQYYFKCKLWDEASTCAQK
CCAFNDTREEGKALLRQILQLRNQGETPTTEVPAPFFLPASLSANNTPTRRVSPL
NLSSVTP
183
Apc8 (1-591)-HiBiT
MVPVAVTAAVAPVLSINSDFSDLREIKKQLLLIAGLTRERGLLHSSKWSAELAFSL
PALPLAELQPPPPITEEDAQDMDAYTLAKAYFDVKEYDRAAHFLHGCNSKKAYF
LYMYSRYLSGEKKKDDETVDSLGPLEKGQVKNEALRELRVELSKKHQARELDGF
GLYLYGVVLRKLDLVKEAIDVFVEATHVLPLHWGAWLELCNLITDKEMLKFLSL
PDTWMKEFFLAHIYTELQLIEEALQKYQNLIDVGFSKSSYIVSQIAVAYHNIRDIDK
ALSIFNELRKQDPYRIENMDTFSNLLYVRSMKSELSYLAHNLCEIDKYRVETCCVI
GNYYSLRSQHEKAALYFQRALKLNPRYLGAWTLMGHEYMEMKNTSAAIQAYRH
AIEVNKRDYRAWYGLGQTYEILKMPFYCLYYYRRAHQLRPNDSRMLVALGECY
EKLNQLVEAKKCYWRAYAVGDVEKMALVKLAKLHEQLTESEQAAQCYIKYIQDI
YSCGEIVEHLEESTAFRYLAQYYFKCKLWDEASTCAQKCCAFNDTREEGKALLR
QILQLRNQGETPTTEVPAPFFLPASLSANNTPTRRVSPLNLSSVTPGSVSGWRLFK
KISGS
Appendix B
Peptide data
For a subset of peptides, only paper copies of LCMS traces were available and have been
scanned in. Some of these data contain handwritten annotations. For all digitial LCMS
data, the mass peak corresponding to the M+H, M-H, M+2H and M-2H modes m/z ratios
are highlighted. Where it has been observed, both the positive and negative ion modes
corresponding to the peptide mass are shown.
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Exact Mass: 1074.50
Molecular Weight: 1075.11
T1-1: Ac-REX3GDGEX3-NH2
hepta-1,6-diyne
Final analytical HPLC trace was not obtained and the sample no longer exists to
generate a chromatogram.
186 Peptide data
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Exact Mass: 1057.55
Molecular Weight: 1058.15
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Exact Mass: 1010.55
Molecular Weight: 1011.13
D2: Ac-RLPLGDVSN-NH2
188 Peptide data
D3
Exact Mass: 968.50
Molecular Weight: 969.05
D3: Ac-RAPLGDVSN-NH2
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D4: Ac-RAPLGDISN-NH2
Exact Mass: 982.52
Molecular Weight: 983.08
190 Peptide data
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Exact Mass: 982.52
Molecular Weight: 983.08
D5: Ac-RAPLGDLSN-NH2
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D6: Ac-RAPLcBuAlaGDISN-NH2
Exact Mass: 994.52
Molecular Weight: 995.09
192 Peptide data
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D7: Ac-RAPC3GDISN-NH2
Exact Mass: 996.54
Molecular Weight: 997.11
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D9: Ac-GRS5ALSDR8TN-NH2
Exact Mass: 1165.65
Molecular Weight: 1166.33
194 Peptide data
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Exact Mass: 956.50
Molecular Weight: 957.04
D10: Ac-RAALGDISN-NH2
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Exact Mass: 968.50
Molecular Weight: 969.05
D11: Ac-RAAcBuAlaGDISN-NH2
Peptide was insoluble H2O/MeCN, therefore no characterisation was done with the
peptide past its synthesis.
196 Peptide data
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D12: Ac-RAAC3GDISN-NH2
Exact Mass: 970.52
Molecular Weight: 971.07
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D13
D13: Ac-GDAAASDGTN-NH2
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Exact Mass: 918.37
Molecular Weight: 918.86
198 Peptide data
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D16: Ac-RS5ALS5DISN-NH2 D16 unstapled: Ac-RS5ALS5DISN-NH2
Exact Mass: 1078.61
Molecular Weight: 1079.25
Exact Mass: 1106.64
Molecular Weight: 1107.30
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Ac
D17: Ac-RS5AcBuAlaS5DISN-NH2 D17 unstapled: Ac-RS5AcBuAlaS5DISN-NH2
Exact Mass: 1090.61
Molecular Weight: 1091.26
Exact Mass: 1118.64
Molecular Weight: 1119.31
200 Peptide data
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D18: Ac-RS5ANptGlyS5DISN-NH2 D18 unstapled: Ac-RS5ANptGlyS5DISN-NH2
Exact Mass: 1092.63
Molecular Weight: 1093.28
Exact Mass: 1120.66
Molecular Weight: 1121.33
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D19: Ac-RAPLSDITN-NH2
Exact Mass: 1026.55
Molecular Weight: 1027.13
202 Peptide data
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D20: Ac-RAPC3SDITN-NH2
Exact Mass: 1040.56
Molecular Weight: 1041.16
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D21: Ac-RAPF3SDITN-NH2
Exact Mass: 1052.49
Molecular Weight: 1053.05
204 Peptide data
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K1: Ac-ELSKENV-NH2
Exact Mass: 858.44
Molecular Weight: 858.94
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K7: Ac-ER5SKENS5-NH2
Exact Mass: 896.46
Molecular Weight: 896.98
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O OH
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O
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O
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H
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O
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O
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O
Exact Mass: 924.49
Molecular Weight: 925.04
K7 unstapled: Ac-ER5SKENS5-NH2
206 Peptide data
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Exact Mass: 924.49
Molecular Weight: 925.04
K8: Ac-ES5SKENS5-NH2 K8 unstapled: Ac-ES5SKENS5-NH2
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K9: Ac-ELSAAAV-NH2
Exact Mass: 700.38
Molecular Weight: 700.78
208 Peptide data
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O
O OH
Exact Mass: 797.36
Molecular Weight: 797.85
A1: Ac-FGLYEE-NH2
209
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O
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Exact Mass: 587.26
Molecular Weight: 587.58
A9: Ac-AGAAEE-NH2
210 Peptide data
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C1: Ac-GDRYIPSR-NH2
Exact Mass: 1003.52
Molecular Weight: 1004.10
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Exact Mass: 741.37
Molecular Weight: 741.79
C5: Ac-GDAAIPSA-NH2
212 Peptide data
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C6: Ac-S5DRYIPS5R-NH2
isomercis 
C6: Ac-S5DRYIPS5R-NH2
isomertrans
C6e: early isomer C6l: late isomer
Exact Mass: 1109.63
Molecular Weight: 1110.31 Exact Mass: 1109.63
Molecular Weight: 1110.31
Early and late isomer are in reference to their relative retention times from analytical
HPLC. The two C6 peptides isomers have not been further characterised to determine
which isomer has the cis or trans configuration in the C-C double bond of the hydrocarbon
staple.
Appendix C
Publications
In the attached publication by Charoenpattarapreeda et al. [258], Mdm2 (6-125) was
purified for the collaborative work as described in Section 2.3.4. The purified protein was
used in downstream high resolution ESI-MS experiments to confirm the modification of
Mdm2 by P1-2 - STPOH (Figure 3). In addition, time-dependant competition fluorescence
polarisation (FP) assays were performed to prove the covalent nature of their interaction
with Mdm2 (Figure 4). All data were fit using equations previously described in Chapter
3, Equation 3.4. The affinity of the tracer peptide used in the assay was previously
described by Lau et al. [96].
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Targeted covalent inhibitors of MDM2 using
electrophile-bearing stapled peptides†
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Herein, we describe the development of a novel staple with an
electrophilic warhead to enable the generation of stapled peptide
covalent inhibitors of the p53–MDM2 protein–protein interaction
(PPI). The peptide developed showed complete and selective covalent
binding resulting in potent inhibition of p53–MDM2 PPI.
Targeted covalent inhibitors (TCIs) are a class of molecules that
have been increasing in popularity and are reviving the field of
covalent inhibitors.1 TCIs employ weakly electrophilic warheads
in their structure that, upon ligand binding, can react with a
nucleophilic residue of the target protein. This results in a more
controlled and selective binding towards the site of interest. The
covalent bond only forms when the ‘‘warhead’’ is brought into
close proximity of the appropriately located nucleophilic residue
as a consequence of the inhibitor binding to the targeted
pocket.1a Compared to non-covalent inhibitors, TCIs can offer
several advantages which include the potential for improved
potency,2 longer duration of action,3 improved selectivity, and
the possibility for inhibiting ‘intractable’ targets.1a,4,5
Most covalent inhibitors have been designed to target a
cysteine residue near the substrate binding site due to its low
abundance in the proteome and its unique reactivity.6 However, not
all binding sites contain cysteine residues in the ideal proximity.7
Lysine is more ubiquitous than cysteine and has been targeted in a
wide variety of biological systems;1b,7 however, examples of inhibitors
targeting surface-exposed lysines are rare. The challenge for targeting
the e-NH2 group of Lys is its high pKaH (10.4) which renders
99.9% of the amino group protonated under physiological
conditions.8 Nonetheless, surface-exposed lysines can be targeted
following a careful design.1h
MDM2, an E3 ubiquitin ligase, is a negative regulator of the
tumour suppressor p539 and ubiquitination of p53 limits its
activity.10 Approximately 50% of human cancers possess mutated
p53, whilst others feature overexpressed MDM2 resulting in the
malignant cells being able to escape apoptosis.11 Therefore,
inhibition of the p53–MDM2 PPI presents a potential target for
cancer therapy as documented by at least 10 compounds currently
in clinical trials.12
Because PPIs generally have relatively large and shallow
binding pockets,13 peptides are a suitable choice for inhibiting
them due to their greater contact surface area, similar to native
proteins, compared to small molecules. However, peptides on their
own may suffer from poor proteolytic stability and bioavailability.14
One of the most successful approaches to inhibit PPIs and over-
come the intrinsic limitations of peptides is the use of stapled
peptides – i.e. peptides constrained into their binding conformation
by chemically cross-linking two amino acid side chains.14a,c,d In the
case of the p53–MDM2 PPI, several stapled peptides have been
developed with one example, ALRN-6924, reaching phase II
clinical trials.14b,d,15
A recent example of a TCI is the stapled peptide mSF-SAH,
which was developed to target the p53–MDM2/4 protein–protein
interaction (PPI) covalently.16 Hoppmann and Wang incorporated
an unnatural amino acid with an electrophilic sulfonyl fluoride
group into the peptide sequence targeting a lysine or histidine
residue near the binding site on MDM2/4; one-component peptide
stapling was then used to constrain the peptide (Scheme 1a).16
Inspired by the work of Hoppmann and Wang,16 we propose
to utilise the non-covalent binding of a stapled peptide to bring
the electrophile into proximity of the targeted surface-exposed Lys
residue near the MDM2 binding site. Thus, the covalent ligand-
protein cross-linking is facilitated via proximity-enabled bioreactivity
(Scheme 1b).17 The resulting covalent linkage would prevent peptide
dissociation and provide better inhibitory activity. Unlike previous
reports, we envisioned to introduce the electrophilic warhead on a
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Cambridge CB2 1PD, UK
d Department of Biological Sciences, National University of Singapore,
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staple core compatible with the copper-catalysed azide–alkyne
cycloaddition two-component peptide stapling (CuAAC 2C-PS).14d
The use of 2C-PS improves the efficiency of the optimisation process
as each variation of the staple does not require a completely new
synthesis of each peptide.18 Moreover, CuAAC 2C-PS provides mild
conditions with reactions conducted at room temperature in aqu-
eous solution and is compatible with unprotected peptides. We
envisaged that by placing the electrophile on the staple and utilising
a 2C-PS approach, simpler proximity tuning, staple screening, and
synthesis can be achieved (Scheme 1b).
Initial analysis of the binding site of MDM2 (PDB code:
5AFG)15d suggested that the solvent-exposed Lys94 may be a
feasible residue for covalent targeting (Fig. 1a). Molecular
modelling methods were used to determine the optimal pep-
tide sequence, staple position, and staple structure for covalent
binding with Lys94.19 We decided to adopt the phage-derived
peptide PMI sequence (H-TSFAEYWNLLSP-OH) as the basis for
our stapled peptide because it offers strong MDM2 binding
ability and good aqueous solubility.20 We employed the same
azido-ornithine amino acid and 1,3-diethynylbenzene staple (4,
Fig. 1b) that were used by Lau et al. for i, i + 7 2C-PS in our
molecular models,14b which showed that the optimal staple
positions are at residues 5 and 12, such that an electrophilic group
at the 5-position of the staple could come into close contact with
Lys94. Leu9 was mutated to Gly to prevent steric clash of the side
chain with the staple (Fig. S1, ESI†). As a result, the peptide P1 was
identified as the optimal sequence to position the electrophilic
staple in the correct location for targeting Lys94 (Fig. 1c).
We chose a sulfonyl fluoride and two activated esters for
initial screening of possible electrophiles (Fig. 1b). The sulfonyl
fluoride electrophile (1) was selected based upon previous
reports of its resistance to reduction, hydrolysis, and exclusivity
to heterolytic cleavage.21 In addition, its biological application
has been demonstrated through a plethora of examples including
peptidic and Lys-targeted small-molecule binders.16,22 Whereas,
activated esters, namely sulfotetrafluorophenyl (STP) ester (2) and
2,4-dinitrophenyl ester (3), were chosen due to their harder
electrophilic character which makes them more susceptible to
an attack by an amine relative to a thiol. Moreover, activated esters
are validated probes for proteomic profiling for lysine reactivity.23
Molecular dynamics simulations showed that the ester and
sulfonamide covalent complexes of the two-component stapled
P1 with Lys94 of MDM2 are stable, with the three key binding
residues of the peptide (Phe3, Trp7, and Leu10) remaining
bound within the p53-binding cleft at the end of all simulations
(Fig. S1, ESI†).
Considering these data, we designed compounds 1–3 as
potential electrophile-containing staples (Fig. 1b). Staples 1, 2,
and 3 were then synthesised and tested for their compatibility
with the CuAAC 2C-PS,18 stability in aqueous media, and reactivity
towards lysine. Compound 3 was insoluble in aqueous conditions;
thus, it was excluded from further testing. Despite the comparable
stability of staples 1 and 2 in physiological pH (49% intact for 1 vs.
42% for 2 after 24 h, Fig. 2a), activated ester 2 was progressed as it
was found to be significantly more stable under the CuAAC 2C-PS
conditions (15% intact for 1 vs. 83% for 2 after 24 h, Fig. 2b). In
addition, 2 showed a faster reactivity with Lys whilst 1 mostly
underwent hydrolysis (5% Lys-conjugated for 1 vs. 95% for 2
after 4 h, Fig. 2c). With these results in hand, we decided to take
forward the STP ester 2 as our electrophile-containing staple.
The optimised peptide P1 was stapled with compound 2 to
Scheme 1 (a) Previous work using one-component stapling and incorporation
of an electrophilic moiety into the peptide sequence for generating a stapled
peptide covalent inhibitor for MDM2/4.16 Covalent-crosslinking occurs through
proximity-enabled bioreactivity.17 Shaded circle denotes resin. Nu = Lys or His
(b) utilising 2C-PS for generation of stapled peptide covalent inhibitors.
Structure of P1-2, the developed stapled peptide covalent inhibitor, is shown.
Fig. 1 (a) Molecular dynamics simulation of PMI-derived stapled peptide
(red) covalently linked with MDM2 (grey) through amide bond with Lys94
close to the binding site. (b) The structures of the proposed staples: aryl
sulfonyl fluoride 1, sulfotetrafluorophenyl (STP) ester 2, and dinitrophenyl
ester 3. The non-electrophilic staple 4 was used as a control. (c) The
optimal linear diazidopeptide P1.
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obtain the stapled peptide P1-2 (Scheme S1, ESI†). Pleasingly,
circular dichroism measurements confirmed the staple used
was able to enhance the a-helical conformation of the peptide
(12% for P1 vs. 22% for P1-2, Fig. S2, ESI†).
In order to assess the ability of P1-2 to form a covalent
complex with MDM2, P1-2 was incubated with MDM2 and the
reaction mixture analysed by mass spectrometry (Fig. 3). After
the incubation, complete formation of the covalent complex was
observed and no unmodified MDM2 remained (Fig. 3a and b).
Pleasingly, by replacing P1-2 with the control peptide P1-4 (no
electrophilic moiety, Scheme S1, ESI†), detection of a covalent
peptide-MDM2 complex was not observed (Fig. S3, ESI†).
Under the same conditions, MS results of the STP ester 2
alone (i.e. without peptide) with MDM2 resulted in only a small
amount of the protein being modified, therefore highlighting
the importance of the specific non-covalent binding of P1-2 to
MDM2 for the cross-linking event to occur (Fig. 3c).
The selectivity of the stapled peptide was investigated further
by the addition of human lysozyme (Lyz) to the incubation. Lyz
contains five highly solvent-accessible lysines out of which, one is
particularly active.24 Following the incubation, formation of the
peptide-Lyz covalent complex was not detected indicating that P1-2
selectively binds MDM2 (Fig. S4, ESI†).
Finally, the apparent dissociation constant (Kd,app) of P1-2 to
MDM2 was examined and compared to the non-covalent peptides
using a competitive fluorescence polarisation (FP) assay (Fig. 4).14b,15c
The linear diazidopeptide P1was found to have an attenuated Kd for
MDM2 (Kd = 47.8 1.5 nM, Fig. 4a) compared to the wild-type (WT)
PMI (Kd = 16.6  0.2 nM, Fig. 4a).20 Pleasingly, the stapled peptide
P1-4 showed an affinity comparable to the WT (Kd = 19.3  0.3 nM,
Fig. 4a). Crucially, over the course of 120 minutes, these dissociation
constants did not change significantly (Fig. 4b and Fig. S5, S6, ESI†).
In contrast, as expected for a TCI, the Kd,app of P1-2 improved
over time as the covalent bond was formed, ultimately resulting
in a potent MDM2 inhibitor after 120 minutes (Kd,app = 30.0 
9.2 nM at 9 min which decreased to 7.1  2.1 nM at 120 min,
Fig. 4c and d)‡.25
In summary, we have developed a novel strategy for producing
stapled peptide covalent inhibitors. Expanding on our CuAAC 2C-PS
technique, the staple was functionalised with a suitable electrophile
for forming a covalent cross-linking with the target protein
upon binding. We validated this approach using an STP ester-
functionalised stapled peptide targeting the oncogenic protein
MDM2: the lead peptide P1-2 demonstrated complete covalent
complex formation and nanomolar inhibition to MDM2.
Fig. 2 Stability and reactivity tests of compounds 1 (red) and 2 (blue)
(a) stability in aqueous media. (b) Stability in CuAAC condition. (c) Reactivity
comparison between compounds 1 and 2 against Na-Ac-Lys-OH. E =
electrophile, LG = leaving group. Solid lines indicate conjugation while
dotted lines indicate hydrolysis. All reactions were monitored by analytical
HPLC and caffeine was used as the internal standard. The results are the
average of two independent repeats and the errors shown as standard
errors of mean.
Fig. 3 ESI-MS spectra for reactions with MDM2 (a) the unmodified MDM2.
[MDM2 + H]+ = 13 783 Da. (b) P1-2 (25 mM) was incubated with MDM2
(25 mM) in PBS buffer (+10% DMSO) at 37 1C for 1 h. ESI-MS spectrum of the
reaction indicated the complete covalent binding of the stapled peptide.
[MDM2 + P1-2  STPOH + H]+ = 15400 Da (c) the same incubation as in
(b) but with P1-2 replaced with compound 2. ESI-MS spectrum showed
low reactivity of the electrophile on its own with most MDM2 unreacted.
[MDM2 + 2  STPOH + H]+ = 13933 Da; STPOH = sulfotetrafluorophenol.
Fig. 4 (a) Dissociation constants for non-covalent peptides. † The Kd
values are the average of every time point and the errors are standard
errors of mean. (b) Competitive FP assay of P1-4 showing no change in
affinity over time. Each curve represents one time point: 9 min (red),
41 min (green), and 120 min (blue). Each data point is arithmetic mean of
triplicate and the errors shown are standard errors of mean. (c) Apparent
dissociation constant of P1-2 at each time point. (d) Competitive FP assay
of P1-2 showing the increase of the apparent dissociation constant over
time which is characteristic of a covalent inhibitor.
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Importantly, the results and concept of our study would
expedite the development of stapled peptide covalent inhibitors
by removing the need to synthesise the peptides anew for
every sequence and requiring less demanding conditions on
the electrophile. We envision that targeting proteins with low
turnover rates would gain the most benefit from using this
strategy.1a,7a A further advantage of using the CuAAC 2C-PS
technique is that extra functionalisation may be achieved by
appending a second functional handle to the staple and hence
further enhance the capability of peptide inhibitors.
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